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ABSTRACT 
Topical Negative Pressure therapy is in widespread use in the management of 
acute and chronic cutaneous wounds. The mechanisms of action are not fully 
understood, but are likely to be multifactorial. Experience of this therapy is based 
on a number of clinical series, case reports and some animal studies. There is a 
lack of direct evidence to determine its mechanisms of action and to support its 
clinical efficacy in human wound healing. This problem stems partly from 
difficulties in applying selective negative pressure to open exudative wounds. A 
new approach was required in applying this technology to wound surfaces in 
consenting patients. 
This thesis describes the design and validation of 'standard' and 'irrigation' devices 
that were used to apply Topical Negative Pressure to one part of a wound thus 
allowing intra-patient control. As a novel research tool, the irrigation device 
provided an opportunity to collect wound fluid from the surface of the wound for 
biochemical analysis. Paired wound biopsies of Topical Negative Pressure treated 
and control wounds were obtained. 
This thesis has demonstrated that Topical Negative Pressure (with intermittent 
suction) modulated the acute donor site wound and partial thickness burn wound 
during the first 48 hours of injury, by altering the distribution of inflammatory 
neutrophils in the dermis. 
Using a cycle of periods of suction-on and suction-off, Topical Negative Pressure 
increased the removal of Neutrophil Elastase from the wound during suction, in 
addition to its endogenous plasma-derived inhibitor, a1-Protease Inhibitor. 
Using this new device on human wounds has provided a means of understanding 
mechanisms in Topical Negative Pressure therapy, and has demonstrated its use 
as a research tool in the collection and analysis of wound fluid. 
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I LITERATURE REVIEW 
1.1 Topical Negative Pressure Therapy 
1.1.1 Definition and History of Topical Negative Pressure 
Topical Negative Pressure has been defined as the application of subatmospheric 
pressure to an open-cell screen (foam, felt, surgical towel or gauze) over a wound 
bed or skin graft, which is covered by an overlying adhesive polymer drape that 
creates and maintains a hermetic seal (Greer, 2000). Controlled subatmospheric 
pressure is applied to this screen using a tube connected to an external suction 
source. A distinction must be made between the use of topically applied pressure 
dressings described above, and a closed wound suction system that is commonly 
employed to coapt tissue surfaces and drain surgical wounds of blood or tissue 
fluid (Fox and Golden, 1976). 
The concept of applying suction to a surface wound is not new. Greer (2000) has 
reviewed the history of Topical Negative Pressure dating back to Junod's 
application of suction glass bells in 1841, to create what was described as 
therapeutic hyperaemia (Greer, 2000). In this paper, Greer also cited the use of 
subatmospheric pressure therapy by a number of international authors who have 
published work dating back from 1966 (in the Russian literature) to the present, 
employing commercially available systems. Despite having the Russian papers 
translated for him, Greer did not provide descriptions of how Russian 'vacuum 
therapy' had been employed on wounds, the nature of the dressings used, or what 
results were obtained. 
Today, there still remains some confusion within the literature about the use of this 
form of therapy, its description and application. There are three reasons for this 
confusion: (1) there are a number of published articles in the world literature in 
many different languages that cite the use of 'vacuum therapy' in the treatment of 
wounds. It is difficult to gain access to translated manuscripts; (2) many terms 
have been introduced to describe this form of 'vacuum therapy'; (3) there are 
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many different ways of applying 'vacuum therapy' to wounds using a number of 
different materials which confounds this problem. 
1.1.1.1 Terminology 
In addition to the commonly used term Topical Negative Pressure (Cooper et at., 
2000; Deva et al., 2000; Evans and Land, 2001; Shaer, 2001), other generic 
synonyms include subatmospheric pressure dressing (Greer, 2000), negative 
pressure therapy (Banwell et al., 1998), negative pressure dressing (Blackburn et 
at., 1998; Masters, 1998), vacuum sealing technique (Fleischmann et at., 1995; 
Müllner et at., 1997), and vacuum-assisted closure (Argenta and Morykwas, 
1997a; De Lange et at., 2000). For the purposes of clarity in this thesis, the term 
Topical Negative Pressure (TNP) will be used to describe all the generic forms of 
this therapy. 
1.1.1.2 Materials and methods used in TNP therapy 
In 1986, Shein et al. described the use of a 'sandwich technique' in the 
management of the open abdomen, in which suction tubes are placed between an 
inner Marlex® mesh (adjacent to the viscera) and an outer Op-site® dressing, in 
the open management of major intra-abdominal sepsis (Schein et al., 1986). They 
illustrated its use in three case studies and mentioned the prevention of bowel 
evisceration, the reduction of insensible fluid losses, the accuracy of fluid 
replacement, and the ease of nursing care, as advantages over traditional 
methods of open wound management. 
Smith et al. (Smith et al., 1997) have described their four-year experience (from 
1992 to 1996) of a vacuum pack technique of temporary abdominal closure, first 
described by Brock (Brock et al., 1995). With suction pressures between 100 to 
150mmHg, a surgical towel was placed around suction tubes sandwiched between 
an inner plastic drape and an outer adhesive dressing in 171 general surgical and 
trauma cases ranging in age from 3 months to 88 years. 
In seven case reports, Nakayama (Nakayama et al., 1990) described a technique 
of applying suction to an adhesive drape to skin grafts of the body, including the 
hands (Nakayama and Soeda, 1991). These case reports were descriptive 
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accounts only, and did not include evidence for improved graft take versus any 
control groups. 
In 1993, Fleischmann et al. were the first to publish (in German) the use of a 
vacuum sealing technique, using foam as an interface (Fleischmann et al., 1993). 
Their new TNP system involved the use of layers of sterile open-porous 
polyvinylalcohol (PVA) foam surrounding two redon-drains (16Ch) along the long 
axis of the foam. The foam was cut to size, and the tubing drawn through the skin. 
The entire area was covered with a semi-permeable polyurethane drape 
connected to vacuum bottles. They described its use on 15 patients with open 
fractures in 1992, as an adjunctive `sealing' procedure prior to definitive closure by 
a number of operative techniques. This work, in conjunction with a further 166 
cases of acute soft tissue injuries, and acute and chronic wound infections from 
1992 to 1993 were later published in English in the European Journal of 
Orthopaedic Surgery & Traumatology (Fleischmann et al., 1995). They claimed 
that this technique had been in use in their surgical practice since 1987. With 
pressures maintained up to a constant suction of 80Kpa (600mmHg), they detailed 
the types of wounds used with this technique, documented the average time of 
vacuum sealing, the number of dressing changes used and the subsequent 
surgical outcomes required to definitive closure. Their work was presented in 
Germany, at the European Bone and Joint Infection Society Meeting in October 
1993. 
Meanwhile, Louis Argenta and Michael Morykwas were working on their version of 
vacuum therapy using a similar open-cell foam dressing since 1989 (unpublished 
data, Kinetic Concepts, Inc. ). The design of their TNP system was slightly 
different. The foam was made of polyurethane ester (PUE) with greater pore sizes 
(400µm to 600µm) to maximise tissue growth. This also allowed for reduced 
subatmospheric pressures of 125mmHg to achieve a uniform collapse of the foam. 
These authors presented their methodology and basic animal studies using the 
technique as early as April 1993 in New Orleans, USA and the outcomes of their 
clinical series at the European Tissue Repair Society meeting in Amsterdam, in 
August 1993. Argenta and Morykwas filed the technique of 'Wound treatment 
employing reduced pressure' for patency in March 1993 (Argenta and Morykwas, 
1997b). The Food and Drug Administration granted approval for its use in the 
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treatment of wounds in 1995. The technology has been licensed to and 
commercially available from Kinetic Concepts, Inc (KCI), and the system 
trademarked as 'Vacuum-assisted Closure' (V. A. C. TM) (Kinetic Concepts Inc., 
1996). V. A. C. dressings include sterile PUE foam, an evacuation tube and a 
transparent adhesive drape. The foam can be trimmed to the necessary size and 
shape to conform to each individual wound. The evacuation tubes are placed 
within the foam, and the foam dressing covered with the adhesive drape, 
extending beyond the wound margins to adhere to dry, normal skin to create an 
airtight seal. The tubing is attached to a separate V. A. C. canister that is housed 
within a V. A. C. pump. The pump can be preset to regulate subatmospheric 
pressures between 25 - 200mmHg, and a sensor detects leaks and provides a 
warning sound to the operator (Kinetic Concepts Inc., 2000). 
From the work by Argenta and Morykwas (1997), the use of suction dressings and 
a foam interface coupled to a regulated subatmospheric pressure (V. A. C. TM) 
system has been widely accepted and commonly quoted in work related to this 
method of wound management (Argenta and Morykwas, 1997a). To avoid 
confusion in this thesis, hereinafter, the term TNP refers directly to sealed foam 
dressings used in conjunction with subatmospheric pressure. 
1.1.2 TNP therapy in the Clinical Setting 
1.1.2.1 Acute wounds 
Fleischmann et al. (1995) mentioned the use of their TNP system as a 'sealing 
procedure' in a series of patients with 63 acute soft tissue damaged wounds and 
47 acutely infected wounds. They described the application of PVA foam (with 
negative pressures of up to 600mmHg) and length of time of TNP therapy (14.7 
and 12.4 days respectively) before further management by delayed primary 
closure, skin grafting, flap transfer or 'open' treatment. No comment was made 
about the indications or timing of wound closure when compared to other (chronic) 
wounds. They observed rapid formation of granulation tissue following TNP in 
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these acute wounds, but did not document or measure this finding (Fleischmann et 
al., 1995). 
Argenta et al. (1997) published a descriptive series of 300 patients, in whom 88 
underwent TNP therapy for the treatment of a variety of acute traumatic and 
acutely infected wounds. 125mmHg was applied to the foam continuously for 48 
hours and then intermittently at 5-minutes-on/2-minutes-off intervals. Rapid rates 
of granulation tissue formation were observed in acute wounds when compared to 
non-controlled chronic wounds (Argenta and Morykwas, 1997a). Similar to 
Fleischmann's report (Fleischmann et al., 1995), they observed that the formation 
of granulation tissue was most pronounced in acute wounds, and that rate of 
healing (measured by time to complete healing or the reduction in wound volume) 
occurred more quickly in this group than the chronic wound groups. No specific 
details were given in this paper to support these findings. No measurements of 
granulation tissue formation were made. The `majority' of the patients either 
healed completely or until an adequate bed of healthy granulation tissue had 
developed, and of these, their definitive treatments included grafting, flap or direct 
closure procedures. 
Müilner et al. (1997) summarised the treatment of 12 patients with acute soft 
tissue traumatic defects. TNP dressings were applied and continuous 
(undisclosed) subatmospheric pressures maintained with the use of vacuum 
bottles. Ten out of the 12 wounds were clinically infected. Three patient wounds 
granulated without secondary closure and nine required skin grafting once 
sufficient granulation tissue was achieved. The mean healing times were 16 days. 
The authors suggested that the TNP dressings maintained a clean wound bed and 
facilitated the earlier application of skin grafts in these wounds, although no 
objective evidence was presented to substantiate these claims (Müllner et at., 
1997). 
In these three prospective series, there was no attempt to randomise any of the 
acute wounds for TNP therapy with matched control groups. The investigators did 
not specify any reasons for not introducing controls in their studies. 
Genecov et at. (1998) applied TNP to 15 human acute donor site wounds to study 
the rate of reepithelization. Grafts were harvested using a dermatome from both 
thighs in all but 2 patients, in whom the donor sites were located on the same thigh 
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with an area of intact skin between the sites. Following grafting, the donor sites 
were covered with adrenaline-soaked pads, punch biopsies obtained, and one 
thigh donor site covered with Opsite, and the other with TNP dressings (or half the 
sites for 2 patients with unilateral donor site wounds). 125mmHg was applied via 
the V. A. C. pump continuously for up to 7 days. Further biopsies were taken at 4 
and 7 days. Biopsies were fixed, sectioned and H&E stained, and a blinded 
evaluation performed by a dermatopathologist. The degree of reepithelization was 
determined on a scale of 0 (no evidence of reepithelization) to 4 (complete, mature 
epithelium). Of the 10 patients who completed the study, seven were noted to 
have reepithelized faster with the TNP dressings than the Opsite-treated controls 
by day 7. Two patients showed no difference and one patient showed more 
reepithelization in the Opsite-treated site. The authors did not provide any 
information on the histological quantification used in their study in order to 
categorise them into one of the five groups mentioned. Despite this, this study is 
the only published human study using TNP dressings against an intra-patient 
control group (Genecov et al., 1998). 
TNP has been used in the effective treatment of acute degloving injuries of the 
extremities and published as case reports (DeFranzo et al., 1999; Meara et al., 
1999). 
TNP has been described as an adjunctive treatment of sternal wound infections 
(Hersh et al., 2001), poststernotomy mediastinitis (Obdeijn et al., 1999) and chest 
wall dehiscence (De Lange et al., 2000) following cardiac surgery. In these three 
reports, TNP therapy was believed to create a clean, well vascularised and more 
'stable' smaller wound defect, promoting granulation tissue development and 
avoiding the need for repeated debridement procedures or further surgery. 
TNP has been used recently to obtain serial closure of dehisced or infected 
abdominoplasties in four cases averting the need for corrective surgery (Fenn and 
Butler, 2001). 
1.1.2.2 Wounds with exposed bone or implants 
The use of TNP has been described to increase granulation tissue formation over 
exposed bone and metal implants (Argenta and Morykwas, 1997a; Fleischmann et 
at., 1995; Müllner et al., 1997). Recently, Defranzo et at. (2001) have published 
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their updated series of 75 patients with lower extremity wounds with exposed bone 
that underwent TNP therapy at 125mmHg and reported successful coverage 
without complications in 71 of these cases. TNP was applied directly over 
exposed bone without periosteum but did not give details of how large the defects 
were, but acknowledged that large exposed plates or large areas of exposed bone 
would not be good candidates for TNP. They suggested that granulation tissue 
developed from surrounding viable soft tissue or possibly from elements beneath 
the fracture site (DeFranzo et al., 2001). 
1.1.2.3 Chronic wounds 
The application of TNP therapy to chronic wounds has been extensively described 
since the early work of Argenta (Argenta and Morykwas, 1997a; Deva et at., 2000; 
Mtillner et al., 1997). Argenta and Morykwas (1997) treated one hundred and 
seventy-five pressure, venous stasis, radiation and diabetic ulcers, and other 
miscellaneous chronic wounds using the V. A. C. system with a mixture of 
continuous or intermittent subatmospheric pressure. They showed that the "... vast 
majority of chronic wounds (171 of 175) responded favourably" to treatment, 
noting that there appeared to be significant removal of oedema and proliferation of 
granulation tissue in their treated cases. The treatment lengths varied between 
patients and successful outcomes were gauged subjectively. Further definitive 
treatments (skin grafting, flap closure or healing by secondary intention with 
dressings) were based on clinical judgement. They did not measure the observed 
attenuation of oedema but stated that the surrounding tissues became `more 
pliable' and they did not measure the rate of increased granulation tissue 
formation either, in these cases. They stressed in their report that many of these 
chronic wounds were recalcitrant to past surgical or dressing procedures (although 
they did not specify exactly how many), or were considered non-surgical 
candidates because of concomitant disease (Argenta and Morykwas, 1997a). 
1.1.2.4 Burn wounds 
Despite suggestions of its potential use in burn wounds (Morykwas et al., 1999a; 
Morykwas and Argenta, 1997), there are no published accounts of TNP therapy in 
the treatment of human burns. 
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1.1.2.5 Miscellaneous uses of TNP 
A number of authors have used TNP as a dressing for skin graft fixation to aid 
contouring the graft to irregular parts of the body (Banwell et al., 1999; Blackburn 
et al., 1998; Schneider et al., 1998). These studies have suggested that the 
advantage of TNP as a method of skin graft fixation may be due to its ability to 
remove excess tissue fluid and haematoma formation from beneath the graft and 
providing secure immobilisation at the wound-graft interface. Despite this, there 
have been no comparative clinically controlled trials published testing this form of 
fixation with standard skin graft bolster techniques. 
Greer et at. (1999) have used TNP to stimulate granulation tissue coverage of 
exposed tendon (without paratenon) to the radial forearm free flap donor site 
where skin graft cover had broken down in two cases (Greer et at., 1999b). 
TNP has also been used in the sealing of lymphocutaneous fistulas (Greer et al., 
2000), suggesting that granulation tissue formation was likely to be the reason for 
its success in the treatment of the two cases they describe. 
1.1.2.6 Clinically controlled trials involving the use of TNP on wounds 
Recently, there has been an attempt to focus work on clinically controlled trials to 
evaluate TNP therapy in wound healing. There are currently only three clinically 
controlled trials published to date, assessing the efficacy of TNP therapy in a 
clinical setting (Genecov et al., 1998; Joseph et al., 2000; McCallon et al., 2001) 
and one preliminary trial in abstract (Greer et al., 1999a). 
One trial involved the use of TNP on skin graft donor sites to assess rates of 
reepithelization by histology, against an intra-patient controlled OpsiteTM dressing 
(Genecov et al., 1998). Details of this work have been described in section 1.1.2.1 
on page 21. 
Two trials have been published to compare TNP therapy with saline-moistened 
gauze dressings in chronic wounds (Joseph et al., 2000; McCallon et al., 2001). 
Both of these have been subject to an extensive review by the Cochrane Wounds 
Group, whose remit was to determine the efficacy of TNP therapy in chronic 
wounds by tracing all available randomised controlled trials (Evans and Land, 
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2001). The two randomised controlled trials reviewed above were conducted on a 
small number of patients and objective outcome measures were difficult to define 
and record. Despite these problems, it was recommended that there is only weak 
evidence to suggest that TNP may be superior to saline-gauze dressings in the 
treatment of chronic wounds (Evans and Land, 2001). 
Recently, Fleischmann and colleagues have conducted a randomised controlled 
trial to determine the influence of TNP on the systemic inflammatory response 
(Buttenschoen et al., 2001). Thirty-five patients who required open reduction and 
fixation of isolated closed ankle fractures (within 6 hours of injury) were 
randomised to direct surgical closure (n=18) or TNP using V. A. C. dressings with 
PVA foam at subatmospheric pressures of 600mmHg for up to 120 hours (n=17). 
They measured a number of inflammatory acute phase reactants (including 
endotoxin, CRP, IL6, al-protease inhibitor and complement) in plasma before and 
at 0.5,12,24,48 and 96 hours after surgery. They reported peak endotoxin levels 
at 0.5 hours after surgery in the skin-sutured group (0.11 EU/ml), which was 
absent in the TNP group (0.07 EU/ml) with pre-op values at 0.06 Eu/ml. This 
difference between the two groups was insignificant at all other times. The other 
inflammatory parameters measured in plasma were not significantly different. 
They suggested that TNP therapy does not alter the systemic inflammatory 
response (Buttenschoen et al., 2001). No attempt was made to determine 
whether TNP might change the local environment of the wound. 
1.1.3 Evidence for Mechanisms of Action of TNP in Wound Healing 
A number of factors have been proposed as mechanisms that might explain the 
observed clinical effects of TNP. The evidence suggesting a putative role for each 
of these factors is reviewed in detail below and, where possible, relates to studies 
using TNP foam dressings, unless stated otherwise. 
25 
1.1.3.1 Enhanced microvascular blood flow 
Using TNP foam dressings on full thickness wounds in pigs, Morykwas et al. 
(1997) have shown that blood flow, measured using Laser Doppler needle probes 
both within the wound and adjacent to it, recorded peak blood flow of four times 
baseline values at subatmospheric pressures of 125mmHg. Furthermore, they 
observed that at constant negative pressures of 125mmHg, the local blood flow 
declined after 5 to 7 minutes to a baseline reading. These flow measurements 
were also immediately depressed below baseline levels at levels of 400mmHg or 
more (Morykwas et al., 1997). Using the results of this work, these authors 
determined an optimal intermittent TNP cycling regimen of 5-minutes-on and 2- 
minutes-off. They postulated that the increase in blood flow measured in their 
experimental cases might be due to active removal of interstitial fluid from the 
tissues surrounding the wound, which decompress small blood vessels and 
restoring blood flow. They did not provide any evidence to support this view. 
Morykwas and colleagues also created 3x12cm random pattern flaps on the backs 
of pig, which were raised and resutured to the skin. Flaps were assigned to one of 
four groups: (1) flap exposed to TNP both prior to (4 days) and following surgery; 
(2) flap exposed to TNP prior to surgery but not post surgery; (3) flap exposed to 
TNP post surgery only; (4) flap that received no TNP. At 72 hours, photographs 
were taken and acetate drawings made to determine % flap survival based on 
areas of discolouration. Their results showed that pre- and post-treated flap 
survival (72.2% +/-10%) was significantly greater than the control group (51.2% +/- 
6.9%). No significant differences were shown between pre- and post- treated 
flaps. The authors suggested that nutrient blood flow might be enhanced using 
TNP as determined by the survival of these random-pattern flap experiments 
(Morykwas et al., 1997). 
1.1.3.2 Stimulation of granulation tissue formation 
Using circular 2.5cm full thickness skin wound models in the pig, Morykwas et at. 
(1997) measured the defect space daily by taking alginate impressions. The 
wounds were created on the dorsal midline, which they claimed did not undergo 
contraction during healing. Rates of granulation tissue formation measured by the 
volume displacement of the casts showed that the TNP treated wounds increased 
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63.3% (SD±26.1%) and 103.4% (SD±35.3%) in continuous and intermittent TNP- 
treated groups respectively, as compared to saline-soaked gauze controls. They 
argued that the diameter of the wounds did not change during the course of the 
study and that any differences in volume were accounted for by increases in 
granulation tissue alone (Morykwas et al., 1997). More recently, Morykwas et al. 
(2001) showed that acute dermal pig wounds treated with TNP, granulated to a 
level equal to surrounding tissue by 8 days with subatmospheric pressures of 
125mmHg with only 21.2% granulation tissue filling with 25mmHg and 5.9% 
granulation tissue filling with 500mmHg. Based on this in vivo animal evidence, 
they proposed that 125mmHg was the optimal subatmospheric pressure in TNP 
therapy (Morykwas et al., 2001). 
Fabian et al. (2000), using a skin-excised rabbit ear wound model, have 
demonstrated significantly greater granulation tissue formation (measured directly 
using a lens micrometer) on TNP-treated experimentally-induced ischaemic 
wounds than a control wound of foam but without suction at 10 days post injury 
(Fabian et al., 2000). The histological features of granulation tissue are dominated 
by the proliferation of new small blood vessels, fibroblasts and macrophages 
(Kumar et al., 1992). From the literature review, no studies have looked directly at 
the effects of TNP on these factors directly. 
1.1.3.3 Reduction in bacterial colonisation 
Experimental wounds in pigs inoculated with a human isolate of Staphylococcus 
aureus (n=3) and a pig isolate of Staphylococcus epidermidis (n=2) were 
subjected to TNP at a constant 125mmHg and compared to a control group on the 
same animal (Morykwas et al., 1997). Daily biopsies of the wounds were taken for 
up to 2 weeks. The tissue collected was homogenised, diluted in sterile saline and 
incubated on the surface of a blood agar plate. Colonies were counted and the 
number of organisms per gram of tissue calculated. The results showed 
significantly reduced organisms, falling from an inoculum of 108 organisms per 
gram of tissue to less than 105 organisms per gram of tissue (the traditionally 
accepted upper level for infection) between day 4 and 5 only in the TNP-treated 
group as compared to controls. The control group did not fall to below 105 until 
after a mean of 11 days (Morykwas et al., 1997). This work mirrors some reports 
using TNP therapy in the clinical setting, which have noted a reduction in 
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superficial purulence and odour (concomitant with the presence of bacteria and 
leucocytes) in the effluent that contained quantitatively reduced bacterial counts 
over a similar time of 3-4 days although no details were given (Argenta and 
Morykwas, 1997a). It remains unclear whether the reduced bacterial counts 
noted in the above studies are due to the direct removal of bacteria or secondary 
to enhanced phagocytosis due to the increase in local blood supply or some other 
mechanism. 
1.1.3.4 Changes to interstitial fluid volume 
Some authors believe that the increase in local blood flow following TNP therapy is 
due to the active removal of excess interstitial fluid volume from the wound and its 
surroundings which might reduce the tissue pressure around the skin 
microcirculation and improve the local blood flow (Argenta and Morykwas, 1997a; 
Cozart et al., 1999). Despite the measurement of large amounts of effluent from 
the drains of patients treated with TNP therapy in clinical series, there are no 
reports in the literature providing direct objective human or animal experimental 
evidence that measure alterations in interstitial fluid volume from wounds under 
the influence of TNP therapy. 
1.1.3.5 Removal of factors within wound exudates 
Elevated levels of proteolytic enzymes present in chronic wound fluids (Bucalo et 
al., 1993; Grinnell et al., 1992; Trengove et al., 1999) and burn wound fluids 
(Grinnell and Zhu, 1994; He et al., 1998; Neely et al., 1997) are hypothesized to 
impede normal wound healing (Section 1.4.3 on page 63). Despite the suggestion 
that TNP therapy might alter the composition of wound fluid (Argenta and 
Morykwas, 1997a; Banwell, 1999), there is no evidence from the literature that the 
use of TNP therapy actually does so, and no comparisons have been reported 
between wound fluids retrieved from TNP-treated wounds and control wounds 
within the same patient. Furthermore, this literature review has been unable to 
trace any published study that has used TNP to collect and analyse the fluid 
composition of TNP-treated wounds in an experimental or clinical setting, to link 
the efficacy of TNP to alterations in the constituents of wound fluid. 
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One paper by Morykwas et at. (1999) has examined the effects of TNP therapy on 
Doxorubicin-injected pig skin (Morykwas et at., 1999b). Doxorubicin was injected 
intradermally through intact skin to simulate an extravasation incident. Following 
this, the epidermis was perforated by two holes created with a 2mm punch biopsy 
to allow a path for egress of the injected Doxorubicin solution, although no tissue 
was removed. In a TNP-treated group (n=16), no extravasation-induced ulcers 
were produced, compared to a control group (n=16) in which 10 ulcers developed. 
They explained that this was most likely due to '... Doxorubicin molecules migrating 
out of the underlying tissues through the epidermis into the vacuum dressing... ' 
and that the prevention of extravasation ulcers might be due to an enhanced 
diffusion gradient formed by the suction. They did not measure the volume of 
aspirate from either the TNP-treated or control sites, nor did they attempt to detect 
Doxorubicin directly from the aspirates. They claimed that the egress of the agent 
was not facilitated by the punch biopsy holes created in the skin, but instead 
directly removed through an intact stratum corneum. Unfortunately, it was not 
made clear in this paper whether extravasation ulcers that formed were directly 
associated with the perforated punch biopsy sites in the epidermis (Morykwas et 
at., 1999b). 
It remains a matter of conjecture whether TNP therapy can directly influence the 
removal of wound exudates through open, injured skin or extravasated 
chemotherapeutic agents through intact skin. 
1.1.3.6 Response of tissues to mechanical forces 
It has been proposed that TNP therapy may exert a mechanical effect on wounds 
at both a 'macroscopic' (directly mechanical) and a 'microscopic' (cellular and/or 
molecular) level (Banwell, 1999). It is difficult to demonstrate a precise 
mechanical effect of TNP on tissues, cells or their humoral effectors (e. g. growth 
factors or proteases), because of the complexities in methodological design. 
For example, section 1.1.3.2 describes a study in which Morykwas et al. (1997) 
evaluated the effects of TNP on granulation tissue formation by measuring the 
decrease in wound size using alginate casts on the dorsum of pigs (Morykwas et 
al., 1997). They claimed that the observed decreases in wound size were not due 
to wound contraction caused by direct mechanical effects of TNP but instead, due 
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to real increases in granulation tissue filling the wound. They postulated that the 
increases in granulation tissue were due to mechanical forces imposed on 
surrounding tissues through viscoelastic flow or directly on cellular proliferation 
(presumably of endothelial cells and of fibroblasts into myofibroblasts). 
It is not clear whether these observations noted are due to: (1) direct mechanical 
forces on tissues, (2) mechanical influences applied to cells or their effector 
functions or (3) indirect, non-mechanical influences, such as the reduction in 
oedema or enhanced blood flow. 
In an effort to define the role of mechanical stress on skin directly, the influence of 
tissue expansion techniques in normal skin of animals and humans has been 
studied supporting the notion that tissue expansion increases mitotic activity in 
skin to generate a net gain in tissue (Austad et al., 1986; Olenius et al., 1993). 
TNP therapy has been described as a form of 'reverse tissue expansion' with the 
implication that any mechanical effects of TNP therapy might be likened to those 
found using tissue expansion techniques (Banwell, 1999). However, caution is 
required in comparing putative mechanical effects of TNP with studies involving 
tissue expansion for two principle reasons. Firstly, the viscoelastic effects on skin 
by tissue expansion and TNP are different. In mechanical terms, tissue expansion 
causes the skin to stretch to a specific length until a force is generated and then 
fixed at that position. The force generated then diminishes as relaxation occurs. 
Gibson described this as stress relaxation: a constant elongation with diminishing 
load (Gibson, 1977). Furthermore, by its intermittent nature, tissue expansion is 
best thought of as 'stepped stress relaxation' (Brody, 1993). Meanwhile, TNP 
therapy is an example of mechanical creep (Gibson, 1977): an elongation 
secondary to a constant force. As the surrounding skin is subjected to a constant 
force under the TNP dressing, the skin is dragged inwards to affect closure, as 
noted clinically in the treatment of chronic ulcers for example. Secondly, Austad et 
al. (1982) described tissue expansion as 'relatively benign'. Conducting controlled 
tissue expansion studies on Guinea Pigs, they found no evidence of necrosis or 
inflammation histologically, during a1 to 18 week period (Austad et at., 1982). In 
contrast, TNP therapy is applied to acute or chronic inflamed wounds and 
circumstantial comparisons to tissue expansion studies performed in normal (non- 
inflamed) skin using foam dressings cannot be safely made. 
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Mechanical (suction) forces directly influence angiogenesis (Ryan and Barnhill, 
1983). In vitro studies have shown that tritiated thymidine-incubated vascular cells 
(Sumpio et al., 1987) and smooth muscle cells (Wilson et al., 1993) demonstrate 
statistically increased cell proliferation and DNA synthesis in vacuum operated 
flexible-bottomed culture plates compared to controls; and blood vessel density is 
also increased following mechanical strain experiments in vitro (Baker and 
Sanders, 2000). 
The mechanism(s) by which cells 'sense' or respond to mechanical stimuli is not 
clear. Little is known about the underlying molecular pathways by which 
mechanical events are transduced into intracellular physiological responses and 
this area is beyond the scope of this review. However, the importance of the ECM 
in mediating mechanical forces has been shown by observations that strain- 
induced cell proliferation is matrix-dependant. For example, strain plates were 
coated with a number of ECM proteins (including fibronectin, vitronectin and 
collagen) to show matrix-induced differences in vascular smooth muscle cell 
proliferation under cyclic strain. Mechanical strain was applied by cyclical 
application of a vacuum (up to 150mmHg) under the plates, to show DNA-labelled 
cells adhering, spreading and proliferating on ECM proteins (Wilson et al., 1995). 
The exact nature of the biomechanical effects of TNP on skin is not known. There 
have been no published studies to specifically evaluate the different mechanical 
effects of TNP therapy (shear stress resulting from fluid flow, direct compression 
or tensile stress) on normal skin or wound histomorphology or the type of 
mechanical loading (incremental, constant or cyclical). Instead, circumstantial 
evidence suggests that at a macroscopic tissue level, centripetal forces may act to 
draw skin edges together under the influence of mechanical creep. Equally, 
mechanical forces may be sensed intracellularly via the ECM or cell membrane 
directly to alter cell growth and proliferation. 
1.1.4 Topical Negative Pressure Therapy in Human and Animal Burn Wounds 
The relationship of blood flow patency to burn wound survival and the possibility 
that the ischaemia (and subsequent necrosis) observed in deep partial thickness 
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burns might be prevented from progressing deeper, has led to the suggestion that 
TNP therapy may provide a useful means of treatment of partial thickness burn 
injury (Morykwas et al., 1999a); see section 1.2.3. 
Morykwas et al. (1999a) conducted a series of experiments to determine whether 
TNP therapy might prevent progressive partial thickness burn injury. Partial 
thickness burns were created on porcine skin, and continuous TNP therapy, at 
pressures of 125mmHg, commenced either immediately or at delayed intervals of 
6,12,18, or 24 hours from the start of injury up to 48 hours later. They wanted to 
establish the maximal interval between burn injury and the application of TNP, 
which might prevent burn progression. A further group of pigs were burnt on both 
the right and left side in the same manner as before, but underwent TNP therapy 
for 6 hours and 12 hours respectively. This was performed to determine the 
minimum duration of TNP to prevent burn progression. On a daily basis, paired 
biopsies of control and TNP-treated partial-thickness burns were excised, paraffin- 
fixed and trichrome-stained for measurements of maximum depth of 'cellular' 
death using collagen denaturation as a histological marker. 
From the histological results of their study, they suggested that TNP-treated burns 
'totally re-epithelized by day 5' regardless of the onset of TNP therapy or its 
duration, whereas control wounds were only partially epithelialised, completely 
reepithelialising by day 9. 
Using depth measurements of collagen denaturation with the trichrome stain 
(which they described as a dark band of tissue), they determined that the 
maximum depths of cellular death for TNP-treated burns were 0.095,0.275,0.613 
and 0.738mm at 0,12,18 and 24 hours delayed treatment. The control wounds 
measured 0.885mm. The depth of cellular death for the 0 and 12 hour delayed 
wounds were significantly less than for the 18,24, or control wounds. These 
authors emphasised the importance of oedema as a critical factor in compromising 
dermal microcirculation, and suggested that by reducing the amount of denatured 
collagen in the TNP-treated wounds, this might reduce the oedema present in the 
skin, the removal of which would result in an increase in local perfusion. They did 
not provide any evidence to support this hypothesis. Furthermore, they suggested 
that colour changes in trichrome staining might be used as a marker of heat- 
denatured collagen (Chvapil et al., 1984), but the thermal energy necessary to 
denature collagen far exceeds that which may cause vascular occlusion or 
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irreparable cellular damage (Watts, 1998), so caution is required in using this 
technique for burn depth assessment. 
They also claimed that the number of inflammatory cells in the TNP-treated burn 
group was less, although they did not mention the types of inflammatory cells 
observed or provide evidence of this (Morykwas et al., 1999a). 
Banwell et al. (2000) randomised 32 partial-thickness skin burn experiments on 
pigs for TNP therapy or foam dressings alone. Microvascular blood flow dynamics 
were determined using laser Doppler scanning and dermal viability recorded by 
the number of tangential burn excisions required to reach healthy bleeding dermis. 
They showed significant increases in flux values (a measure of perfusion through 
the microcirculation) using the laser Doppler scanner at 48 and 72 hours 
compared to controls. The average number of burn wound excisions in the TNP- 
treated group (6.25 excisions) was also significantly reduced compared to the 
controls (14.9 excisions). They concluded from this work that TNP might reduce 
dermal ischaemia and preserve dermis in partial thickness burn wounds. 
Unfortunately, they did not support these finding with histological correlates 
(Banwell et al., 2000). 
No published studies have reported on the efficacy of TNP therapy in the 
treatment of partial-thickness burns in humans. 
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1.2 Pathophysiology of Cutaneous Wound Healing: The Role of Neutrophils 
1.2.1 Wound repair 
Wound healing is a highly regulated and complex interaction involving cells, 
extracellular matrix and soluble mediators, including growth factors and cytokines 
(Tarnuzzer and Schultz, 1996). Three overlapping phases of wound repair exist: 
(1) the inflammatory phase; (2) the proliferative phase; and (3) the 
maturation/remodelling phase. Problematic wound healing can occur following an 
imbalance between cellular proliferation and local degradative processes, which 
can lead to either excessive scarring (collagen deposition) or a delay in wound 
healing (due to extracellular matrix degradation) (Clark, 1996). 
1.2.2 Neutrophils in wound repair 
The non-specific inflammatory phase of wounding is characterised by the 
activation and recruitment of neutrophils followed later by monocytes. Neutrophils 
are the most common of all the circulating leucocytes (70%). Following injury, 
neutrophil numbers peak at 24 hours and then gradually fall in inflamed tissues 
(Slavin, 1996). Under normal circumstances, neutrophils disappear from the 
wound by 3 days (Mast and Schultz, 1996), most likely by apoptosis (Greenhalgh, 
1998). Neutrophil activation and recruitment is mediated by a large number of 
vasoactive mediators and chemotactic factors generated from the activation of the 
coagulation, complement and arachidonic acid pathways, and from injured or 
necrotic parenchymal cells within the damaged tissues (Clark, 1996). 
1.2.2.1 Complement components and related factors 
Complement products induce a range of neutrophil activation events, including 
polarization, chemotaxis, oxygen-free radical production, degranulation and 
upregulation of neutrophil adhesion molecules (Khan et al., 1996). Injured tissue 
activates the complement cascade and becomes coated in fragments of C3. The 
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role of C3b, in particular, is to facilitate attachment of neutrophils to objects coated 
with them. Neutrophils express complement receptors CR1 and CR3 
(CD11/CD18), which are required for opsonization of bacteria and cellular debris. 
C3a and C5a expression from the complement cascade are potent chemotactic 
agents for neutrophils into sites of tissue injury and upregulates the expression of 
neutrophil surface receptors, including CR1 and CR3. Increased levels of these 
anaphylatoxins are considered to regulate neutrophil function in the plasma of 
burned patients (Arturson, 1995). 
1.2.2.2 Cytokines 
Cytokines (including growth factors and interleukins) are soluble peptides, which 
mediate inflammatory events at low concentrations. A range of cell types produce 
cytokines, which behave in a complex autocrine and paracrine fashion to activate 
endothelial cells and leucocytes (Ravage et al., 1998), including neutrophils 
(Piccolo et al., 1999). The effects of individual cytokines are difficult to determine 
since multiple interactions between them affect their synthesis and clinical effects 
in diverse ways (Cohen and Cohen, 1996). 
Following any skin injury, the inflammatory phase is initiated by the release of 
PDGF, IGF-1, EGF and TGF-ß from platelet degranulation. TNF-a produced by 
damaged endothelial cells, keratinocytes and fibroblasts chemotactically draw 
inflammatory cells in to the wound (Mast and Schultz, 1996). Newly arriving 
neutrophils release additional growth factors following activation (Tarnuzzer and 
Schultz, 1996). Levels of active cytokines have been measured in both burn 
wound fluid (Ono et al., 1995b), donor site wound fluid (Ono et al., 1995a) and 
other surgical wound fluids (Tarnuzzer and Schultz, 1996). By direct sampling of 
wound fluid over time within the same wound using advances in assay technology, 
it is possible to measure the patterns of cytokine expression, which have provided 
insights into the roles these mediators play during the course of both normal 
(Dvonch et at., 1992) and poorly-healing wounds (Cooper et at., 1994). 
Neutrophils also secrete further pro-inflammatory cytokines (TNF-a and 
interleukins) to recruit more neutrophils and macrophages (Dubravec et al., 1990; 
Mast and Schultz, 1996). 
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1.2.2.3 Arachidonic Acid Metabolites 
Arachidonic acid (AA) is released from cell membranes following injury. The 
metabolism of AA results in prostaglandin production via the cyclo-oxygenase 
pathway or leukotrienes via the lipoxygenase pathway. These products activate 
neutrophils. A massive release of prostanoids occurs after burns, the commonest 
are prostacyclin (PGI2) and thromboxane A2 (TxA2). TxA2 is thought to be 
responsible for increase platelet aggregation and neutrophil margination and may 
be responsible for the decrease in blood flow in burn tissue. PGI2 is a potent 
vasodilator and accentuates the vascular permeability. Leukotrienes are produced 
by neutrophils, macrophages and vascular tissue and some are potent neutrophil 
chemoattractants. Their current role in burn injury is unclear (Youn et al., 1992), 
but may be involved in neutrophil adhesion or activation of Reactive Oxygen 
Species (ROS) and proteolytic enzymes (Smedly et al., 1986). 
The accumulation of leucocytes in inflamed tissue results from adhesive 
interactions between leucocytes and endothelial cells within the postcapillary 
venules of the microcirculation. An orderly sequence of events underlies the cell- 
cell interactions, which are mediated by specific adhesion molecules, and involves 
neutrophil rolling, adherence, and emigration (Granger and Kubes, 1994). These 
important processes have been uncovered by the use of in vitro binding assays of 
leucocytes to endothelial monolayers (using immunoneutralisation MoAbs), and in 
vivo using leucocyte-endothelial cell adhesion models (intravital videomicroscopy) 
and 'knock-out' mice (Panes et al., 1999). 
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1.2.3 Neutrophils in the pathophysiology of thermal injury 
Burns are classified according to the depth of tissue damaged (British Burns 
Association, 1996). In practice, burns usually exhibit areas of mixed depth. 
Epidermal burns are the most superficial burn and involve the epidermis alone. 
Healing occurs quickly within 7 days without treatment. Superficial partial 
thickness burns include the epidermis and upper (papillary) dermal layers of the 
skin. The blister is the hallmark of this burn. These burns heal with conservative 
treatment within 14 days from epidermal remnants within the base of sweat ducts 
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and hair follicles. Scarring is minimal. Deep partial thickness burns cause 
damage deeper into the reticular dermis. The clinical appearance of the remaining 
dermis is a blotchy red colour (fixed capillary staining), due to extravasation of 
haemoglobin from red blood cells leaking from damaged vessels. Pinprick 
sensation is reduced since a greater proportion of sensory nerves are destroyed at 
this deeper level of skin injury. Healing takes longer than 2 to 3 weeks and is 
characterised by residual scarring. Full thickness burns damage the entire 
thickness of the skin and may penetrate more deeply into underlying structures. 
Due to the loss of epithelial elements, the nature of healing can only occur by 
wound contraction and epithelial cell migration. Surgery is usually mandatory. 
Jackson (1953) described patterns of dermal blood flow in partial thickness burn 
wounds that mirror the clinical depths of burn injury. He described a burn wound 
as consisting of three concentric zones of decreasing degree of cellular injury: a 
zone of coagulation, a zone of stasis and a zone of hyperaemia (Jackson, 1953). 
He identified the middle 'zone of stasis' burns microscopically, observing that the 
capillaries were dilated and packed with red blood cells by four hours. He 
described a cessation of the circulation within the dermis, as the zone became 
progressively ischaemic and then necrotic over a period of 24 - 48 hours following 
burn injury (Jackson, 1953). This phenomenon of dermal ischaemia seen in some 
partial thickness burns, which become deeper over this time, has been noted 
clinically (Godina et al., 1977). Histologically, this secondary tissue loss is seen as 
necrosis within the zone of stasis, and occurs as a sequel to progressive vascular 
occlusion (Smahel, 1991). Zawacki et al. (1974) described how the progressive 
injury in the zone of stasis was reversible with the prevention of wound 
dehydration (Zawacki, 1974). 
Bränemark (1968) described the appearance of granulocytes during microvascular 
stasis in human burns as '... often rigid and may block the nutritive capillaries 
temporarily or even permanently. ' when observing these under light microscopy. 
He also observed the '... disruption of granulocytes with liberation of their granules 
into the lumen... ' which he suggested was significant in the development of tissue 
injury (Branemark et al., 1968). 
Boykin et al. (1980) studied the cutaneous microcirculation dynamically in the ear 
of a hairless mouse model following an experimental scald. He noted a zone of 
complete capillary occlusion, then partial zone of occlusion and then zone of 
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hyperaemia in these experimental cases that corresponded to Jackson's original 
descriptions. Furthermore, he also reported a 10-fold progression of complete 
capillary occlusion during the following 48 hours postburn. He observed sticking of 
leucocytes to the endothelium of post capillary venules causing partial occlusion of 
the vessels between 8 and 24 hours, although he never observed 'leucocyte 
sticking' as causing complete vascular occlusion. He suggested that the cause of 
this capillary occlusion was a combination of red cell aggregates, leucocyte 
adhesion to venular walls and platelet thromboembolism (Boykin et al., 1980). 
Tyler (1998) has observed neutrophil extravasation into surrounding tissues in 
partial thickness burns, which was apparent within 6 hours of burning and reported 
that neutrophil counts correlated directly with burn depth at 48 hours (Tyler, 1998). 
1.2.4 Evidence for neutrophils as mediators of burn depth progression 
Experiments that have excluded neutrophils from the burn environment by 
manipulation of the adhesion molecules that control their vascular transmigration 
have provided insights into the role of neutrophils in progressive dermal injury. 
Mileski et al. (1992) investigated the role of neutrophils in progressive 
microvascular injury following burns to rabbit skin. They used systemic 
monoclonal antibodies directed against the CD18 part of the adhesion complex 
(MoAb R15.7), and its endothelial ligand ICAM-1 (MoAb R6.5) given 30 minutes 
postburn. Using laser Doppler blood flow as an assessment of microcirculation, 
they demonstrated that both R15.7 and R6.5 resulted in improved microvascular 
blood flow during the following 72 hours. They concluded that blocking neutrophil 
adhesion to the endothelium with antiCD18 and anti-ICAM-1 improved 
microvascular perfusion in the marginal zone of stasis following thermal injury in 
this model (Mileski et at., 1992). 
Bucky et al. (1994) used a MoAb (60.3) directed to CD18 in a similar rabbit model, 
30 minutes following partial-thickness burns. They reported a reduction in burn 
surface area at 24 hours, and higher hair follicle counts and reepithelialisation at 8 
days compared to controls. They concluded that neutrophil adherence played an 
important role in progressive tissue destruction within 'zone of stasis' burns (Bucky 
et al., 1994). 
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Choi et al. (1995) administered a MoAb (M2) directed against CD11b following a 
brass comb burn that create unburned interspaces as a model of the zone of 
stasis, to monitor microvascular blood flow. Prevention of loss of dermal vascular 
flow in the interspaces was demonstrated by laser Doppler monitoring. Latex 
vascular casts revealed patency of vessels within the comb interspaces compared 
to controls. Histologically, neutrophil extravasation was blocked in the interspaces 
using this MoAb, with intraluminal and perivascular neutrophil counts significantly 
greater in the control groups. They concluded that by reducing or eliminating the 
infiltration of neutrophils into dermal tissues adjacent to a burn prevented delayed 
secondary necrosis (Choi et al., 1995). 
Mileski and colleagues (1996) repeated some of their experimental work in rabbits 
using MoAbs to L-selectin (Dreg 200) and CD18 (R15.7). The degree of 
neutrophil infiltration was recorded after immunohistochemical staining and 
matched to dermal blood flow assessed by laser Doppler. They showed that 
neutrophil accumulation was partially L-selectin dependent, but wound perfusion 
and tissue necrosis were unaffected. This contrasted with CD18, which improved 
perfusion and reduced tissue necrosis, but did not affect the degree of neutrophil 
infiltration when compared to controls (Nwariaku et al., 1996). 
Similar neutrophil-mediated tissue injury has also been demonstrated in skin flaps 
(Cetinkale et al., 1998) and ischaemic-reperfusion injury (Hernandez et al., 1987) 
and this damage has been prevented by a number of different anti-neutrophil 
agents including monoclonal antibodies (Hernandez et at., 1987) and 
immunosuppressive agents such as cyclosporin (CyA) and FK506 (Cetinkale et 
al., 1997; Cetinkale et al., 1998). 
1.2.5 Mechanisms of Neutrophil-mediated injury 
Neutrophil-mediated tissue injury following the activation of neutrophils at sites of 
inflammation has been implicated in a number of inflammatory diseases 
(Anderson et al., 1991). Neutrophils produce over 50 toxins, mainly reactive 
oxygen species (ROS) and proteases (Henson and Johnston, 1987). 
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1.2.5.1 Reactive oxygen species 
Free radicals are generated deliberately by neutrophils (Paty et al., 1990) to 
catalyse intracellular reactions and during the 'respiratory burst' in which oxygen is 
consumed during phagocytosis by activated cells, as part of their bactericidal role 
(Latha and Babu, 2001). However, the balance between normal free radical 
production and their endogenous scavengers can be lost; the local production of 
ROS is a common factor responsible for secondary tissue damage in ischaemic- 
reperfusion (IR) injuries (Welbourn et al., 1991) and burns (Latha and Babu, 
2001), with the neutrophil implicated as the primary source of ROS (Weiss, 1989). 
Cellular damage by ROS includes lipid peroxidation of cell membranes, disruption 
of intracellular organelle membranes, direct endothelial damage with increasing 
vascular permeability and inactivation of anti-proteases, which may lead to 
unopposed protease activity with increased cellular and ECM destruction 
(Kaufman et al., 1989; Latha and Babu, 2001). 
A number of investigators have provided evidence that ROS is implicated in the 
pathogenesis of progressive ischaemia in the zone of stasis in animal models 
(Cetinkale et al., 1997; Cetinkale et al., 1999; Choi and Ehrlich, 1993), although 
others have reported no significant effects (Dyess et al., 2000; Melikian et al., 
1987). 
Despite the role of neutrophil-derived ROS in cellular and tissue injury, these 
agents alone are not capable of reproducing all the events associated with tissue 
destruction and cooperation between proteases may enhance its effects 
synergistically (Ginsburg and Kohen, 1995). Indeed, Weiss (1989) forwarded the 
hypothesis that synergy might exist between proteases and ROS in neutrophil- 
mediated tissue injury. He described neutrophil-derived elastase in tissue 
destruction of connective tissue matrix and its activity, which could be greatly 
facilitated if its endogenous inhibitor al-protease inhibitor (al-PI) were destroyed. 
The hypohalous acid, HOCI, generated by the PMN myeloperoxidase-H202-halide 
system could destroy these inhibitors, thereby augmenting the effect of the 
protease on host tissues (Weiss, 1989). 
Ginsburg and Kohen (1995) have reviewed these concepts and have proposed 
that matrix proteolysis correlates more closely to the release of proteases from 
neutrophils than with the generation of ROS (Ginsburg and Kohen, 1995). 
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1.2.5.2 Neutrophil Proteases 
These proteases have the capability to degrade key components of the 
extracellular matrix (Weiss, 1989) and have been implicated in neutrophil- 
mediated endothelial cell injury (Ward and Varani, 1993). A review of leucocyte- 
derived proteases is discussed in detail in section 1.3 on page 42. 
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1.3 Neutrophil Elastase and its Inhibitors in Wound Healing 
1.3.1 Classification of Leucocvte Proteases 
Four distinct classes of leucocyte proteases have been identified by the 
biochemical mechanisms responsible for their catalytic activity. 
1.3.1.1 Serine Proteases 
Serine proteases are the largest class of mammalian proteases. Their activity is 
dependent on a catalytic triad consisting of residues Asp102, His57, Ser195 (Owen 
and Campbell, 1999). This family includes pancreatic trypsin, chymotrypsin, 
kallikrein, coagulation and complement proteases (plasmin, thrombin, PA), 
Neutrophil Elastase (NE), Cathepsin G (CG) and Proteinase 3 (PR3). Some 
serine proteases are synthesised as inactive precursors that require limited 
proteolysis to activate them. However, NE, CG and PR3 are notable exceptions 
because they are stored in an active form within neutrophil azurophilic granules 
(see Table 2 on page 45). 
The importance of serine proteases in physiological and pathological processes is 
underscored by the fact that the inhibitors of these enzymes (Serpins) comprise 
about 10% of all plasma proteins. The major class of Serpins (a, -protease 
inhibitor, ai-antichymotrypsin, a2-plasmin inhibitor, antithrombin III, plasminogen 
activator inhibitors, Cl inhibitor) are synthesised and secreted by hepatocytes, 
along with the universal inhibitor, a2-macroglobulin (Owen and Campbell, 1999). 
1.3.1.2 Meta I loprotein ases 
Metalloproteinases (MMPs) are dependent on intrinsic zinc ions for their catalytic 
activity. At least 20 different MMPs have been characterised (Parks, 1999); 9 of 
these are know to be expressed by leucocytes, and two (MMP-8 and MMP-9) are 
released from neutrophils. MMP-8 is capable of degrading collagens I, II, Ill, VII, 
X, gelatin, proteoglycans, bradykinin and substance P, and can degrade a, - 
protease inhibitor. MMP-9 degrades gelatin, collagen IV, V, VII, X, XI, fibronectin, 
laminin and elastin. The majority of MMPs are not secreted from cells in an active 
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form but require cleavage of their pro-forms (zymogens) into active enzymes. 
Latency of MMPs is maintained by the linkage between cysteine in the proenzyme 
domain and zinc at the catalytic site (Parks, 1999). 
Regulation of MMP activity occurs at the level of: (1) gene transcription, (2) 
activation of pro-forms, and (3) inhibition by inhibitors. MMPs are specifically 
inhibited by the naturally occurring tissue inhibitors of metalloproteinase (TIMPs), 
which are synthesised by connective tissue cells and leucocytes and form non- 
covalent complexes with MMPs. Four members of the TIMP family have been 
identified (TIMP-1, -2, -3, and -4) (Owen and Campbell, 1999). 
1.3.1.3 Cysteine Proteases 
Four human lysosomal proteases (Cathepsin B, H, L and S) are synthesised as 
proenzymes and are activated within lysosomes. Functioning at acidic pH, these 
enzymes play important roles in intracellular protein digestion, although they have 
been implicated in extracellular proteolytic events (Owen and Campbell, 1999). 
This class of leucocyte protease will not be discussed further. 
1.3.1.4 Aspartic Proteases 
Examples of aspartic proteases include Cathepsin D and E. Two aspartic acid 
residues are integral to their catalytic activities, which are functional at acidic pH. 
Cathepsin D has been shown to degrade proteoglycans extracellularly and is 
released by macrophages during the inflammatory response. This class of 
leucocyte protease will not be discussed further. 
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Table I Classification of Leucocyte Proteases 
Mechanism pH optimum Examples 






Metalloproteinases Neutral (pH 7-9) 





























Lysosomes of most cells 
Aspartic Proteases Acidic (pH 2-5) Cathepsin D Lysosomes of most cells 
Cathepsin E 
PMN : Polymorphonuclear cells, neutrophils 
The proteases of neutrophils are primarily formed during myelopoietic 
development and stored within a variety of granules. They can be classified 
according to their activities in antimicrobial defence, protease and phagocytic 
activities (see Table 2) (Borregaard et al., 1993). 
Neutrophil proteases can be released freely from neutrophil granules into the 
extracellular space: (1) during phagocytosis, (2) by exposure of neutrophils to 
immune complexes or opsonised substrates (e. g. bacteria) or (3) by 
pharmacological agents, experimentally. The contents of azurophilic granules 
may also be freely released from dead or dying cells (Owen and Campbell, 1999). 
Alternatively, exposure of neutrophils to cytokines and other chemoattractants can 
result in mobilisation of serine proteases (including NE and CG) to the external 
surfaces of the plasma membrane (Owen et al., 1995; Owen et al., 1997). 
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Table 2 Enzymes and other constituents of human neutrophil granules 
Granules 
) Specific (secondary) Small storage (tertiary) Constituents Azurophil (Primary 
Antimicrobial Myeloperoxidase Lysozyme 
Lysozyme lactoferr in 
Defensins 
Bactericidal/permeability- 
increasing protein (BPI) 
Neutral Neutrophil elastase 
proteases Cathepsin G 
Protease 3 
MMP-8 (Collagenase) MMP-9 (Gelatinase B) 
Complement activator Plasminogen activator 


















Janoff et al. (1968) provided evidence of a neutral protease from extracts of 
human neutrophil granules that exhibited elastin-degrading activity on vascular 
basement membranes at physiological pH in vitro and in vivo (Janoff and Zeligs, 
1968). They recognised the enzyme as an elastase (Janoff and Scherer, 1968), 
present in azurophilic (primary) granules of human neutrophils (Dewald et al., 
1975). The interest in Neutrophil Elastase (NE) at this time stemmed from its 
putative role in connective tissue damage (Janoff, 1972; Reilly and Travis, 1980) 
and its link to the pathogenesis of pulmonary emphysema (Janoff, 1985). 
NE (E. C. 3.4.21.37) is a 29.5 kDa cationic glycoprotein (Farley, 1992). Of the 
serine proteases, NE is regarded as quantitatively the most prominent and potent 
of all the neutral proteases (Senior and Campbell, 1983). The elastase content of 
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human neutrophils is quoted as being greater than 107 molecules/cell (Plow, 
1982). Thus, neutrophils contained in a single millilitre of blood can release over a 
microgram of NE. 
NE exists as four isoenzymes (Baugh and Travis, 1976) with sequence analysis 
showing that it is a single chain polypeptide of 218 amino acids containing the 
catalytic triad His-57, Asp-102 and Ser-195 common to all serine proteases (Sinha 
et al., 1987). The isoenzyme character of NE detected is due to minor differences 
in carbohydrate content. DNA sequence analysis has been performed to map the 
NE gene (Farley et al., 1989). Fouret et al. (1989) using in situ hybridisation 
studies has demonstrated that NE gene expression occurs at the promyelocytic 
and myelocytic stages of cell differentiation in the bone marrow. NE mRNA levels 
declined to undetectable levels by the stage of the neutrophil metamyelocyte and 
thereafter. This provides evidence that gene expression for NE is tightly 
controlled, with synthesis of NE occurring only in the bone marrow (Fouret et al., 
1989). Unlike the MMP's, there is no evidence for pro-forms (zymogens) of NE 
(Sinha et al., 1987) and it remains in an active form at a concentration of 2- 
4pg/neutrophil (10-12 mM) within the granules. After cellular activation, about 10- 
12% of the cellular content of NE rapidly translocate from the azurophilic granules 
to the external surface of the cell membrane (Owen et al., 1997). Using ELISA 
assays, human NE has also been discovered in the peroxidase-positive granules 
of a sub-population of monocytes (Campbell et al., 1989; Owen et al., 1994), 
which can be released in response to injury in much the same way as neutrophil- 
derived NE. The content of NE identified from monocytes compared to identically 
prepared neutrophil extracts was 6.2% (Campbell et al., 1989). Macrophages are 
known to internalise extracellular NE, which casts doubt on the true source. 
1.3.3 Physiological roles of Neutrophil Elastase 
NE is implicated in the hydrolysis and degradation of a number of extracellular 
matrix proteins including elastin (Werb et al., 1982), collagen type I (Kafienah et 
al., 1998), type 11 (Starkey et al., 1977), type III (Gadek et al., 1980); type IV 
collagen (Pipoly and Crouch, 1987) and laminin (Heck et al., 1990) in basement 
membranes; fibronectin (McDonald and Kelley, 1980), and proteoglycans 
(Malemud and Janoff, 1975). With such broad substrate specificities against 
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extracellular matrix components, NE may play a significant role in normal wound 
healing and remodelling (Senior and Campbell, 1983). Despite this, the exact 
physiological role(s) of NE in normal wound healing is not fully understood (Bieth, 
1986). Further biological activities of NE include the inactivation and activation of 
cytokines and growth factors, cleavage of plasma proteins, coagulation factors and 
complement components, and lymphocyte and platelet activation (Bieth, 1986; 
Owen and Campbell, 1999). An overview of these physiological roles is discussed 
below. 
1.3.3.1 Coagulation and fibrinolysis 
Allen and Tracy (1995) have demonstrated that NE bound to the cell surface of 
monocytes catalyses the activation of cofactor Va which itself binds to the 
monocytes surface and facilitates factor Xa-catalysed activation of prothrombin 
(Allen and Tracy, 1995). NE has been shown to cleave and inactivate inhibitors of 
coagulant proteases such as antithrombin III and a2-antiplasmin, which may 
facilitate local coagulation (Sie et al., 1987). NE can also potentiate platelet 
aggregation (Selak, 1992). Plow (1982) has suggested that NE may be a 
fibrinolytic enzyme, which can be released from neutrophils in association with 
coagulation (Plow, 1982). 
1.3.3.2 Neutrophil adhesion, chemotaxis and migration 
To undertake phagocytosis of cells and necrotic debris, neutrophils must exit the 
circulation and enter inflamed tissues. There is evidence that NE might play a role 
in the adhesion and migration of neutrophils from the circulation into sites of tissue 
injury during inflammation by modulating integrin-mediated cell adhesion. 
Zimmerman and Granger (1990) and Woodman et al. (1983) performed in vivo 
videomicroscopy animal experiments to study the role of NE and its specific 
inhibitors, Eglin C and L658,758 on neutrophil-endothelial cell interactions and the 
rate of neutrophil migration in inflamed tissues. Using direct immunofluorescence 
studies in vitro, Woodman et al. identified that NE induced the surface expression 
of CD11/CD18 integrin. These investigators proposed that NE might be involved 






In further support of a role for NE in mediating neutrophil-endothelial cell 
interactions, Remold-O'Donnell (1995) used flow cytometry to demonstrate that 
low levels of NE could specifically cleave CD43, an anti-adhesive surface 
glycoprotein present on neutrophils that acts to impede neutrophil adhesion to 
endothelial cells. Related azurophilic proteases (CG and PR3) failed to cleave 
CD43 (Remold-O'Donnell and Parent, 1995). 
In vitro, Cai et al. (1996) showed that NE bound specifically to CD11b/CD18 on 
neutrophils. They also demonstrated that the active (serine triad) site of NE was 
involved in the binding to the integrin by measuring the binding of NE to 
CD11b/CD18 in the presence of a number of serine protease inhibitors, including 
al-PI and the monoclonal antibody (MoAb), NP57. They provided evidence to 
show that NE might modulate neutrophil adhesion and migration since blocking 
NE with the MoAb NP57, prevented detachment, and reduced (by 40%) the 
chemotactic movement, of neutrophils from a fibrinogen-coated surface. This 
appears consistent with Woodman's and Zimmerman's interpretation that NE 
might regulate chemotaxis. Cai et al. (1996) were unable to establish whether NE 
retained its proteolytic activity when using its active binding site to ligate with 
CD11b/CD18 (Cal and Wright, 1996). 
Cepinskas et al. (1997) assessed the effects of a MoAb against NE and the 
elastase inhibitor, L658,758 on PAF- and fMLP-induced neutrophil transendothelial 
migration through HUVEC monolayers in vitro. They reported that both the MoAb 
and the inhibitor to NE completely inhibited neutrophil migration at low doses of 
PAF and formyl tripeptide (fMLP, a bacterial peptide analogue). They claimed 
these in vitro experiments were in agreement with the above in vivo work although 
similar in vitro work is in contrast with this view (Huber and Weiss, 1989). 
Nozawa et al. (2000) measured elastase activity using flow cytometry to 
demonstrate that the adhesion reaction between neutrophils and TNFa-activated 
HUVEC was dose dependently inhibited by ZD8321, a potent NE inhibitor 
(Nozawa et al., 2000). 
NE has be shown, in vitro, to degrade several components of the vascular 
basement membranes including collagen (Pipoly and Crouch, 1987), fibronectin 
(McDonald and Kelley, 1980) and laminin (Heck et al., 1990). Taken together with 
the above in vitro and in vivo studies, there is strong evidence to support the role 
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for NE during diapedesis, in which neutrophils could effectively 'digest' their way 
through the ECM following adhesion to the endothelial wall in inflammation. 
1.3.3.3 Antimicrobial properties 
Belaaouaj (1998) investigated the role of NE in host defence against bacteria in a 
strain of mice made deficient in NE (NE'). They showed that NE' mice were more 
susceptible to sepsis and death following intraperitoneal infection with the gram- 
negative bacteria (Kiebsiella pnemoniae and Escherichia Coli) than their normal 
littermate controls. They claimed that neutrophils migrated normally to sites of 
infection in the absence of NE, but suggested that NE may be required for 
intracellular killing by phagocytosis (Belaaouaj et al., 1998). Neutrophils and 
monocytes actively ingest cellular and matrix debris and foreign material into 
phagosomes, with both acid and serine proteases (including NE) degrading this 
material following fusion of the azurophilic granules with the phagosome (Owen 
and Campbell, 1999). 
1.3.3.4 Modulation of inflammation 
NE can modulate the recruitment of monocytes and leukocytes by inducing the 
release or activation of cytokines and growth factors from endothelial cells, 
epithelial cells and monocytes (Owen and Campbell, 1999), and by cleaving them 
into biologically active forms (Ariel et al., 1998; Coeshott et al., 1999). 
With respect to other proteases, NE has also been shown to activate MMP's 
(Delclaux et al., 1996; Ferry et al., 1997; Nagase, 1997), and inactivate TIMPs 
(Okada et al., 1988), resulting in an imbalance between MMP and TIMP (Itoh and 
Nagase, 1995). Despite evidence that NE has a regulatory 'down-stream' role on 
other proteases, the significance of this behaviour in a pathophysiological setting 
remains unclear. 
Trevani et al. (1997) have studied the effects of serine proteases on apoptosis. 
Stimulation of human neutrophil apoptosis was observed and quantified in culture 
in the presence of different concentrations of chymotrypsin, trypsin, and human 
NE under fluorescence microscopy and flow cytometry. They confirmed that 
proteolytic activity might be responsible for stimulating apoptosis, since the serine 
protease inhibitor aprotinin, abrogated the protease-induced apoptosis but they did 
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not test the use of a specific NE inhibitor to directly confirm a role for NE. They 
concluded that neutral proteases might have a physiological role in the normal 
resolution of inflammation (Trevani et at, 1996). 
The evidence that the physiological release of NE in tissues for proteolysis may be 
a controlled process is supported by work from Owen et at. (1995), who were the 
first to demonstrate that NE could be expressed on the cell surface of neutrophils 
(Owen et al., 1995). Using a number of pro-inflammatory mediators, these authors 
reported dose-dependent upregulation of catalytically active surface-bound NE 
using both immunofluorescence staining and immunogold localization in vitro, 
whilst unstimulated cells demonstrated minimal expression (Owen et al., 1995; 
Owen et at, 1997). Catalytic activity of cell-surface NE was confirmed by 
exposing these same stimulated neutrophils to soluble fibronectin in vitro. 
Fragments of fibronectin were determined on SDS-polyacrylamide gel 
electrophoresis (SDS-page). A specific inhibitor to NE (methoxysuccinyl-ala-ala- 
pro-val chloromethylketone, CMK) inhibited this behaviour. They also claimed that 
the catalytic activity of the bound NE persisted for at least 3 hours following 
activation in vitro (Owen et al., 1997). They also demonstrated that al-PI (the 
naturally occurring inhibitor to NE, with the highest reported association constant 
for an inhibitor with a protease) was ineffective as an inhibitor to the cell-surface 
bound NE. When testing other inhibitors of varying molecular sizes in the same 
system, they noted an inverse relationship between molecular size of inhibitors 
and their capacity to inhibit surface-bound NE. They concluded that steric 
hindrance was likely to be the major mechanism by which cell-surface bound NE 
evaded inhibition from al-PI (Owen et at, 1995). 
This work suggests that long-lived catalytically active cell-surface bound NE might 
be able to focus its powerful extracellular degrading capacity to facilitate neutrophil 
emigration through the vasculature as well as the penetration of tissue barriers, 
such as basement membrane (Delclaux et al., 1996), whilst at the same time 
evading endogenous inhibitors at a pericellular level (Campbell and Campbell, 
1988). This mechanism might explain how localised, physiological degradation of 
ECM proteins could be achieved with minimal injury or disruption to the 
surrounding tissues in normal growth and repair as well as modulate the functions 
of other cells, without inciting an inflammatory response through overt injury. 
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1.3.4 Pathological roles of Neutrophil Elastase 
Since NE is the major protease responsible for extracellular proteolysis mediated 
by neutrophils and that NE has broad substrate specificity, NE has been strongly 
implicated in neutrophil-mediated tissue injury (Döring, 1994; Owen and Campbell, 
1999). In the literature, there is a considerable amount of circumstantial evidence 
supporting the view that neutrophil-derived NE is implicated in inflammatory 
disease states and extracellular matrix degradation. NE and its imbalance with a, - 
PI have been historically associated with the development of pulmonary 
emphysema, cystic fibrosis, Adult Respiratory Distress Syndrome (ARDS), and 
Rheumatoid Arthritis, which have been extensively reviewed by Janoff (1985) and 
Bieth (1986). 
1.3.4.1 Neutrophil Elastase as a mediator of endothelial cell injury 
NE has been reported to play a crucial role in neutrophil-mediated endothelial cell 
injury and thus contribute to vascular injury (Nakatani et at, 2001; Smedly et al., 
1986; Westlin and Gimbrone, 1993). Nakatani et al. (2001) investigated the 
effects of a number of synthetic protease inhibitors (against the proteases trypsin, 
plasmin, kallikrein, thrombin and NE) on neutrophil-mediated human endothelial 
cell injury in vitro (Nakatani et al., 2001). Endothelial cell lysis was measured by 
the release 51Cr-labelled HUVEC following neutrophil priming with TNF-a. Of the 
serine protease inhibitors tested in this model system, only ONO-5046 (a specific 
synthetic inhibitor of NE) decreased HUVEC cytotoxicity compared to controls. A 
role for elastase in inducing endothelial cell injury was confirmed by incubating 
purified NE with stimulated 51Cr-labelled HUVEC. NE increased the % lysis of 
HUVEC in a dose-dependent fashion, which was further negated by ONO-5046 
(Nakatani et at., 2001). These results strongly implicated NE as a mediator of 
endothelial injury in vitro. 
Investigators have attempted to demonstrate a clear correlation between 
increased neutrophil-derived NE and the clinical course of a disease or injury, 
suggesting that increasing levels of NE might mediate the intensity of the 
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inflammatory process. A number of clinical studies have been published to 
evaluate whether plasma levels of NE might be a good marker for determining 
disease activity such as psoriasis (Orem et al., 1997), provide a predictor of MOF 
(Jochum et al., 1994; Nast-Kolb et al., 1997), post-operative marker of wound 
healing complications (Hofer et al., 1995) or a predictor of wound healing in 
chronic wounds (Hoffman et al., 1999). 
1.3.4.2 Evidence of direct Neutrophil Elastase-mediated tissue damage in skin 
In vitro studies have directly demonstrated structural epidermo-dermal damage 
caused by NE. Briggaman et al. (1984) removed split-thickness skin from human 
volunteers and subjected them to purified human NE for periods of 2-8 hours at 
concentrations of between 100 and 700nM, which might be found under 
physiological and pathological conditions in skin respectively. Using electron 
microscopy (EM), they noticed a decrease in the density of the lamina densa, 
within 2 hours compared to controls, which was absent by 6 hours. The lamina 
densa of blood vessels was also destroyed, which was not observed for other 
serine proteases. Distinctive epidermal-dermal separation was noted. 
Immunohistochemical staining of collagen type IV and laminin were absent which 
they suggested was an indication of profound dissolution of the basal lamina 
(Briggaman et al., 1984). 
A similar study was also performed confirming epidermo-dermal junction damage 
with widening of intercellular spaces and the disappearance of the basal lamina on 
EM (Glinski et al., 1991). 
Ludolph-Hauser et al. (1999) have demonstrated widening of the keratinocyte 
intercellular spaces under EM, in vitro, when NE was applied topically at 
concentrations as low as 3nM. The difference in this study was that the horny 
layer was tape-stripped to ensure penetration of NE through the lower 
keratinocytes, and the skin was cultured to remove contamination by serum- 
derived proteases inhibitors (Ludolph-Hauser et al., 1999). 
The exact local elastase concentration in skin during tissue injury is not known, but 
these studies at least demonstrate the directly damaging effects of NE on skin 
constituents. 
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1.3.4.3 Elevated Neutrophil Elastase in tissues of non-healing skin wounds 
Herrick et al. (1997) assessed the protease activity in wound tissue derived from 
chronic venous ulcers compared to control acute wound biopsies. Tissue extracts 
were obtained by homogenising the tissue samples in buffer solution before 
centrifuging the supernatant. They determined that the predominant protease 
responsible for fibronectin degradation (identified by fibronectin zymography) in 
both acute wound tissue extracts and venous ulcer tissue extracts was a serine 
protease, since this activity was abolished by AEBSF (a broad range serine 
protease inhibitor) but not by EDTA (a metalloproteases inhibitor). Immunoblotting 
studies using a specific anti-neutrophil elastase antibody confirmed that this 
protease activity seen on fibronectin zymography was NE. They also 
demonstrated that NE activity was upregulated in chronic wounds and acute 
wounds of aged subjects compared to acute wounds of younger subjects. 
Specifically, they showed that the NE activity increased from the surrounding 
"normal" skin to the ulcer base in the biopsies of chronic wounds in the same 
subject. This finding correlated with immunohistochemical staining for NE, 
showing that elastase staining was more prevalent in the ulcer base and edge 
than in the surrounding skin and present in greater quantities in acute aged 
subjects compared to younger controls. Since there were no age- or gender- 
related differences in elastase activity in circulating neutrophils and that the total 
number of neutrophils measured in the peripheral blood did not significantly vary 
with age, they suggested that the elevated elastase activity present in wounds was 
due to a greater number of neutrophils infiltrating the wound site (Herrick et al., 
1997). 
The actual mechanism by which NE might achieve neutrophil locomotion through 
the extracellular matrix remains unclear as well as the degree to which the 
presence (and action) of NE contributes to `normal' physiological or pathological 
inflammatory roles. 
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1.3.5 Inhibitors of Neutrophil Elastase 
1.3.5.1 Alpha -1 protease inhibitor 
Alpha-1 protease inhibitor (a, -PI), formally known as ai-antitrypsin, is a 51 kDa 
serine protease inhibitor (SERPIN) consisting of 394 amino acids and three 
carbohydrate chains that can diffuse readily throughout the interstitial fluids. It has 
a single active site at Met358 - Ser359 and is capable of binding avidly to serine 
proteases, most notably with NE (Jeppsson, 1996). 
The main production of a, -PI resides in the hepatocytes of the liver. Synthesis of 
a, -PI is increased (up to 4-fold) as part of the acute phase response, notably in 
inflammatory reactions and following trauma (Gabay and Kushner, 1999). 
Synthesis and storage of ai-PI has been confirmed in monocytes, alveolar 
macrophages and alveolar and intestinal epithelial cells (Jeppsson, 1996). 
Surprisingly, a1-PI gene expression, synthesis and secretion have also been 
demonstrated in neutrophils (Du Bois et at., 1991). Furthermore, Mason et at. 
(1991) carried out ultrastructural immunohistochemical double staining of 
neutrophils with antibodies directed towards NE and al-PI to reveal colocalisation 
within the azurophil (primary granules) of the cells (Mason et at., 1991). Pääkkö et 
at. (1996) used immunofluorescence microscopy with antibodies against al-PI on 
neutrophils, with CD3 double staining to delineate monocytes. They demonstrated 
al-PI in the cytoplasm of all neutrophils, with fewer staining in monocytes (Pääkkö 
et at., 1996). From the work by Du Bois and Pääkkö, neutrophil-derived al-PI may 
provide an important role in regulating the local release of NE following its 
activation. The current view is that the amount of al-PI synthesised, stored and 
released from neutrophils, alone, would not be large enough to overcome the 
massive tissue destruction by NE in vivo; instead, neutrophil-derived al-PI serves 
as a local modulator of neutrophil diapedesis or to provide protection from cellular 
leakage during phagocytosis. 
a1-PI is the predominant endogenous inhibitor to NE in plasma, capable of 
diffusing from the circulation into the interstitial space (Travis and Salvesen, 1983). 
An understanding of the role of a, -PI has been gained from observing patients with 
a, -PI deficiency, in which emphysema develops because of inappropriate and 
uncontrolled NE-mediated elastolytic lung injury (Janoff, 1985). Elimination of 
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extracellular NE occurs through the formation of a tight stable 1: 1 complex with al- 
PI, which is later removed and catabolised within the circulation (Carrell, 1986). 
Oxidative (Clark et al., 1981; Ossanna et al., 1986) and proteolytic inactivation 
(Michaelis et al., 1990; Zhang et al., 1994) of al-PI can occur. Beith (1986) 
reported that oxidation of al-PI resulted in a 2000-fold decrease in the inhibition 
rate for NE (Bieth, 1986), the implication being that an imbalance of protease/anti- 
protease would favour NE-mediated tissue destruction. 
In addition to its important protease inhibitory functions, al-PI has also been 
reported to influence neutrophil behaviour via both direct and indirect mechanisms. 
There is evidence that al-PI may be responsible for modulating the migratory 
capacity of neutrophils to sites of inflammation. Proteolytically modified al-PI 
(Banda et at., 1988b) and at-PINE (Banda et al., 1988a) complexes and can act 
as potent chemoattractants to neutrophils and may play a role in sustaining 
inflammatory responses at sites of tissue injury. 
1.3.5.2 Skin-derived antileukoproteinase (SKALP/ELAFIN) 
SKALP is a skin-derived protease inhibitor (Mr of 10 kDa and 20 kDa) with 
specificity for NE and PR3 (Schalkwijk et al., 1990). Others have coined the term 
ELAFIN to describe a similar (if not the same) Elastase specific inhibitor with a Mr 
of 6kDa (Wiedow et al., 1990). The kinetics of the inhibition of NE by ELAFIN 
suggests that it is a potent but fully reversible skin-derived inhibitor of NE (Ying 
and Simon, 1993). Whilst it is absent in normal human skin, SKALP/ELAFIN is 
strongly induced in inflammatory skin diseases (van Bergen et al., 1996). 
1.3.5.3 Secretory leukocyte proteinases inhibitor (SLPI) 
SLPI is another human NE inhibitor of between 10 and 14 kDa, which has been 
identified in peripheral blood neutrophils. Sallenave et al. (1997) assessed the 
anti-NE activity of SLPI from neutrophil cytoplasm to determine its activity in vitro. 
They suggested that the binding characteristics of NE/SLPI at a molar equivalence 
of 80: 67.8 (= 1.12) strongly supported the view that SLPI was the main active 
inhibitor of NE in the neutrophil cytoplasm. SLPI can also be secreted from the 
cells upon stimulation. Although al-PI is also present in neutrophils, Sallenave et 
at. (1997) claimed that it represented as little as 0.8% of the molar amounts of 
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SLPI, but they did not provide any data to substantiate this. They reported that 
ELAFIN was also present in neutrophil cytoplasm but at 0.05% of SLPI levels and 
suggested that both a, -PI and ELAFIN were unlike to be important contributors to 
the NE-inhibitory capacity of the neutrophil (Sallenave et al., 1997). 
Little is known about the functions of both SKALP/ELAFIN and SLPI, but they 
appear to represent a set of highly specific regulators of NE at the level of the 
neutrophil cytoplasm, whose function might be to protect the cell from NE leakage 
from the primary granules. In addition to this, skin-derived SKALP/ELAFIN has 
also been demonstrated within keratinocytes during wound healing but the 
functional significance of this has yet to be fully elucidated. 
1.3.6 The balance of NeutroDhil Elastase and inhibitors 
Owen and Campbell (1999) have reviewed the methods that might allow 
proteases to circumvent the effects of high-affinity protease inhibitors that are 
present in the extracellular space (Owen and Campbell, 1999). 
1.3.6.1 Inactivation of protease inhibitors 
Inhibitors can be inactivated by oxidative or proteolytic mechanisms (Reddy et at., 
1994; Weiss and Regiani, 1984). For example, MMPs can inactivate al-PI 
(Michaelis et at., 1990) and NE can inactivate TIMPs (Itoh and Nagase, 1995; 
Okada et at., 1988). Therefore, activated neutrophils might be able to create 
microenvironments in which extracellular proteolysis is facilitated via inactivation of 
inhibitors. 
1.3.6.2 Adherence and compartmentalization 
Neutrophil proteolysis can occur when cells are in direct contact with the substrate, 
despite the presence of protease inhibitors in the immediate pericellular 
environment (Campbell and Campbell, 1988). 
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1.3.6.3 Tight binding of protease to substrate 
In vitro studies have demonstrated that NE binds stably to elastin, and that a, -PI 
and Secretory leucoprotease inhibitor (SLPI) have reduced effectiveness against 
the catalytic site of NE when bound (Morrison et at., 1990). 
1.3.6.4 Membrane binding of proteases 
In contrast to NE and CG that are freely released from leucocytes, it has been 
shown that membrane-bound NE and CG demonstrate a resistance to inhibition by 
naturally occurring inhibitors (such as al-PI) (Owen et al., 1995). The mechanism 
by which this is achieved remains unclear. This work suggests that binding of 
proteases to the cell surface focuses and preserves their catalytic activity to the 
immediate pericellular environment, even in the presence of inhibitors. 
9.3.6.5 Overwhelming of inhibitors 
NE may overwhelm inhibitors by releasing massive quantities of enzymes from 
large numbers of persistently activated inflammatory cells (as in the case of 
rheumatoid arthritis, cystic fibrosis or abscesses, for example). Alternatively, high 
concentrations of NE may be released from individual cells. Liou and Campbell 
(1996) reported that quantum bursts of NE-mediated proteolytic activity occurs 
when neutrophils release their azurophilic granules following their adherence to, or 
migration on, opsonised matrix proteins. The brief catalytic activity exceeds the 
concentrations of local extracellular inhibitors until diffusion of the granule contents 
allows the ratio of NE: a1-PI concentration to drop to less than a 1: 1 ratio (Liou and 
Campbell, 1996). 
1.3.7 Neutrophil Elastase and extracellular matrix degradation 
The extracellular matrix (ECM) is no longer viewed as a supportive structure and 
physical barrier, but instead an active zone that functions to instruct cellular 
differentiation by initiating signal transduction pathways and controlling the 
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activities of cytokines and growth factors (Streuli, 1999). Therefore remodelling of 
the ECM during wound healing can have profound effects on its function and the 
behaviour of the cells that reside within it. 
Controlled degradation of the ECM is required for the removal of damaged 
components of tissue injury, dissolution of the basement membrane and to allow 
cell migration and angiogenesis (Clark, 1996). Neutrophil extravasation through 
the ECM during inflammation appears to be dependent on neutrophil-derived 
proteases (Murphy and Gavrilovic, 1999). 
Excessive destruction of ECM molecules by neutrophil-derived proteases has 
been implicated as a contributing factor in a variety of acute and chronic 
inflammatory states (Yager and Nwomeh, 1999), and the failure of wounds to heal 
(Falanga et al., 1995). For example fibronectin, which is an important ECM protein 
required for wound repair (Clark et at., 1982), appears very susceptible to NE 
degradation (McDonald and Kelley, 1980; Wysocki and Grinnell, 1990), the 
fragments of which can even induce the release of more elastase from activated 
neutrophils (Wachtfogel et at., 1988). 
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1.4 Wound Fluid Analysis in Wound Healing Research 
Wound fluid provides a useful means of understanding wound pathophysiology. 
The wound exudate is the medium in which wound repair takes place, the contents 
of which is believed to reflect the status of the wound (Falanga, 1992; Hunt, 1991). 
An assumption has been made that the biochemical composition of wound fluid 
represents the extracellular environment of the wound, and is supported by studies 
that have profiled electrolytes and proteins from paired wound fluid and serum 
taken from healing and non-healing chronic wounds and burns (Trengove et al., 
1996; Young and Grinnell, 1994). The wound fluid bathing the cells and 
extracellular matrix proteins within the wound environment provides a valuable 
source of quantitative information about the in vivo activities of different wounds at 
a local level. Analysis of wound fluids from acute and chronic wounds may identify 
different cell types, matrix proteins and their fragments, and biological factors 
(including growth factors, cytokines, proteases and their inhibitors), which either 
impair or facilitate wound healing (Tarnuzzer and Schultz, 1996; Yager et al., 
1997). Many wound fluid studies have been performed which aim to identify 
differences in wound constituents between acute and chronic wounds (Falanga, 
1992; Trengove et al., 1999), between different acute wound types (Baker and 
Leaper, 2000) and chronic wound types (Trengove et al., 1999). 
1.4.1 The significance of wound fluid analysis 
The wound fluid milieu can change rapidly over time, reflecting the dynamic 
changes between cell to cell, and cell to matrix interactions. Tarnuzzer and Shultz 
(1996) suggested that an impairment or imbalance in wound environments might 
promote and maintain the chronicity of wounds (Tarnuzzer and Schultz, 1996). 
Different investigations into the protease activities within wound fluid provide 
evidence that different proteases are participating at different stages of wound 
healing. The integrated, functional activities of proteins expressed (or not) within 
wound fluid might yield clues as to the factors responsible for healing or non- 
healing wounds. 
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Whilst biopsies may be homogenised for analysis of the tissue or cellular extracts, 
the technique of fluid extraction from biopsy material in wound healing research is 
limited because: (1) repeated biopsy sampling within the same patient precludes 
frequent sampling; (2) biopsy sampling itself might change the nature of the wound 
environment; (3) homogenised extracts of the cells and tissues may not provide an 
accurate reflection of the changing extracellular fluid environment; (4) careful 
standardization of the methods is required. Young and Grinnell (1994) have 
suggested that the analysis of the human wound environment using wound fluid 
provides information similar to that obtained when tissue is excised and analysed 
(Young and Grinnell, 1994). 
1.4.2 Methods and models used in wound fluid analysis 
Models can be classified into artificial material models (in which something is 
placed onto or into a wound) or tissue models (the wound can be created or 
manipulated for wound fluid collection; for example, blister wounds) (Gottrup et al., 
2000). A review of some of the more common methods by which researchers 
have collected or analysed wound fluid in vivo is described below. 
1.4.2.1 Chamber models 
A wire mesh chamber model placed subcutaneously into wounds becomes filled 
with wound fluid and connective tissue matrix components (Hunt, 1967). Reliable 
samples can be obtained from the wound chambers after seven days, and 
continuous sampling can be carried out for weeks and or months. The advantage 
of this model includes the frequent sampling of large quantities of tissue fluid and 
granulation tissue. Ehrlich et al. (1983) used a stainless steel mesh chamber to 
collect repeated fluid samples from experimentally induced burn and freeze 
injuries to the skin in rats (Ehrlich et al., 1983). Hurtenbach et al. (1995) have 
used a perforated 30 x 10 mm polytetrafluoroethylene (Teflon) tissue chamber 
implanted subcutaneously in mice to collect wound fluid following infection-induced 
inflammation (Hurtenbach et al., 1995). The disadvantages of these implanted 
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chambers are their size and the need for surgical placement and the irritant nature 
of the material used. 
Open wound fluid collection chambers is a common way of collecting wound fluid 
(Breuing et al., 1992; Marikovsky et al., 1993). Breuing et al. (1992) developed a 
surface wound chamber with a flexible transparent vinyl top bonded to an 
adhesive vinyl base (Breuing et al., 1992). Vogt et al. (1998) adapted Breuing's 
design to collect donor site wound fluid from humans (Vogt et al., 1998). The 
device was mounted on silicone sheets with a 15 x 15 mm opening directly onto 
the wound surface. After split-skin excision, the apparatus was placed onto the 
wound, and the chambers were filled with Normal Saline and sealed. After 24 
hours, the total fluid was aspirated and replaced with a further Saline. 
The problem with collecting chambers concerns the length of time the wound fluids 
or diluent fluid is left in situ. This might lead to problems of interpretation given 
that many of the constituents of wound fluid may breakdown or digest other 
endogenous factors (Egger et al., 1997). 
1.4.2.2 Subcutaneous tubes 
A subcutaneous implanted porous expanded polytetrafluoroethylene (ePTFE) tube 
can be implanted into the skin or wound using a trochar (Goodson and Hunt, 
1982). A standard tube of 90 to 120 µm porosity, with a 1.2mm internal diameter 
and 0.6mm wall thickness can be bought commercially. The tube allows for 
diffusion of gas and fluid through the device. It is commonly used to promote 
granulation tissue formation and for the study of collagen and inflammatory cells. 
The disadvantage is that it is less good for the study of early wound healing, and 
does not represent a good way of collecting fluid. Haukipauro et al. (1987) 
described the use of a silicone rubber device to collect up to 16 samples over 1-5 
days using this technique (Haukipuro et al., 1987). Despite this, there is a delay 
between fluid production and collection. 
1.4.2.3 Sponges 
The polyvinyl alcohol sponge model incorporates a sponge placed inside a 
perforated silicone tube (Diegelmann, 1986). Implanted using a needle and 
trochar technique, the model is minimally invasive and acceptable to patients. The 
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Cellstick® is a similar model which consists of a silicone material containing a 
viscose cellulose sponge implant, allowing fluid to exit the wound continuously, 
behaving much like a minor wound drain (Viljanto, 1976). The main advantage of 
these models is the suitability in studying wound fluid components in the early 
phase of wound healing. Inflammatory cells can also be collected. The 
disadvantages are the complicated interpretations of the results and the 
experience required for its use. 
1.4.2.4 Dressings 
Polyurethane adhesive dressings are common ways of trapping donor site wound 
fluid or chronic wound fluid (Grayson et al., 1993; Ono et al., 1995a). The problem 
with this technique is that the wound surface area from under the dressing is not 
standardised and the collection of wound fluid from under these dressings has to 
be taken after a period of some hours before a sizeable volume can be obtained. 
Other issues concern the frequency with which fluid collection is obtained. Some 
investigators have used methods to manually express wound fluid from dressings 
(Rao et al., 1995) or soaked them in buffered detergents (Hoffman et at., 1998) in 
order to collect their contents. Each technique may create discernible differences 
when measuring the activities of proteases from wound fluids. 
1.4.2.5 Drainage bottles 
Collection of acute wound fluids from operative sites (such as breast and 
abdomen) using drainage bottles under gravity or suction is widely reported in the 
literature (Nwomeh et al., 1999; Tarlton et al., 1997). Despite the ease of 
collection, significant disadvantages include the time taken before the sample is 
collected and stored, mixing over a number of hours, failure to collect over ice and 
the possible contamination by blood. 
1.4.2.6 Cutaneous microdialysis 
The microdialysis technique makes it possible to investigate the dynamic 
behaviour of compounds made up of smaller molecules in the environment of the 
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wound (Church et al., 1997). A typical microdialysis probe has an outer diameter 
of about 200µm, a wall thickness of 8µm and a molecular weight cut-off of 2 kDa. 
Whilst not a technique for collecting wound fluid per se, these probes can perform 
precise quantitative measurements of the concentration of substances (usually 
drugs or chemical mediators) in the immediate vicinity of the probe. The 
disadvantages are that large proteins cannot be measured given their size, the 
sample volumes are small and the cost of equipment and the expertise required is 
considerable. 
1.4.2.7 Miscellaneous methods 
Paloahti et at. (1993) collected chronic wound fluid exudates using blunt glass 
microcapillaries, but only small amounts of fluid could be retrieved for analysis 
using this method (Palolahti et al., 1993). Cooper et al. (1994) have used inert 
porous dextranomer beads placed in patient's pressure ulcers over 24 hours to 
recover endogenous growth factors from chronic wounds (Cooper et al., 1994). 
Ono et al. (1995) have directly aspirated fluid from blisters of human burns to gain 
insights into the make up of burn wound fluid constituents (Ono et at., 1995b). The 
problem with this is that usually only one sample can be collected from the wound 
site, which makes comparisons difficult within and between patients over time. 
1.4.3 Proteases and their inhibitors in wound fluid 
1.4.3.1 Protease and anti-protease profiles in acute wound fluid 
Moses et al. (1996) utilised SDS-PAGE, radiometric assays and Western blot 
analyses to determine the temporal pattern of appearance and activity of MMPs 
and their inhibitors during the healing process in a partial thickness wound model 
in four pigs over a 10 day period (Moses et al., 1996). They placed 1.2mls Normal 
Saline containing penicillin and streptomycin into an open wound chamber device 
described by Breuing et al. (1992). The fluid was retrieved every 24 hours and 
further fluid replaced. They observed no MMP activity in the first hour samples. 
The most prominent proteolytic activity, which was observed on each day, 
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migrated at 94 kDa on SDS-PAGE, consistent with the pro-form of MMP-9. They 
never observed active MMP-9 in any of their wound fluid samples. They 
suggested that the pattern of appearance is consistent with the time course of 
appearance of the inflammatory cells, neutrophils and macrophages that are 
known to store and release MMP-9 (Owen and Campbell, 1999). 
Tarlton et al. (1997) collected acute wound fluid (AWF) from the drains of 9 
patients undergoing surgery for mastectomy (for up to 96 hours after operation), 
and 9 patients after colectomy (from 24 to 120 hours after operation). Collections 
were obtained via sterile drainage systems over six time points. Using gelatin 
zymography, these authors reported the predominance of MMP-9 and MMP-2 pro- 
forms and a MMP-9 complex in their AWF, with no differences in levels between 
the two wound groups. The proMMP-9 levels peaked at 24 hours, which then fell 
significantly over the 96 and 120-hour time points. Interestingly, they found that 
proMMP-9 levels did not drop in infected mastectomy fluids, reaching 2.2 times 
greater than non-infected acute mastectomy fluid. Casein zymography was used 
to identify NE, with corroboration of identification using both PMSF (a serine 
protease inhibitor) and elastatinal (a specific NE inhibitor). No activated MMP-2, 
MMP-9 or NE was detected in normal acute drain wound fluids using these tests 
(Tarlton et at., 1997; Tarlton et at., 1999). 
Further evidence suggesting that latent MMP-2 and MMP-9 are elevated in acute 
human wound fluid compared to plasma has been derived from a number of 
studies of post-mastectomy and post-abdominoplasty or post-hernia drainage 
fluids (Agren et al., 1998; Bullen et al., 1995; Wysocki et al., 1993; Yager et al., 
1996). The major problem with studies that involve surgical drainage fluid is that 
the wound fluid comprises a mixture of blood, serum, lymph and inflammatory 
exudate from muscle and subcutaneous tissue, which is unlikely to resemble 
dermal wound interstitial fluid and so results of these cases have to be interpreted 
with a degree of caution with respect to human dermal wounds. Despite this, all 
these studies showed that the amount of MMP-9 (predominantly derived from 
neutrophils) was relatively higher than MMP-2 (secreted mainly from fibroblasts), 
which is consistent with the established pattern of large numbers of neutrophils in 
both wounds and wound fluid obtained during the early inflammatory phase 
following wounding. 
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Nwomeh et at. (1998) examined exudates from under occlusive film dressings 
covering full-thickness skin biopsy sites in 20 healthy human volunteers. Exudate 
fluid was collected on days 1,2,3,4,7 and 8. Using ELISA kits for MMP-1 and 
MMP-8 (which is almost exclusively derived from neutrophils) they demonstrated 
quantitatively more MMP-8 than MMP-1 (up to 200-fold) in these wounds, with 
peak levels of MMP-8 in dermal exudates occurring on day 4, and peak MMP-1 
levels on day 7. They argued that their data, showing significantly increased 
levels of MMP-8, reflect the numbers of neutrophils in the wound at this time 
(Nwomeh et al., 1998). 
Nwomeh et al. (1999) compared MMP-1 and MMP-8 levels taken from the same 
cutaneous wound fluid exudates (n=20) with acute surgical wound fluid taken from 
drains of patients (n=4) who had undergone either mastectomy or myocutaneous 
flap reconstruction procedures. At each corresponding time point (days 1,2,3,4,7 
or 8) and using the same ELISA assay, they found that the levels of both 
collagenase were significantly lower in surgical drain fluids than in fluids collected 
from healing dermal wounds. Again, regardless of wound type, MMP-8 was at 
least 100-fold higher than MMP-1 at all time points (Nwomeh et al., 1999). This 
study clearly highlights the limitations when comparing the same wound fluid 
constituents from different acute wound fluids (such as dermal exudate and 
drainage fluid from surgical wounds). 
Bullen et al. (1995) analysed AWF taken from 5 drains of patients following 
mastectomy every 12 hours for up to 10 days post surgery. Gelatin zymography 
and immunoprecipitation identified relative changes in the temporal profiles of 
MMP-2 and MMP-9. MMP-9 was consistently greater throughout the 10 days but 
gradually dropped over this time. TIMP-1 levels were also measured and found to 
increase 10-fold over the first two days among the five patients studied. Hence, 
the ratio of MMP-9 to TIMP-1 rapidly decreased in acute wound fluid, which they 
suggested might represent a shift in the wound environment from one favouring 
tissue turnover to one favouring matrix deposition (Bullen et al., 1995). 
Some studies have measured the activity of the serine proteases in AWF and 
compared them to chronic wound fluids (discussed in section 1.4.3.2 below). 
However, three studies are worthy of mention. 
Rao et al. (1995) collected AWF (n=4) from under occlusive dressings covering 
donor site wounds and from breast suction drains, and quantified the NE activity. 
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NE activity was comparable to normal human serum samples, but remained 
significantly lower than chronic wound fluid samples (see below) (Rao et at., 
1995). 
Yager et at. (1997) measured the NE activity from AWF (n=10) taken from the 
drains of 5 patients following abdominoplasty. They also found that the NE activity 
levels were comparable to plasma levels but remained significantly lower than the 
NE activity of chronic wounds (see below) (Yager et at., 1997). 
Weckroth et at. (1996) collected AWF from six donor site wounds on the operation 
day, and postoperative days 3 and 5. They provided evidence suggesting that 
both NE and CG activity was greater than serum and chronic wound fluid. 
However, they clearly demonstrated that AWF showed remarkable variation 
between their six patients, with rapidly changing activities of both serine proteases 
between different postoperative days (Weckroth et at., 1996). 
1.4.3.2 Protease and anti-protease profiles in chronic wound fluid 
The protease profile of chronic wound fluid (CWF) has been studied extensively 
over the last 10 years in an attempt to understand the pathophysiology of chronic 
wounds. An interest in studying CWF was fuelled by the discovery that the 
mitogenic activities of acute and chronic wound fluids differed (Bucalo et al., 1993; 
Katz et al., 1991) and that wound fluid samples from chronic wounds were found 
to contain degraded adhesion proteins (Wysocki and Grinnell, 1990), indicating 
that the wound environment might contain active proteases. Attention has focused 
on the discovery of increasing amounts of neutrophil-derived, matrix-degrading 
enzymes present in CWF that are released into the wound environment following 
activation of neutrophils during wounding. Recent studies suggest that the main 
groups of protease include the metalloproteases, MMP-1 and MMP-8 (Nwomeh et 
at., 1999), MMP-2 and MMP-9 (Bullen et at., 1995; Wysocki et al., 1993; Yager et 
al., 1996), and the serine proteases, Plasmin (Palolahti et al., 1993), and NE 
(Grinnell and Zhu, 1996; Hoffman et al., 1998; Rao et at., 1995). These papers all 
reported greater protease levels in chronic than acute wound fluids, although 
these findings are not universal (Trengove et al., 1999; Weckroth et al., 1996). 
Concomitant studies have also shown that linked to their respective proteases, the 
presence of both TIMPs (Bullen et al., 1995; Nwomeh et al., 1999; Trengove et al., 
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1999) and a1-PI (Grinnell and Zhu, 1996; Rao et al., 1995; Yager et al., 1997) in 
CWF were reduced or degraded when compared to AWF. 
With particular reference to NE, Rao et al. (1995) analysed the activity of elastase 
retrieved from 10 chronic ulcers and compared them to AWF (from donor sites or 
drains following mastectomy). CWF samples contained 10- to 40-fold more 
elastase activity than AWF or serum. Immunoblot analysis of these CWF samples 
revealed that fibronectin and al-PI were degraded in 9 out of 10 samples, but were 
intact in all the AWF samples. Furthermore, they suggested that MMPs were not 
responsible for fibronectin degradation in their chronic wounds, since incubation of 
the fluids with fibronectin in the presence of EDTA (a potent inhibitor of MMPs) did 
not prevent the appearance of specific fibronectin fragments. Following incubation 
of fibronectin in the presence of CWF samples accompanied by a number of 
serine-, cysteine-, and acid-protease inhibitors, they discovered that fibronectin 
degradation was completely inhibited by PMSF (a specific inhibitor of serine 
proteases) only. Given the elevated levels of elastase present in their CWF 
samples, they suggested that it was this serine protease that was responsible for 
fibronectin degradation. They supported this with further evidence demonstrating 
that the degradation of fibronectin by their CWF proteases was indeed inhibited by 
al-PI and not by other SERPINS (Rao et al., 1995). 
Grinnell and Zhu (1996) examined fibronectin degradation and NE levels in wound 
fluid sampled longitudinally from 3 patients with venous ulcers. CWF was 
obtained at weekly intervals over a period of four weeks, obtained after a 4-hour 
period under occlusive dressings. AWF comparisons were made with mastectomy 
fluid. These authors noted that fibronectin degradation patterns were unique to 
different patients, and that this was occurring locally since fibronectin was intact in 
paired plasma samples taken from the same patient. They demonstrated that 
elastase activity was elevated in all the wound fluid samples that contained 
degraded fibronectin, with little detectable elastase activity found in those samples 
that contained mostly intact fibronectin. Moreover, they demonstrated a close 
correlation between the presence of elastase activity and the appearance of 
fibronectin fragments in CWF. Despite high levels of MMP-9 profiles present in 
these same CWF samples which also appeared to correlate with fibronectin 
degradation, specific elastase inhibitors (ICI 200,355 or MDL 27,367) as well as 
the general serine protease inhibitor AEBSF, blocked the ability of their CWF to 
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degrade fibronectin. On the other hand, the meta I lop roteinase inhibitor, EDTA, 
had no effect. Grinnell and Zhu also performed experiments to determine if the 
inhibitors a2-macroglobulin and dj-PI were present in their ulcer wound fluid. They 
showed both of these inhibitors had undergone significant cleavage in those same 
samples that contained fibronectin fragments. In vitro, increasing concentrations 
of human NE was added to acute mastectomy fluid and fibronectin and gelatinase 
profiles of this AWF determined. In the absence of NE, fibronectin was intact and 
elevated levels of MMP-9 and its complexes were evident. With increasing 
concentrations of NE, fibronectin was completely degraded and interestingly MMP- 
9 appeared to be cleaved from its proenzyme form. When NE was incubated with 
mastectomy fluid in the presence or absence of EDTA (to block MMP activity), the 
pattern of fibronectin degradation was similar. These results also implicate wound 
fluid Elastase as the dominant protease in fibronectin degradation in CWF, which 
appeared to regulate MMP-9 activity too. The drawback with this study is that only 
3 patient CWF samples were analysed (Grinnell and Zhu, 1996). 
Although definitive evidence directly implicating NE as the dominant protease 
present in CWF falls short in these studies by Rao et al. (1995) and Grinnell et al. 
(1996), the circumstantial evidence is compelling. They also provide evidence that 
an imbalance of NE and its potent endogenous inhibitor, al-PI, is present in CWF 
which may contribute to the enhanced NE activity noted, since Rao et al. (1995), 
Grinnell et al. (1996) and Yager et al. (1997) all confirmed that al-PI was degraded 
in these fluids compared to AWF controls. 
1.4.3.3 Protease and anti-protease profiles in burn wound fluid 
In contrast to CWF, studies that have examined proteolytic activity in human burn 
wound fluid are few. There is evidence that the NE activity in blood samples 
following burn injury is increased sharply (Miskulin et al., 1978; Neely et al., 1992), 
that this is proportional to the extent of the burn (Barisoni et al., 1991; Neely et al., 
1988; Ozkan et al., 1988), and that an imbalance with al-PI has been noted 
(Faymonville et at, 1987). There is also evidence to show that protease activity in 
burn tissue is increased compared to unburned skin (Neely et al., 1997; Stricklin 
and Nanney, 1994). 
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The paucity of data available on burn wound fluid may be due to the practical 
difficulties of collecting the fluid from burn wound surfaces. MMP activity has been 
noted in burn wound fluid (Grinnell et al., 1993; Grinnell et al., 1998), especially 
that of MMP-9, consistent with neutrophils as the initial source of this enzyme 
(Young and Grinnell, 1994). Serine proteases have also been identified (Grinnell 
and Zhu, 1994; He et al., 1998). 
Grinnell and Zhu (1994) provided the most recent literature on NE in burn wound 
fluid. They analysed wound fluids from 11 patients who had either superficial or 
deep partial thickness burns or full thickness burns using zymography, 
immunoblotting studies and a human NE activity assay. One burn wound fluid 
sample was taken from each patient from between days 1 to 8 by trapping burn 
fluid under a sterile glove over a 4-hour period. Compared to paired plasma 
samples, which contained intact adhesion proteins, all the burn fluids had 
evidence of fibronectin or vitronectin degradation in variable amounts, with 
particularly large amounts of degradation in three cases. Using zymography, all 
burn wound fluids contained proteases (MMP-9 and MMP-2), the highest levels 
corresponding to the three burn wound fluids with the greatest fibronectin 
degradation. However, when they performed the NE activity assay on the same 
three burn wound fluids, they also showed high elastase activity. 
Using protease inhibitors to block fibronectin degradation, they demonstrated that 
the protease activity was blocked most effectively using AEBSF (the broad 
spectrum serine protease inhibitor) with degradation being unaffected by o- 
phenanthroline or EDTA (MMP inhibitors), or by the serine inhibitor aprotinin or 
leupeptin (trypsin class of serine protease blockers). From this work, they 
suggested that elastase or the chymotrypsin class of serine protease (like CG) 
might be primarily responsible for fibronectin degradation. 
In vitro, samples of fibronectin were then added to the burn wound fluids shown 
previously to have excessive fibronectin degradation, along side purified human 
NE as a control, and demonstrated similar fibronectin degradation profiles, which 
they suggested was consistent with NE as the primary protease causing 
fibronectin degradation in human burn wound fluid. This finding is also consistent 
with reports that have described the ability of NE to degrade fibronectin in vitro 
(McDonald and Kelley, 1980). 
69 
In order to rule out CG as a possible contender, they compared fibronectin 
degradation by elastase and CG and wound fluid in the presence of specific NE 
inhibitors (ICI 200,355 and MDL 27,367) or chymostatin (inhibitor of chymotrypsin- 
related serine protease, CG). The results showed that the activity of the protease 
responsible for burn wound fluid fibronectin degradation was blocked by NE 
inhibitors but not by the CG inhibitor. Indeed, fibronectin degradation profiles with 
synthetic NE in the presence of the same inhibitors matched those of burn wound 
fluid. In other experiments, a series of fluid samples from one burn were 
incubated with polyclonal antibodies against human NE and tested for fibronectin 
degradation. They reported that addition of the anti-NE antibody completely 
neutralised fibronectin degradation by NE or burn wound fluid but had no effect on 
fibronectin degradation by CG. 
Finally, after attaching fibroblasts on to fibronectin-coated cell culture dishes, they 
applied burn wound fluid which caused the fibroblasts to round up and stop 
spreading, an activity that could be neutralised by the NE inhibitors (ICI 200,355 
and MDL 27,367). 
From this detailed work, these authors concluded that NE was the most likely 
protease responsible for fibronectin degradation in burn wound fluid (despite the 
presence of active MMPs and other serine proteases) and that its presence in 
burn wound fluid was able to interfere directly with fibroblast adhesion to 
fibronectin. The high elastase activity measured in the burn wound fluid samples 
could not be detected at all in the corresponding plasma, which they interpreted as 
suggestive of local production and release of active NE from migrated neutrophils 
(Grinnell and Zhu, 1994). 
Unfortunately, much of this work was focused on just three out of the 11 (one-off) 
burn wound fluid samples in light of their marked protease activities and fibronectin 
degrading profiles. They did not explain why the pattern of protease activity on 
fibronectin degradation was not universal to all fluid samples, but they did concede 
that differences might be because of (or a combination of) different classes of 
enzymes. 
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1.4.4 Considerations and cautions in wound fluid analysis 
The biochemical characterization of wound fluid can be difficult to interpret. The 
exact composition depends on the mode of injury, the wound itself, and the 
collection technique (Falanga, 1992). It is essential to standardise the methods 
and storage of fluid collection, for this will have a direct impact on the composition 
of the fluid. Although peripheral blood samples were used as an example, Egger 
et al. (1997) demonstrated the variability of NE measured in samples of 5 patients, 
which were subjected to differences in storage time, temperature and agitation. 
They reported significant increases in NE measurements with time (5 minutes to 
24 hours) and concluded that in order to obtain reliable results from PMN 
functional tests, processing of samples should occur within 20 minutes after blood 
withdrawal (Egger et at., 1997). 
in some of the studies discussed above, there were clear discrepancies in the 
collection times of wound fluid samples both between and within the same 
patients. This is likely to have a significant bearing on the quantification of the 
results. The type of acute wound fluid used in comparative studies with chronic 
wound is also important. Nwomeh et at. (1999) highlighted the limitations of using 
drainage bottles from acute surgical wounds in cutaneous wound healing 
research, since they demonstrated significant differences in MMP-1 and MMP-8 
profiles in fluids from both mastectomy or myocutaneous flap reconstructive 
procedures compared to acute dermal wound fluid retrieved from under occlusive 
dressings covering full thickness biopsy sites. MMP activities were significantly 
more pronounced in the dermal wound fluid group. Therefore, in comparative 
cutaneous wound healing studies, caution is required taking AWF samples from 
sub-dermal or deep fascial drains as opposed to fluids taken from under acute 
cutaneous wounds, when compared with CWF samples from the skin (Nwomeh et 
al., 1999). The sensitive assays employed for identification and quantification may 
contribute to the observed variability and confounding results noted between 
studies, hence the importance to perform these tests in the same batches 
(Staiano-Coico et al., 2000). 
A single sample of wound fluid does not give a useful indication of the influence of 
proteases present on the wound healing process; multiple collections need to be 
easily reproducible and validated within each collection model (Stacey and 
Trengove, 1999). Caution is required when comparing fluids between patients 
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with age-matched, sex-matched and site-matched variables taken into 
consideration (Stacey and Trengove, 1999). Different cell types secrete many of 
the same growth factors and cytokines at different times, and maybe with differing 
roles (Staiano-Coico et al., 2000). 
There are also difficulties maintaining control over the variables that exist within 
the wound bed and the patient's condition might complicate studies on human 
wound fluids. There is still great difficult in determining which factors present in 
wound fluids are causative to either active or inactive healing processes, or simply 
a reflection of that improved or impaired process. 
It is also important to highlight that in many of these studies (some of which do 
lack sizeable numbers), there appeared to be significant patient-to-patient 
variability in protease activity and patterns of protease degradation in CWF (Bullen 
et al., 1995; Grinnell et al., 1992; Trengove et al., 1999; Wysocki et al., 1993; 
Yager et al., 1997). Grinnell and Zhu (1996) suggest that since the overall 
patterns of fibronectin degradation were similar for all the wound fluid samples 
taken from each patient, but very different from one patient to the next, the 
variability is with the ulcer itself and not the time at which the fluid sample is taken. 
Yager et al. (1997) also comment that any variability in protease activity noted in 
ulcer fluids, for example, may simply be a reflection of ulcers that are in different 
phases of healing or non-healing (Yager et al., 1997). 
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1.5 Summary of Literature Review 
TNP therapy is the application of a sealed foam dressing into or onto a surface 
wound which is under the influence of topical subatmospheric pressure. TNP has 
been used in the treatment of a heterogeneous group of acute and chronic 
wounds over the last 10 years, but is less well described in the treatment of burns. 
An accepted foam dressing and controlled subatmospheric pressure machine 
(V. A. C. TM) has been commercially available for 7 years. 
Despite numerous case reports and larger clinical series, there has been a paucity 
of randomised controlled clinical trials to test the efficacy of TNP on wound 
healing. Large, properly randomised, inter-patient clinically controlled trials are 
currently in progress. Much of the difficulty in studying the effects of TNP in 
human cutaneous wound healing stems from the inherent problems surrounding 
the selective application of TNP therapy on an open, exudative wound surface, 
which up to now has not been achievable in the same patient. To establish and 
maintain negative pressure within the foam dressings the whole wound surface 
and surrounding dry skin needs to be sealed. This precludes the selective use of 
TNP therapy on adjacent wound sites in intra-patient controlled conditions when 
testing its efficacy in wound healing. 
The mechanisms of action of TNP therapy in wound healing appear to be 
multifactorial. TNP increases blood flow and has been shown to improve skin flap 
survival experimentally. Granulation tissue formation in TNP-treated wounds is 
prolific. There is evidence for a reduction in bacterial colonisation in inoculated 
experimental wounds. An attenuation of interstitial fluid and the removal of 
substances (including proteins and inflammatory cells) from TNP-treated wounds 
have also been proposed following experimental conditions but has not been 
confirmed in human wounds. There is circumstantial evidence to support a 
mechanical role implicating TNP in wound healing. Despite these proposed 
mechanisms, there is very little objective evidence in the literature to directly 
support these claims and the significance of each of these individual factors 
remains undetermined. The role of TNP therapy in the treatment of burns has not 
been examined extensively and there are no published accounts of its effect on 
human burn injury. 
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Neutrophils are the most prominent of the inflammatory cells that enter wounds 
following injury to the skin. With the progression of local burn wound inflammation, 
local and systemic mediator production increases. The relative roles of these 
mediators both directly and through neutrophil-mediated events in normal and 
burn wound healing, remain to be fully determined. 
Following burn injury, capillaries are progressively occluded in a zone emanating 
from the point of greatest trauma. Preceding this is a zone of reduced blood flow, 
which becomes static over a period of 24 to 48 hours. This zone of stasis is 
reversible and consequently the progressive dermal necrosis is potentially 
preventable. There is evidence that the migration of activated neutrophils into the 
zone of stasis of partial thickness burns may play an important role in the 
progression of dermal ischaemia. Blocking neutrophil access into burn tissue is 
associated with improvements in dermal vascular blood flow when observed in 
animal models. Neutrophils are capable of releasing massive amounts of 
oxidants, arachidonic acid metabolites and proteases; supporting the role of 
neutrophils as central mediators of progressive ischaemia noted in partial 
thickness burns. 
Neutrophil-derived proteases have been implicated in the aetiology of difficult-to- 
heal wounds such as chronic wounds and some burn wounds. Evidence suggests 
that the most potent of these proteases might be NE. Elastase is implicated in a 
number of physiological processes in wound healing including the emigration of 
neutrophils into sites of tissue injury and the breakdown of extracellular matrix 
proteins to aid tissue repair. Pathological tissue destruction can occur when the 
proteolytic activities of NE by neutrophils is excessive, inappropriate or prolonged, 
although the mechanisms by which this is established are not fully understood. 
Endogenous inhibitors, the largest and most important of which is ai-PI, tightly 
controls elastase activity. Unregulated protease activity may mediate extracellular 
tissue damage in a number of acute and chronic inflammatory wound states, and 
may be caused by an imbalance between NE and a, -Pl. 
Wound fluid provides a valuable opportunity to understand the temporal activities 
of the extracellular environment of healing and poorly healing wounds. To 
examine the protease/anti-protease hypothesis more closely, investigators have 
measured the relative temporal ratios of proteases and their inhibitors in wound 
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fluid. A number of methods of collecting wound fluid have been described; the 
most suitable of which depends on the type of wound under investigation, the 
frequency and amount of fluid required. The current literature suggests that the 
levels and activities of proteases measured in wound fluids are elevated in both 
healing and non-healing wounds compared to normal skin. There is corroborative 
evidence from these studies that some MMPs and serine proteases may play a 
significant role. Furthermore, the majority of these active, elevated proteases are 
primarily, if not exclusively, of neutrophil origin. 
The analysis of wound fluid collected from acute and chronic wounds is being 
increasingly used as an investigative tool in wound healing research. However, 
standardisation in the methods of wound fluid collection and storage is mandatory 
if correct temporal interpretation is to be made. Quantitative analysis of wound 
fluid parameters using intra-patient controlled studies may provide a more 
accurate means of addressing this problem. 
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2 HYPOTHESIS AND STUDY AIMS 
Hypothesis: Topical Negative Pressure alters the acute wound environment 
Four study chapters are presented in this thesis. The aims of each study chapter 
are laid out below. 
Chapter 3: The design of a Topical Negative Pressure Device for selective 
subatmospheric pressure therapy on human dermal wounds 
This study describes a new method of applying selective TNP to unwounded 
human skin and acute human dermal wounds. The application of two TNP 
designs is described, one of which can be utilised as a research tool to collect 
wound fluid. The second part of this chapter is concerned with validating this new 
model both in vitro and in vivo. 
Chapter 4: Temporal analysis of Total Protein in wound fluid under the influence of 
TNP following partial thickness dermal injury 
The `irrigation' TNP device described is used on acute human donor site wounds 
and acute partial thickness burn wounds to assess the effects of TNP therapy on 
the constituents of wound fluid, measuring Total Protein as a marker. 
Chapter 5: Histological investigation into the effects of Topical Negative Pressure 
therapy on neutrophils and their distribution in partial thickness dermal wounds 
A histological study is conducted to determine whether TNP can directly influence 
neutrophil numbers and their distribution in acute dermal wounds by 
immunohistochemical comparisons of TNP-treated and control-treated sites. 
Chapter 6: The influence of Topical Negative Pressure therapy on the temporal 
analysis of Neutrophil Elastase activity and a-1 Protease Inhibitor in wound fluid of 
human donor site and partial-thickness burn wounds 
Neutrophil Elastase and its endogenous inhibitor, a, -PI, are assessed under the 
influence of intermittent TNP therapy. The aim is to demonstrate a relative 
temporal profile of both the protease activity and its inhibitor and to establish 
whether the protease/anti-protease ratio can be modulated by intermittent TNP 
therapy. 
76 
3 The design of a Topical Negative Pressure Device for selective 
subatmospheric pressure therapy on human dermal wounds 
3.1 Introduction 
The contribution of Topical Negative Pressure (TNP) to human wound healing has 
been demonstrated in a number of individual case reports and uncontrolled clinical 
series. An understanding of the mechanisms by which TNP facilitates wound 
healing remains unclear, yet the evidence suggests that this is likely to be 
multifactorial. 
There is a paucity of published work describing the effects of TNP against 
concurrent patient controls. Human skin is unique and varies according to age, 
sex, race and region of the body. Some wounds are also heterogeneous in 
behaviour. To determine true differences in the effects of TNP, an ideal study 
would apply TNP therapy to part of the same wound with an adjacent area treated 
as a control. 
The use of a sealed foam dressing on exudative acute and chronic wounds 
determines that the whole wound surface must be covered hermetically, to ensure 
that negative pressures are maintained. For this reason, there is no good method 
of testing TNP therapy against standard treatments, in intra-patient controlled 
human trials. 
Hence, a new approach is necessary. To simplify this problem, a design construct 
is required that might allow one aspect of a wound surface to be treated with TNP 
independently of an adjacent site. In this way, the creation and maintenance of a 
discrete subatmospheric pressure system might allow comparable testing of TNP 
versus controls, and provide ways of exploring its mechanism(s) of action. 
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The aim of Study One was as follows: 
1. To design a TNP device that could be applied selectively to an open, acute 
dermal wound surface. 
2. To create within the design, an opportunity to frequently and reliably collect 
wound fluid using an irrigation system over a designated wound surface 
area 
3. To validate the newly designed TNP devices and provide evidence for its 
efficacy 
4. To test the safety of the new device on normal skin and acute wounds 
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3.2 Materials and Methods 
Any novel construct, designed to provide TNP to a wound surface for subsequent 
studies, required certain criteria to be met (see Table 3). 
Table 3 Criteria required in the design of a TNP device 
1. A device that would mimic standard TNP therapy in the clinical setting 
2. Manufactured easily on-site, within the hospital, at minimal cost 
3. Manufactured and stored, prior to its use in an elective or emergency setting 
4. Robust and reliable enough to allow subatmospheric pressure therapy over a 48-hour period 
5. Used on, and surrounded by an exudative wound surface 
6. Not move from its original site of application once the therapy is commenced 
7. Not move from its original site of application despite turning the suction device off during therapy 
8. Utilises standard VACT"" dressings, which are the most widely used and accepted clinically 
9. Ensure sterility to the wound surface 
10. Physically safe and harmless to use on an open wound surface 
11. Not create discomfort over and above that tolerated using standard dressings in clinical practice 
For the purposes of wound fluid analysis, further criteria would need to be met 
(see Table 4). 
Table 4 Criteria required in the design of a TNP device for wound fluid collection 
1. Allow for surface wound fluid collection within a specified TNP site under investigation 
2. Allow for reliable and frequent wound fluid sampling over a 48-hour time period 
3. A system that would not interfere with the post-operative day-to-day medical and nursing care 
4. Retrieval of fresh wound fluid directly for immediate centrifugation and storage at JOT 
The following TNP devices were designed and constructed at the Stoke 
Mandeville Burns and Reconstructive Surgery Research Trust at Stoke Mandeville 
Hospital. Some of the materials used in the construction were adapted from 
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commercially available dressings manufactured by Kinetic Concepts, Inc. (KCI)1, 
Dorset, UK. In order to measure the effects of TNP on normal or wounded skin, a 
system of sponge 'containment' was required. A foam dressing placed within a 
fixed outer wall can be established by using a ring design. 
A 'standard' TNP device was designed to exactly mimic the normal application of 
the VACTM dressings supplied commercially. An 'irrigation' TNP device was also 
designed to enable wound fluid collection. 
3.2.1 The design of a standard TNP device 
The first prototype ring created, utilised the top 1.5cm and expanded flange of a 
plastic beaker. A second prototype ring was made from the top 1.5cm of a 40mm 
and 60mm diameter GalipotTM (Warwick Sasco Ltd. UK). A 9.5mm diameter hole 
was drilled through the sides of the plastic rings and a protective polyvinyl chloride 
(PVC) grommet with an internal diameter of 6.0mm placed within it (Farnell 
Electronics, Ltd. ). See Figure 1 on page 82. 
Sterile, medical-grade, PUE foam of a standard thickness (3.2cm) can be cut into 
a circular shape to fit inside the rings. 
An evacuation tube with drainage holes at the distal end (the same tubing 
available in the standard VACTM dressing pack provided by KCI) is placed within 
the PUE foam and exits the ring device through the PVC grommet (see Figure 2 
on page 82). 
An adhesive transparent dressing (available in the VACT"" foam dressing packs) 
loosely seals the 'sponge-in-ring' construct, to mimic the standard application of 
TNP dressings to wounds. The evacuation tubing is attached to a VACTM pump 
via the canister provided. Sub-atmospheric pressure, pre-set by the operator, is 
then regulated by the VACTM pump as required. In this fashion, the sponge can 
1 All the work described in this thesis remained independent of KCI, Ltd. 
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collapse unhindered within the firm outer plastic ring, whilst under the influence of 
negative pressure. 
A significant problem, created by the use of such a device, concerns the pressure 
effects imposed by the base of the ring directly onto the skin or wound surface. 
Whilst under sub-atmospheric pressure, a protective material was necessary to 
prevent pressure ischaemia caused by the base of the ring. In addition, the 
material used must also have sterile, semi-adherent properties that would ensure 
that a seal could be maintained throughout the duration of a study (up to 2 days). 
Furthermore, it was important to make sure that the whole device could be 
removed as necessary for observations or measurements of the wound surface as 
required. 
Tested with the device on normal skin, the first protective material used was 
VarihesiveTM Wafers (Convatec Ltd., UK. ); a hydrocolloid product designed for use 
in stoma care. 100x100mm sterile wafers can be cut to fit the base of the 
prototype ring designs described, and is shown in Figure 3 on page 82. 
The protection afforded by the hydrocolloid dressing was shown in testing, both on 
normal skin and subsequently on acute dermal wounds, to fail over a period of 12 
hours. Firstly, as the hydrocolloid takes up fluid, it swells and distorts under the 
application of sub-atmospheric pressure. The base of the ring becomes visible 
and pressure marks become apparent on the skin surface (see Figure 17 on page 
94). The second difficulty was that the TNP device could not be removed from the 
surface of the wound for inspection without disrupting the hydrocolloid base. 
Thirdly, as the TNP device was to be adapted later to include an irrigation port for 
wound fluid collection (see section 3.2.2), the collection of fluid samples would 
likely to be contaminated with proteins present in the material (including gelatins) 
from the dissolving hydrocolloid base padding. 
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Figure 1 Prototype ring designs with holes and PVC grommets in situ 
0 
Figure 2 Polyurethane foam is cut to fit inside the ring device, the evacuation tubing 
placed within the foam which exits through the ring as shown 
Figure 3 Construction of TNP device with a hydrocolloid base dressing 
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The above problems concerning protection to the skin during TNP therapy were 
overcome by the use of a sterile flexible polymer sheet (Dermal Pad TM, Spenco 
Healthcare International Ltd. ) The 10cm x 10cm sheet with a thickness of 3mm 
was glued directly onto the base of the GalipotTM ring design using LoctiteTM 
adhesive glue. A hole was then cut from inside the ring (see Figure 5 on page 85). 
The TNP device was constructed in the same fashion with the outer adhesive 
transparent dressing sealed to the blue ring itself. 
This new protective base dressing conferred the following advantages. 
A. The `tacky' quality of the dermal pad allowed for adherence to the skin or 
wound without a direct adhesive nature to it. A film of fluid between wound 
and dermal pad also helped to establish a seal if necessary 
I 
B. The Dermal Pad TM dressing does not distort or breakdown 
C. It would now be possible for the TNP device to be removed at any stage of 
a study to inspect, measure or biopsy the TNP-treated wound. The same 
device could then be replaced 
An example of the final TNP design is shown in Figure 4 below and Figure 6 on 
page 85. Testing on normal skin and a number of different acute wound surfaces 
demonstrated that the most suitable device involved the 40mm and 60mm 
diameter galipotTM ring systems. 
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Figure 4 Schematic diagram of standard TNP device 
tion off 





Figure 5A 40mm diameter plastic ring is glued to the polymer pad and a hole cut within it 
Figure 6 The TNP devices under suction on the author's right thigh. The foam collapses 
down on to the skin unimpeded by the surrounding outer ring. The smaller ring 
(40mm diameter) within the dermal pad can be used over convex surfaces as 
shown 
Figure 7 Irrigation tubing, with holes in the tubing, within the lower chamber of the 
irrigation TNP device 
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3.2.2 The design of an irriaation TNP device for fluid irriaation and collection 
The above design was adapted to enable the collection and analysis of wound 
fluid regularly every few hours as necessary. Normal Saline irrigant fluid (0.9% 
w/v Sodium Chloride, B. Braun Medical Ltd, Sheffield, UK. ) was instilled into the 
foam within the device and the diluted wound fluid present within the system could 
then be collected. To ensure that Normal Saline bathed the surface of the wound 
directly, it was necessary to incorporate a lower circular foam chamber (adjacent 
to the wound surface), separated from an upper circular foam chamber by a 
perforated film barrier. The purpose of a perforated barrier was to contain the fluid 
for a specified period at the wound surface before being sucked away under the 
influence of negative pressure. 
A TNP ring and polymer pad was constructed as described above. Irrigation 
tubing with holes along the distal 3.5cm was placed within the ring through the 
PVC grommet (Figure 7 on page 85). 
A 1.6cm thick circular piece of PUE foam was cut to fit inside the ring. A 6cm x 
7cm transparent film dressing (TegadermTM, 3M Healthcare, Canada) was placed 
over the foam and sealed to the blue outer ring. Four 1.5cm perforations were 
made in the transparent dressing 0.5cm from the edge of the ring (as shown in 
Figure 8 on page 87). Placement of these perforations peripherally was performed 
to ensure that the fluid instilled into the lower chamber had to traverse the wound 
surface before being taken up by the foam in the upper chamber above. 
Circular PUE foam of a standard thickness (which was also used in the standard 
device described in section 3.2.1) was placed over the lower chamber and an 
evacuation tube, with similar distally based holes, positioned within it. The upper 
chamber and evacuation tubing was sealed as before (Figure 9 on page 87). 
After application of 125mmHg subatmospheric pressure to the upper evacuation 
tubing, the upper circular foam (in continuity with the lower foam) collapses down 
onto the skin. The dermal pad itself is not directly under the influence of suction 
(Figure 10). 
86 
Figure 8 Construction of the lower chamber using 1.6cm thick foam and a transparent 
dressing sealed to the edges of the ring. Note the 1.5cm perforations at the 
periphery of the TegadermTM dressing 
Figure 9A TNP irrigation device showing the irrigation tubing entering through the ring 
(right) and the evacuation tubing exiting from the sealed upper foam (left) 
Figure 10 The irrigation TNP device under 125mmHg negative pressure on normal skin. 
The dermal pad is not under the direct influence of suction 
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The volume of the foam in both the small and large irrigation TNP devices were 
calculated and displayed in Table 5. The volume of foam used in the small 
irrigation TNP device is half that of the larger device. 
Table 5 Volume of foam in the two sizes of irrigation TNP device 
Small irriization Laree irritation 
TNP device TNP device 
Internal diameter of ring 5.8cm 8.2cm 
Area within ring 26.42em 52.81 cm 
Height of upper foam chamber 3.2cm 3.2cm 
Height of lower foam chamber 1.6cm 1.6cm 
Total height of foam 4.8cm 4.8cm 
Volume of foam 127cm 254cm 
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Figure 11 Annotated schematic drawing of the irrigation TNP device. 
Evacuation tubing to VAC pump 
Outer ring glued to dermal pad 
skin surface 
Irrigation tubing placed through the 
grommet into lower foam chamber 
. --- 
Outer rim design containing 
the polyurethane foam construct 
Tegaderm1Mfilm barrier with four 1.5cm 
(pink dotted line) perforations at edge of 
outer ring device 
Upper foam enclosed within the 
transparent film dressing 
, Perforated film barrier (green) 
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3.2.3 Validation studies on the TNP devices 
The following studies were performed on normal skin or on the laboratory bench to 
validate their use as alternatives to the use of V. A. C. TM dressings. 
3.2.3.1 Subatmospheric Pressure Measurements 
Polyurethane foam, of identical volume to the foam within the TNP devices, was 
sealed under standard V. A. C. T"' dressings on one normal leg. The TNP devices 
were placed on the contralateral leg. Subatmospheric pressures set at 125mmHg 
were applied to both the standard VACTM sealed dressing and the TNP devices 
(see Figure 12 on page 91). Subatmospheric pressure readings were established 
using a pressure gauge calibrated on air (Budenberg, Manchester UK. Courtesy 
of Bioquell Plc, Andover, UK) attached to a needle probe placed within the foam 
(see 
Figure 13 on page 91). Pressure measurements were recorded directly within the 
foam from the following devices (and where necessary from each individual upper 
and lower chamber) compared to the standard VAC" control dressings in the: 
1. Small (40mm diameter) standard TNP device 
2. Large (60mm diameter) standard TNP device 
3. Small Irrigation TNP device 
4. Large irrigation TNP device 
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Figure 12 Testing the small TNP device against the standard VACTM dressing technique 
Figure 13 Needle probe placed within the upper chamber of the small TNP device whilst 
under negative pressure of 125mmHg 
Figure 14 The pressure gauge at -0.16bar with the VACTM pump set at a subatmospheric 
pressure of 125mmHg 
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3.2.3.2 Dermal blood flow studies of normal skin measured using laser Doppler 
The assessment of subatmospheric pressure on dermal blood flow using the TNP 
device was required for the following reasons: 
1. to establish whether the lower foam in the TNP irrigation device uniformly 
distributed a suction effect to the skin surface, by assessing spatial changes 
in skin microcirculation 
2. to determine whether there was any alteration in dermal blood flow under 
the rim of the ring with or without the use of a protective dressing 
3. to determine whether the effects of TNP therapy on dermal blood flow 
extended beyond the TNP device 
Measurements of dermal blood flow can be achieved by using Laser Doppler 
Perfusion Imaging (LDPI, Moor Instruments, Ltd., Axminister, UK). The laser 
Doppler scanner comprises a 2-mW helium-neon laser mounted behind 
photodiodes and lenses. In principle, laser light is directed onto tissues such as 
the skin by a mirror that is moved in a controlled fashion using a stepper motor. 
Back-scattered light from moving blood and surrounding tissues is detected by 
photodiodes, and processed to produce images and values of perfusion using the 
Doppler principle. From this, blood flow can be measured in terms of flux (a 
quantity proportional to the product of the velocity of blood cells and their number 
concentration). The values can be expressed in arbitrary 'perfusion units'. A 
scanning depth of up to 3mm can be obtained. 
The flux is measured and displayed as a 6-colour scale image directly on a 
portable laptop computer. The coloured pixels correlate to the blood flux (flow) 
within the dermis; red indicating high flow and blue, low flow. Purpose-built LDPI 
software provides mean perfusion units +/- standard deviation (SD). Additionally, 
the LDPI also produces a concomitant 16-scale grey 'photographic' DC image of 
the area undergoing scanning. This image is derived from the unprocessed light 
intensity reflected from the skin surface back to the photodetector. The DC and 
flux image is matched pixel for pixel that provides an accurate anatomical map. 
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3.2.3.3 Bonney's Blue dye testing 
The irrigation TNP device as described in Figure 11 on page 89, was designed so 
that irrigant fluid can be instilled into the lower foam chamber and after a specified 
period, the fluid can be drawn away into the upper foam chamber via the four 
1.5cm perforated cuts made in the TegadermTM film dressing, whilst under suction. 
The following test using Bonney's blue dye (Man Med, Bucks, UK) was performed 
for the following reasons: 
1. to determine the distribution of blue dye over the surface of the skin 
2. to establish whether the blue dye is seen to extravasate beyond the 
boundaries of the ring design 
Bonney's blue dye tests were performed on both the large and small irrigation TNP 
devices using both the hydrocolloid base and SpencoTM dermal pad designs. 
The protocol used in all of these tests is shown in Table 6. 
Table 6 Protocol for dye testing in irrigation TNP device 
I. Bonney's blue dye was diluted in Normal Saline (1: 4 dilution) 
2. 2mls of the blue irrigant fluid was instilled via a three-way tap into the irrigation tube with the VACTU 
pump switched off and the foam normally expanded 
3. 2mis of air was instilled into the lower irrigation tube over 5 seconds to ensure that all of the fluid 
was within the lower chamber and not lying in the irrigation tubing 
4. A sterile universal container (Sterilin, Ltd., UK) was attached to the upper evacuation tube, which 
was connected to the VAC*"" pump 
5. After 1 minute, the VACTM pump was switched on, the foam dressings collapsed and the blue dye 
was collected within the universal container 
6. The device was switched off and the foam dressings expanded again to the resting position 
7. The procedure was repeated every 2 minutes up to 10 occasions before the device was removed 
from the skin and photographs taken 
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Figure 15 Large TNP irrigation device with hydrocolloid base on a granuflexTM dressing. 
(a) suction off and (b) suction on. Note the collapse of foam chambers and the 
blue dye collecting in the fluid trap when TNP therapy is commenced 
Figure 16 Large irrigation TNP device with hydrocolloid base under suction on author's 
lateral right thigh with Bonney's blue testing. Note the red laser dot on the 
upper foam that is in position for scanning from the LDI above (not shown). 
Figure 17 Removal of small irrigation TNP device following dye testing at 120minutes. 
Note the visible (now unprotected) blue rim of the device and the skin imprint. 
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3.2.3.4 Radiopaque dye testing 
To establish a real time view of the distribution of irrigant fluid within the TNP 
device during instillation, Urograffin® contrast was used under radiological 
imaging. In vitro testing of the irrigation TNP device was performed in the 
Department of Radiology, Stoke Mandeville Hospital on both large and small TNP 
device attached to a GranuflexTM base or dermal pad using the protocol outlined in 
Table 6 on page 93. Video footage recorded both instillation of contrast dye and 
washout Normal Saline in an anterior-posterior and lateral view. 
3.2.3.5 Fluid volume measurements on normal skin 
The following tests described below were performed on dry, normal skin for the 
following reasons: 
1. to determine the optimum volume of Normal Saline irrigant fluid that could 
be used in the small irrigation TNP devices for use during subsequent 
clinical experiments 
2. to establish whether there was any evidence of pooling of fluid within the 
foam of the TNP device over the test period, despite application of 
125mmHg subatmospheric pressure 
Using the small irrigation TNP device, a number of tests were performed to 
determine the volume of irrigant fluid that could be used to ensure that fluid could 
be reliably retrieved through the system. 
Three irrigant fluid tests were performed every ten minutes for up to 2 hours each 
using a different small TNP device. 2mls of Normal Saline was instilled through 
each device as described in the Bonney's Blue dye tests (see Table 6). The 
volume of irrigant fluid collected over the first minute was recorded; followed by the 
volume collected over the subsequent 9 minutes. These tests were performed on 
different days. 
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3.2.4 Testing the safety of the new devices on normal skin and acute wounds 
The above validation tests on unwounded skin, using both the standard and 
irrigation TNP devices, were evaluated for safety and compliance. Testing the 
effects of the irrigation devices on open wounds in a clinical setting was carried out 
in conjunction with subsequent studies described later in this thesis. The patients 
described in section 4.2.2 were seen at variable times following their wound 
treatment with TNP therapy. The wounds studied included the acute donor site 
wound and partial thickness burn wound. 
It was important to evaluate in these patients: 
1. the effects of the TNP device on wounds undergoing TNP treatment 
2. the safe use of the TNP device on acute wound surfaces 
3. the risk of wound healing complications 
4. patient compliance 
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3.3 Results 
3.3.1 Standard TNP device 
The design of the standard TNP device has been described. The validation of this 
device is documented below. This device was not used further in this thesis. 
3.3.2 Irrigation TNP device 
The irrigation TNP device has been described and further evaluated in the 
validation tests documented below. This device is used in the following chapters 
of this thesis. 
3.3.3 Validation studies on the TNP devices 
3.3.3.1 Subatmospheric Pressure Measurements 
Pressure readings taken during these tests gave identical results of -0.16bar +/- 
0.02bar (which equates to a subatmospheric reading of approximately 120mmHg). 
There was no evidence of pressure differences between the standard VACTM 
dressings and TNP devices. Furthermore, there were no differences between the 
different sized TNP devices, or between the lower and upper chambers within the 
irrigation TNP devices. 
3.3.3.2 Dermal blood flow studies of normal skin measured using Laser Doppler 
The scanned laser Doppler image of the skin surface is presented along side a 
concomitant photographic image of the same area. 
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The results of initial laser Doppler tests of a standard TNP device with no 
protective skin padding or barrier, was scanned as shown in Figure 18 on page 99. 
The flux image shows a circle of high flux (red colour) corresponding to the base of 
the unprotected rim, as noted in the corresponding photographic view. 
Furthermore, in the centre of the suction, patches of green and blue identify an 
area of lower flux. This suggests that the pressure effects imposed by the base of 
the outer ring device may influence the dermal blood flow within the device as well 
as directly under the unprotected rim. 
The results of LDPI scanning of the first standard prototype device using the 
hydrocolloid dressing show that the hydrocolloid pad provided some protection to 
the skin, in that a mild 'halo' effect was seen on the flux image after 1 hour of TNP 
therapy (see Figure 19 and Figure 20 on page 99). The photographic image in 
Figure 20 shows the circle of normal skin directly under the influence of TNP as a 
slightly raised area. The corresponding flux image demonstrates that the area 
under the hydrocolloid dressing may also be influenced by TNP therapy as shown 
by the red, yellow and green colours. 
Results using the small standard TNP device and small irrigation TNP device with 
the SpencoT"" dermal pad as rim protection are shown in Figure 21 and Figure 22 
respectively. A uniform circle of enhanced flux can be recorded which 
corresponds to the area of foam contact in both the devices tested with no 
evidence of a `halo' effect seen, even after 5 hours of suction. The distribution of 
flux extends a few millimetres beyond the ring boundary when compared to its 
corresponding photographic image taken at the same time using the LDPI. 
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Figure 18 DC and flux image of author's left sided chest after 5 minutes of TNP therapy at 
125mmHg using the small blue ring device without skin pressure protection 
(scan distance: 32cm) 
Figure 19 DC and flux image of normal left thigh skin before application of small standard 
TNP device. The black marker pen marks the outer boundary of the hydrocolloid 
protective dermal pad (scan distance: 37cm) 
Figure 20 The same DC and flux image as shown above after 1 hour of TNP therapy at 
subatmospheric pressure of 125mmHg (scan distance: 37cm) 
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Figure 21 DC and flux image of right calf skin using the small standard TNP device, blue 
ring and SpencoTM pad for 5 hours at subatmospheric pressure of 125mmHg. 
The device is identical to that shown in Figure 6 (scan distance: 40cm) 
Figure 22 DC and flux image of left sided chest skin using the small TNP irrigation device, 
blue ring and SpencoTM pad for 30 minutes at subatmospheric pressure of 
125mmHg. The device used is identical to that shown in Figure 10 (scan 
distance: 30cm) 
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Statistical analysis, using the LDPI software on the results of Figure 21 and Figure 
22, is shown in Table 7 below. Each pixelated colour represents a perfusion unit 
(PU), which corresponds to dermal blood flow in that area. The PU values in the 
table represent the blood flow within the three surfaces under investigation using 
the small standard TNP device and the small irrigation TNP device. By drawing 
around the areas noted in the photographic image using the software provided, 
perfusion units were measured: 
i. directly under the TNP device 
ii. under the SpencoTM dermal pad alone 
iii. beyond the pad on surrounding normal skin 
Table 7 Perfusion units (PU) measured directly under TNP therapy. A small standard 
TNP device and a small irrigation TNP device were tested. Measurements of flux 
were made directly under, surrounding and beyond the device. 
Surface of skin mean SD Min Max 
Skin tinder small standard TNP device 415.1 PU 152.7 PU 34 PU 819 PU 
Surrounding skin under the Speneolm pad 88.3 PU 51.3 PU 0 PU 640 PU 
Normal skin beyond the SpencoTM pad 75.7 PU 37.6 PU 0 PU 640 PU 
Skin under small irrigation TNP device 653.9 PU 280.5 PU I1I PU 2273 PU 
Surrounding skin under the SpencoTM pad 208.1 PU 96.7 PU 44 PU 1230 PU 
Normal skin beyond the Spencorm pad 204.8 PU 93.8 PU 41 PU 2015 PU 
The results demonstrate that a significantly raised mean flux value in the area 
under TNP therapy is apparent (P<0.0001, t-test) compared to the mean flux 
values of normal skin in both the standard and irrigation TNP devices (5.5-fold and 
3.2-fold, respectively). These results are consistent with those of Morykwas et al. 
(1997) who observed in full thickness experimental swine skin wounds (n=5) a 4- 
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fold increase in perfusion units between TNP treated and baseline readings. 
There is no significant difference between the flux values under the SpencoTM pad 
compared to the values representing normal skin (83.3PU and 75.7PU for the 
standard device; 208.1 PU and 204.8PU for the irrigation device, respectively). 
Comparisons between the three different skin sites can be made with confidence 
because the LDPI can scan the whole site in one sifting. Caution is required when 
attempting to compare the efficacy of the two TNP devices directly in terms of 
perfusion/flux. The observed differences in flux values between the standard and 
irrigation devices (415.1 PU and 653.9PU, respectively) are most likely due to 
differences in the skin surface quality, texture and thickness under investigation 
(normal right calf and normal left chest skin), the duration of application (5 hours 
versus 30 minutes) and technical differences with the machine. 
Given that the pressures within each device are the same, the observed difference 
in flux between the devices is less likely to be due to the differences in their design 
but most likely due to the differences in skin quality and suction time. Repeat 
studies need to be performed using both these devices to confirm this further. 
3.3.3.3 Bonney's Blue Dye Testing 
The first tests using the hydrocolloid base were performed on the laboratory bench 
using a large irrigation TNP device as shown in Figure 15 (on page 94) before 
similar tests were performed on normal skin as shown in Figure 16. 
Figure 17 shows how the blue dye distributes itself uniformly over the skin and is 
contained within the ring design. Nonetheless, two significant problems of using 
the hydrocolloid base as protection to the skin are well illustrated. Firstly, the 
hydrocolloid material is easily deformed after a few hours of suction. This results 
in a loss of protection as noted in the photograph by the evidence of the blue rim 
of the ring design. Secondly, due to the failure of the hydrocolloid base in 
protecting the normal skin, there is a significant imprint on the skin surface. 
The pressure effects noted using this design might compromise injured and 
ischaemic skin such as donor site wounds or burns. Also, there was concern 
about whether a circumferential imprint around the TNP device would impede 
dermal blood flow in a lateral direction at the level of the rim. 
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Further work using this hydrocolloid design ceased after it became clear that the 
hydrocolloid product deformed quickly as it took up moisture and could not 
withstand subatmospheric pressures of 125mmHg for up to 48 hours without 
losing its protective barrier. Moreover, the adhesive properties of the product 
added to the discomfort noted when the device was removed from both normal 
skin and injured skin. Removal of the device to inspect or record parameters at 
the skin surface broke the seal and damaged the hydrocolloid base. 
The above dye tests were repeated using the SpencoTM dermal pad protective 
base design. The results of these tests are shown in Figure 23 through to Figure 
25 on page 104. The dye is uniformly distributed on the skin surface and no 
leakage is noted beyond the ring. In these tests, the SpencoTM product remains 
intact; the skin is protected from the blue rim by the dermal pad and can be easily 
removed for inspection of the skin surface as necessary. 
3.3.3.4 Radiopaque Dye Testing 
These results supplemented the Bonney's blue dye tests, confirming the uniform 
distribution of the dye throughout the device on repeated testing. The radiopaque 
contrast could be seen permeating through the lower foam chamber and onto the 
'skin' surface. The contrast could be seen within the upper foam chamber and 
leaving through the exit tubing after connection to the pump. 2mls of air 
insufflation following 2mls of contrast helped expel irrigant fluid from the tubing. 
Despite repeated washouts with Normal Saline, small traces of contrast could still 
be seen throughout the device, mainly in the upper foam chamber. 
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Figure 23 Small irrigation TNP device under suction using the SpencoTM dermal pad. Note 
Figure 24 Uniformity of dye without evidence of leakage on removing the device from the 
skin. Note that the blue rim is still well protected by the dermal pad. 
Figure 25 View of underside of small irrigation TNP device. Note the perforations within 
the TegadermTM dressing (after removing the lower foam chamber). 
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the black ink used to mark out the boundary. 
3.3.3.5 Fluid Volume Measurements on Normal Skin 
The results demonstrate some variability between the onset of fluid that was 
collected in the three tests (20,40 and 50 minutes). The differences noted in 
'priming' each system might be explained by the variability of each individual TNP 
device used. By 100 minutes, the devices appeared to reach equilibrium, in that 
irrigant fluid delivered through the system provided near constant volumes 
retrieved from it. Despite the differences between the tests, at 2 hours 
approximately 75% of the irrigant fluid could be collected through each TNP device 
over the first 60 seconds. At the 120-minute time point, 2mls of Bonney's Blue 
was instilled through the device instead of Normal Saline. Blue dye was seen 
immediately following the onset of suction at 1 minute, confirming that the same 
fluid instilled was likely to be retrieved during each collection. 
It was possible that some fluid remained within the device, even during prolonged 
(10 minute) suction, although the volume would remain low as suggested by the 
results in Table 8. The volume of fluid potentially trapped within the system was 
not measured. 
Table 8 Results of 3 similar tests involving 10-minute irrigations on normal skin using 
the small TNP irrigation device. 2mls of Saline is instilled every ten minutes for 
2 hours. Fluid volumes collected at 1 minute and at a further 9 minutes are 
recorded 
Test 
No. 1 2 3 
Time (in 
minutes) 












0 0.0 0.0 0% 0.0 0.0 0% 0.0 0.0 0% 
10 0.0 0.0 0% 0.0 0.0 0% 0.0 0.0 0% 
20 0.0 0.0 0% 0.8 0.0 40% 0.0 0.0 0% 
30 0.0 0.0 0% 1.2 0.0 60% 0.0 0.0 0% 
40 Droplets Droplets Droplets 1.0 +0.7 50% 0.0 0.0 0% 
50 2.3 +0.5 115% 1.0 +0.5 50% 0.0 +0.5 0% 
60 1.5 +0.6 75% 1.7 r 0.5 851, % 0.1 43.0 5% 
70 1.6 +0.5 80% 1.5 10.7 75% 0.0 10.0 0% 
80 1.5 +0.7 75% 2.0 10.5 100% 0.7 4 0.4 35% 
90 1.5 +0.6 75% 1.5 11.0 75% 2.0 +0.4 100% 
100 1.5 10.7 75% 1.2 11.0 60% 1.5 10.1 75% 
120 1.5 +0.5 75% 2.0 11.0 1000/,, 1.5 + 0.1 75% 
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3.3.4 Evaluating the small irrigation device on acute dermal wounds 
The surfaces of the TNP treated wounds are pinker when compared to the 
surrounding wound surface. No active bleeding was noted following TNP therapy 
on either the donor site or burn wounds. It was noticeable on the acute donor site 
wound that the effects of suction therapy on the wound surface might extend up to 
1cm beyond the area of suction, since a circle of clotted blood was noted 1cm 
beyond the foam (see Figure 26). This suggests that subatmospheric pressure is 
having an effect on the wound surface beyond that of the foam, possibly dragging 
surrounding wound fluid into the TNP system. 
There was no evidence that the effects of TNP therapy using the TNP devices 
caused any harm to acute donor site wounds and partial thickness burn wounds. 
Using the SpencoTM dermal pad, no pressure effects from the base of the ring 
were seen after TNP therapy. 
No direct wound healing complications were noted in any patient studied. One 
patient with a donor site wound (not involved in the wound fluid study described in 
the following chapters) developed a superficial Staphylococcus Aureus wound 
infection four days following TNP therapy using the device. The device became 
dislodged during therapy, which might have exposed the wound surface to an 
increased risk of contamination. No TNP-treated burn wound became infected. 
All the patients who agreed to participate in the following studies in this thesis 
completed the 48-hour TNP therapy using these devices, except in one case in 
which accidental damage to the device occurred. The level of discomfort was 
variable between patients, yet patient compliance remained 100%. During TNP 
device testing on wounds, a number of young patients had also been studied 
without difficulty (see Figure 28). 
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Figure 26 Examples of selective TNP therapy to donor site wound surfaces. Note the pale 
area around the foam, which suggests a wider area of TNP influence. 
Figure 27 The use of a TNP device on a superficial burn wound. Note the position of two 
sets of biopsy samples in this case 
Figure 28 A contented young boy undergoing standard TNP therapy to a burn on his left 
leg. A device has been positioned distally as a control 
107 
3.4 Discussion 
Two TNP devices have been described in this chapter, based upon a plastic ring 
in which V. A. C. TM foam is contained. The smaller type of TNP device was the 
most effective on the extremities on which suction could be maintained, given the 
convexity of the skin surface. 
The principle advantage of these devices is that TNP therapy can now be applied 
selectively over open wounds, and surrounded by non-adherent surfaces, to allow 
comparisons to be made against standard dressings. Furthermore, the devices 
may also provide an opportunity to examine the possible mechanisms of action of 
TNP therapy more closely in an intra-patient clinically controlled setting. 
The second part of this study was concerned with testing and validating the TNP 
devices to ensure their reliability and safety on unwounded and wounded skin. 
The topical negative pressures measured between the two types of TNP device 
and within the chambers of the irrigation device, support the view that suction 
pressures are distributed equally across the foam(s) within all the TNP devices 
described. 
Using the LDPI to map blood flow characteristics in skin, these tests also confirm 
that the open-cell nature of the PVA foam provides a uniform distribution of topical 
negative pressure directly under the foam area, within both the standard and 
irrigation TNP devices with an appropriate skin protector. Indeed, when the base 
of the outer plastic ring is padded using the SpencoTM dermal pad, for example, 
the 'halo' effect is prevented as demonstrated with the LDPI tests. The flux 
distribution also suggests that the TNP devices do limit the effects of suction 
therapy to the area of contact when measured using laser Doppler techniques. 
Recently, Droog et al. have highlighted some of the difficulties in LDPI 
interpretation (Droog et al., 2001). They demonstrated that significant variations in 
perfusion values might occur due to the curvature of the skin under LDPI and 
differences in scanning distance. In this case, the area undergoing scanning was 
no more than 10xlOcm with minimal skin curvature. The scanning distances 
remained between 30 and 40 cm only, with no difference in Figure 19 and Figure 
20. This allows for direct visual comparisons between images to be made more 
accurately. Ambient light intensity, temperature and humidity were standardised 
as much as possible in all these tests. 
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The dye tests confirm that the irrigant fluid permeates without hindrance through 
the tower foam chamber and onto the skin surface. Air insufflation ensures that no 
fluid is left in the irrigant tubing. The passage of dye, in both the Bonney's Blue 
and Urograffin® experiments, through the two chambers of foam is unimpeded and 
the four 1.5cm perforations appeared adequate to allow the suction of fluid 
between the chambers. The distribution of blue dye is contained within the foam 
and no leakage beyond the ring is apparent using the irrigation TNP device. In 
these tests, the SpencoTM dermal pad appears more superior and the skin 
remained protected from pressure effects of the rim of the plastic ring that might 
have been a potential problem using this device. Furthermore, this protective 
barrier does not lose its competence when the device is removed for inspection of 
the surface, for example, which is not the case using the hydrocolloid barrier. 
Early variability of fluid collection exits using the irrigation TNP devices on normal, 
dry skin, both within and between devices. To ensure that wound fluid/irrigant fluid 
could be reliably retrieved from the system at frequent time points, 2mis was 
chosen as the optimum volume to use when tested on dry skin. After 2 hours, it 
appeared that approximately 75% of the fluid instilled is retrieved over the first 60 
seconds. 
The safe use of the TNP device to deliver TNP therapy on acute dermal wounds is 
demonstrated in studies performed over an 18-month period. There was no 
subjective evidence of a delay to wound healing or damage to the surface of the 
wound during TNP therapy for up to 2 days using this new system. Following 
removal of the TNP sponge after 48 hours of therapy no bleeding was seen, 
suggesting that the surface of the wound was not traumatised clinically. In 
agreement with other studies using TNP therapy on acute human donor site 
wounds, TNP did not cause significant discomfort (Genecov et al., 1998). Indeed, 
throughout prolonged TNP therapy on both wound types, patients slept with the 
device switched on. No conclusions can be made with respect to the efficacy of 
TNP therapy on acute donor site or partial thickness burn wounds at this time. 
Patients are still being followed up. 
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3.5 Conclusion 
This study chapter has detailed the design of two TNP devices, based on 
commercially available V. A. C. TM dressings, which can be used on acute open 
dermal wound surfaces. The 'standard' TNP device mimics the use of the TNP 
dressings currently available commercially. The 'irrigation' TNP device provides a 
further opportunity to allow collection of wound fluid frequently from the same site 
under investigation. 
The validation tests help to confirm that the devices are intended to do what they 
were designed to do; which is to provide discrete TNP therapy to a wound surface 
and also to allow frequent and specific wound fluid sampling over the surface of 
the wound under investigation. 
The use of the 'irrigation' TNP device is used exclusively in the following chapters. 
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4 Temporal analysis of Total Protein in wound fluid under the 
influence of TNP following partial thickness dermal injury 
4.1 Introduction 
Modulating the extracellular wound fluid environment has been suggested as one 
mechanism by which Topical Negative Pressure (TNP) Therapy may influence 
wound healing. The design of an irrigation TNP device described in Chapter 3 
provides an opportunity to test this hypothesis. 
In order to determine whether TNP therapy can modulate the extracellular wound 
fluid environment, the aim of this study was to retrieve fluid from the wound 
surface and measure the total protein content during cyclical 'on/off TNP therapy 
over a 48-hour period using the newly developed irrigation TNP device. Two 
human dermal wounds were chosen; the donor site wound and the partial 
thickness burn wound. TNP therapy has been used safely on both of these wound 
surfaces in a clinical and experimental setting as described in Chapter 3. 
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4.2 Materials and Methods 
4.2.1 Study Design 
A prospective, longitudinal study was devised based on patients attending the 
Department of Plastic Surgery and Burns Unit at the Stoke Mandeville NHS Trust. 
Using the irrigation TNP device, intermittent TNP therapy was applied to acute 
donor site wounds at the time of surgery, or to partial thickness burns on 
admission to the Burns Unit, for a period of up to 48 hours. TNP therapy was 
applied uniformly, every six hours over the duration of the study period, and wound 
fluid samples collected during both the on and off 6-hourly cycles. 
4.2.2 Patient Selection and Details 
Ethical approval was obtained from the Aylesbury Vale Local Research Ethics 
Committee to study the effects of TNP therapy on human donor site wound 
healing (Project Code: NC903) and human burn wound healing (Project Code: 
NC973). Approval was also granted to allow for fluid collection and obtaining skin 
biopsies (see Chapter 5 on page 135). In addition, the history and examination of 
patients with burns were recorded and digital photographs taken of TNP treatment 
sites. 
Patients were selected in accordance to the following criteria: 
Inclusion criteria: 
a. Age group between 12 - 90 years. 
b. Any donor site wound or any partial thickness burn on the trunk or 
limbs in adults and children that may or may not require operative 
treatment. 
c. Fully conscious adult patient who is able to give informed consent. 
d. Fully conscious child patient, aged 12 years or older, who is either 
able to understand the treatment proposed and who are willing to 
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give informed consent, or a willing child whose parents/guardian 
wish to provide consent on the child's behalf. 
e. Total percentage body surface area burned between 1-40%. 
Exclusion criteria: 
a. Burns to face and perineum. 
b. Presence of inhalation injury. 
c. Presence of any other serious medical condition or generalised ill 
health. 
d. Inability to give informed consent. 
Small irrigation TNP devices, previously constructed under sterile conditions, were 
applied immediately on to donor site wounds created using an air-driven 
dermatome (Zimmer Ltd., UK) in the operating theatre (see Figure 29 on page 
116). Small irrigation TNP devices were applied to clinically homogeneous partial 
thickness burns (see Figure 30 on page 116). The starting time point for each 
burn wound fluid collection experiment depended on the arrival of each burn 
patient to the Burns Unit at Stoke Mandeville Hospital. Subatmospheric pressures 
of 125mmHg were used throughout all of the experiments. The following patients 
were enrolled into the study2: 
Donor site wounds: (n=7) 
Six patients consented for TNP therapy of their donor site wounds using the 
irrigation TNP device. One patient consented for two donor site wound fluid 
collections. Their details are summarised in Table 9 on page 114. 
Partial thickness burn wounds: (n=5) 
Three patients consented for TNP therapy of their partial thickness burn wounds 
using the irrigation TNP device. Two of these patients consented for two separate 
areas for TNP therapy and burn wound fluid collection. Their details are 
summarised in Table 10 on page 115. 
2 For clarity in this thesis, the same identification (ID) numbers are assigned to the same patients 
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Figure 29 Application of small TNP device to a donor site wound. The irrigation port and 
evacuation tube are above and below respectively (Donor site ID 3) 
Figure 30 Application of small TNP device to one area of deep partial thickness burn 
wound (Burn ID A) 
Figure 31 Donor site wound under suction with sterile container in situ for wound fluid 
collection 
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4.2.3 Wound fluid collection and storage 
At each of the wound fluid collection times, an identical procedure was performed 
for each fluid collection, as described in Table 11 below. 
Table 11 Method of wound fluid collection 
1. TNP therapy stopped (if during the'suction on' phase) and the foam dressing allowed to rise to its 
pre-suction position 
2. A sterile fluid collection container was connected close to the exit port of the device (see Figure 31) 
3. 2mls of Normal Saline (irrigant fluid) gently instilled through the lower irrigation port 
4. 2mls of air instilled through the irrigation port 
5. One minute was recorded to allow irrigant fluid to distribute throughout lower chamber of device and 
onto the wound surface 
6. Suction started and wound/irrigant fluid collected into sterile container over a further one minute 
7. Suction stopped 
8. The volume of wound/iirrigant fluid in the container was measured 
9. TNP therapy resumed (if during the 'suction on' phase) or left off (if during the 'suction off phase) 
10. Fluids were transferred to 1.5ml vials and centrifuged for 5 minutes at 4000g (Eppendorf 5416, 
Netheler, Germany) to remove cells/debris 
11. Aliquots of the supernatant (400µl) were snap frozen in liquid nitrogen 
12. Samples were stored at -70°C prior to analysis 
The time from wound fluid collection to snap freezing was less than 10 minutes in 
each case. The donor site wound fluid from Patient ID 1 (the first patient using this 
device) was snap frozen immediately prior to storage. In this case, the wound fluid 
was not centrifuged until after thawing. See Results section 4.3. 
Three sets of wound fluid were collected every 2 hours during each of the 6-hourly 
'suction on' phases and two sets of wound fluid collected every three hours during 
each of the 'suction off phases up to two days from the onset of injury (see Figure 
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32 below). The actual time, the experimental time and the volume of wound fluid 
at each collection point were recorded. Reprints of the data collection sheets are 
given in Appendix 10.1 and 10.2. 
Figure 32 Schematic diagram to demonstrate wound fluid collection time points 
Suction on 
for 6 hours 2 hours 
Suction off 3 hours 
for 6 hours 
4.2.4 Total Protein Assav of fluid samples 
Black marker 
represents wound 
fluid collection point 
Principles: 
The labelled wound fluid samples (n=194) were analysed using a bicinchoninic 
acid (BCA) protein assay technique (Perbio Science, UK). This method combines 
the reduction of copper ions by proteins (the biuret reaction) with the highly 
sensitive and selective colourimetric detection of Cu' cations in the samples when 
combined to bicinchoninic acid as a complex. A purple-coloured reaction product 
is formed by the chelation of two molecules of BCA with one cuprous ion; the 
intensity of colour is proportional to the protein concentration. 
The BCA-Protein Reaction: 
1. Protein (peptide bonds) + Cu2+ OH = tetrad entate-Cu+ complex 
2. Cu' + BCA(x2) : BCA + Cu' complex (purple coloured) 
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This water-soluble complex exhibits strong absorbance at 562nm that is linear with 
increasing protein concentrations over a broad working range of 20µg/ml to 
2000µg/ml. 
4.2.5 Method for the BCA Protein assay: 
A fresh set of protein standards (bovine serum albumin, Perbio Science, UK) was 
prepared over a range of 25µg/ml to 1750µg/ml by diluting a 2.0mg/ml stock 
solution in 0.1 M HEPES buffer, pH7.4. A working reagent was prepared by mixing 
50 parts of OH" with 1-part Cu2+ ions, according to the manufacturers instructions 
(Perbio Science, UK). To achieve optimum results, the wound fluid samples were 
diluted 1: 50 (in HEPES buffer) to ensure a position on the linear part of the protein 
standard curve (see results section 4.3 on page 121). 25µI of each standard or 
unknown sample were pipetted into a 96-microwell plate. Each plate was able to 
house one complete set of patient samples, a range of protein standard 
concentrations and blanks (containing 25µI of HEPES buffer alone) in triplicate. 
200µI of working reagent was added to each well, and the plate was covered and 
incubated at 37°C for 30 minutes. 
After cooling the plate for 5 minutes to room temperature, the colour change was 
measured photometrically at 550nm on a plate reader (Titertek Multiskan 
MCC/340, Labsystems, Finland). The average reading from the three blanks was 
subtracted from the triplicate readings for each protein standard and unknown 
sample. 
A standard curve was prepared by plotting the average blank-corrected reading for 
each protein standard versus its concentration in pg/ml. Using the standard curve, 
the protein concentration for each of the unknown samples was determined by 
formulating a linear equation and determining protein concentrations from the 
absorbance readings. 
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Automated Total Protein Measurements 
Total Protein was also measured photometrically using an automated Biuret 
method on a COBAS MIRA Plus (Roche, UK) courtesy of Dr. Joanna Sheldon at 
the Protein Reference and Immunopathology Unit, St. George's Hospital, London. 
A Total Protein reagent (ABX Diagnostics, Montpellier, France) was used which is 
standardised against bovine albumin. 
Quality Control: coefficient of variation 1.4% for low, medium and high 
concentrations. 
Statistical analysis (ANOVA) was performed using STATVIEW 5.0 (SAS Institute, 
Ltd. ) and DATADESK 6.0 (Data Description, Inc. ) software, with the assistance of 




4.3.1 Total Protein concentrations 
There was a good correlation between the automated (COBAS MIRA Plus) and 
the manual (BCA) methods used to determine the Total Protein concentrations for 
each of the donor site wound fluid and burn wound fluid samples as shown in 
Figure 33 (r=0.95). 
Figure 33 Correlation between the automated and manual Total Protein measurements in 


















All the following Total Protein results displayed were those calculated using the 
manual BCA technique. 
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05 10 15 20 25 30 35 40 45 50 
Total Protein measured using manual BCA technique (mg/ml) 
4.3.2 Effects of `on/off TNP therapy on Total Protein in donor site wound fluid 
The results of intermittent TNP therapy on Total Protein concentration from donor 
site wound fluid collected using the small irrigation TNP device are shown in 
Figure 34. These same results are also displayed together in Figure 35. 
The following observations can be made: 
1. In each of these donor site wound fluid samples, Total Protein gradually 
falls from t2 hours throughout the collection times to t48, despite cyclical 
TNP therapy (P<0.0001). 
2. Intermittent (6-hourly) TNP therapy influences the concentrations of Total 
Protein throughout each set of donor site samples. During the 'on' suction 
phase, an increase in Total Protein is recorded. When TNP therapy stops, 
a fall in Total Protein is measurable (differences between 'on' and 'off 
phases in each set of samples, P<0.0001). 
3. Within each 6-hourly period, there appears to be a trend of decreasing Total 
Protein values for each of the three consecutive samples collected during 
the 'on' suction phase, and for each of the two consecutive samples during 
the 'off suction phase (not significant, NS). The sudden changes in Total 
Protein values occur most noticeably between the change in 'on' and 'off 
cycle periods. 
4. Total Protein concentrations can vary between patients as noted in the case 
of donor site ID5. Interestingly, donor site 1D2 and 1D5 wound fluid samples 
were collected following skin grafting procedures with the dermatome set at 
0.01 inch whilst in the other donor site cases, the dermatome was set at 
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4.3.3 Effects of `on/off TNP therapy on Total Protein in burn wound fluid 
The results of intermittent TNP therapy on Total Protein concentrations from partial 
thickness burn wound fluids collected using the small irrigation TNP device are 
shown in Figure 36. Unlike the donor site wound fluid samples, the start of 
collection times (and therefore on/off cycle times) vary between burn wound fluid 
cases. For this reason, a collective overview of the burn data can not be displayed 
as a line graph. 
The following observations can be made: 
1. There is a less characteristic fall in Total Protein concentration than in the 
donor site wound fluid cases. This may be due to the fact that burn wound 
fluid samples were not collected until as late as t10 hours post burn where 
as the most significant fall in Total Protein in donor site wound fluid 
occurred within the first six hours (P<0.0001). 
2. Intermittent (6-hourly) TNP therapy does influence the concentrations of 
Total Protein throughout each burn patient case. During the 'on' suction 
phase, an increase in Total Protein is recorded, and during the 'off suction 
phase, a fall in Total Protein is recorded (P<0.0001). 
3. From the burn cases demonstrated in Figure 36, there is slightly greater 
Total Protein concentration in the wound fluid samples of A, Ba & Bb. 
These patients represent those with deep partial thickness burn wounds 
(P<0.0001). 
Donor site and partial thickness burn wound fluid Total Protein concentrations 
cannot be readily compared since the time intervals at which samples were taken 
vary between the two groups. There does appear to be a degree of inter-patient 
variability between patient samples at the same time points in similar wounds. 
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Despite this, overall concentrations of Total Protein are greater in the burn wound 
fluid cases compared to the donor site wound fluid cases for given sample times 
(P<a. 0001). 
4.3.4 Comparing volumes measured during collection against Total Protein 
Since the results above strongly suggest that the concentration of Total Protein is 
greater during the 'on' suction phase of TNP therapy than during the 'off phase, it 
is possible that these significant observations may be due to the nature of the fluid 
collection technique during these phases. For example, there might be a dilutional 
effect in the method of sample fluid retrieval during 'off phase, which might 
account for the measured differences between 'on' and 'off phases. 
To establish whether larger fluid volumes from each sample retrieved during the 
collection method were linked to a reduction (dilution) in Total Protein levels, a 
scatter plot was constructed to demonstrate the volume of each wound fluid 
sample versus the measured Total Protein concentrations, for the entire donor site 
samples and then for all the burn samples. 
Figure 37 demonstrates that there is no evidence of a correlation between the 
volume of fluid collected and the concentration of Total Protein measured over a 1- 
minute collection time (correlation coefficient = 0.047). Of 2mls Normal Saline 
irrigant fluid, approximately 75% is commonly retrieved over this time 
(mean=1.59mis; SD= 0.61; n=93 samples). This is in keeping with the fluid 
volume measurement tests carried out on normal skin (see Table 8 on page 105). 
Furthermore, there is no association between Total Protein and volume of fluid 
collected during the 'on' versus 'off phases (P=0.12). 
Figure 38 also demonstrates that in burn wound fluid collections, there is no 
correlation between volume and the concentration of Total Protein measured in 
the samples collected over a 1-minute period (volume mean=2.05mis; SD=1.14; 
n=63 samples, correlation coefficient = -0.114). One isolated value of 7mls 
measured on one occasion might account for the larger standard deviation (SD). 
This particularly large value was due to a failure to ensure that the sterile collection 
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container cap was secure. Subatmospheric pressure leaked from the system and 
when recognised and corrected, the pressure in the pump (that had increased to 
compensate for the leak) resulted in a transient and sudden increase in fluid 
sucked up through the TNP device over the 60-second collection period. 
Again, there is no association between Total Protein and volume of fluid collected 
during the 'on' and 'off phases (P=0.62). 
Figure 37 Scatter plot of Total Protein concentrations against volume of sample in donor 
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Volume of donor site fluid retrieved from TNP device over 11 minute (mis) 
Figure 38 Scatter plot of Total Protein concentrations against volume of sample in burn 
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4.4 Discussion 
4.4.1 TNP in the modulation of acute human cutaneous wounds 
This study has clearly demonstrated that TNP therapy is capable of modulating the 
dermal wound fluid environment in both acute donor site and burn wounds in 
humans as determined by measuring Total Protein in samples retrieved from the 
wound surface during on/off TNP suction cycles. 
There were a number of reasons for using the iatrogenic donor site wound as a 
model to assess the effects of TNP therapy on wound healing. Firstly, the donor 
site wound is readily available following skin grafting procedures in plastic surgical 
departments. Secondly, the wound can be easy to create uniformly using a 
mechanical air-driven dermatome on a readily accessible thigh in most cases. 
Thirdly, Genecov et al. (1998) have used TNP safely on the donor site wound in 
both pigs and humans for up to 14 days to assess rates of reepithelialization. 
Human partial thickness burn wounds represent a distinctly different acute dermal 
injury. TNP has been mentioned as a possible treatment for burns in humans 
(Morykwas and Argenta, 1997). TNP therapy has been applied to experimentally 
induced partial thickness burn wounds in a swine model for up to 48 hours to 
demonstrate that it might be a useful modality in the prevention of burn wound 
progression (Morykwas et al. 1999a). 
This study also utilised TNP therapy on donor site and burn wounds for a period of 
48 hours. However, the intention in this study was not to assess the efficacy of 
TNP directly on clinical wound healing, but to determine if TNP might be able to 
alter the fluid environment of wounds, which might be attributable to one of its 
mechanisms of action. 
Follow-up of these patients after this treatment at 2-3 weeks was performed to 
ensure that each patient was happy about their healing wounds and to exclude 
complications that might have been caused by this TNP device. No complications, 
such as pressure effects that might have been created by the rim of the device or 
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infection, were noted in these cases. No attempt was made at this time to 
measure rates of healing in terms of reepithelialisation, for example. There was 
no subjective evidence for any differences in the TNP-treated and control-treated 
wounds noted at any stage post-operatively. 
4.4.2 Correlation between Total Protein concentrations and fluid volumes 
There was no evidence to suggest that the changes in Total Protein 
concentrations measured during on/off suction might be accounted for by any 
differences in the method in which the samples were collected during the 'on' or 
'off periods. Since the majority (=75%) of the irrigant fluid is sucked up within the 
60 second collection time, any observed differences in Total Protein concentration 
measured is less likely to do with a dilutional effect of excess irrigant fluid in the 
device during the 6-hourly 'off period. There was no evidence that greater wound 
fluid volumes were matched by a decrease in Total Protein concentration using 
this device. The differences in on/off periods measured here are more likely to be 
the direct result of subatmospheric pressure drawing proteins from the wound 
itself. This was graphically illustrated in Figures 35 and 36. 
The donor site wound creates an open, blood filled injury with direct damage to the 
dermal circulation with leakage of blood directly onto the denuded skin surface. 
The partial thickness burn wound is a 'blood-sealed' exudative wound. Despite 
this, there appeared to be more wound fluid retrieved during TNP therapy on burn 
wounds than donor site wounds during the collection times, with statistically 
significant increases in Total Proteins measured in burn wound fluid samples than 
donor site wound fluid samples in this study. Although, the method of collection 
was different, the total proteins measured in this study are consistent with those of 
Rao et al. (1995), who measured total protein of between 15-40mg/ml of acute 
donor site wound fluid. 
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4.4.3 TNP irrigation device as a research tool in wound fluid collection 
The use of Normal Saline as an irrigant medium to wash the surface of a wound 
and to allow collection of wound fluid has been employed by others (Breuing et al., 
1992; Vogt et al., 1998). Vogt et al. used open wound chambers mounted on 
similar silicone sheets directly on human donor site wounds following split-skin 
graft excision, and filled them with 2.5mls of Normal Saline. After 24 hours, the 
total fluid (between 2-4mls) was aspirated and replaced with a further 2.5mis. 
Samples were collected every 24 hours using this method over an 11-day period. 
In their wound fluid samples, total protein concentrations dropped from an average 
5.5mg/ml on day 1 to a baseline of 0.1 mg (unwounded skin), indicating a return to 
barrier function. Using the irrigation TNP device employed in this study, 2mls of 
Normal Saline was instilled for 1 minute only, directly onto the wound surface and 
removed over a subsequent 60 seconds before being centrifuged and stored. By 
day 1, in this study, total protein concentrations varied from 9.03-24.4mg/ml. The 
total protein in this study fell significantly over 48 hours. Exact comparisons of 
total protein concentrations cannot be made with the results of Vogt et al., since 
the method of dilution and wound fluid extraction differ. However, it is possible 
that the greater total protein concentrations measured in this study using 0.5mls 
less Normal Saline and collected over 1 minute as opposed to 24 hours, may be 
accounted for by the use of suction therapy. This suggests that TNP therapy 
might actively remove total protein from the wound. 
The advantage of this irrigation TNP device is that it allows for frequent `fresh' 
sampling of wound surfaces every two or three hours. Extraction of biologically 
active wound fluid might be achieved almost instantly, without the problems of 
delay between collection and freezing prior to analysis (see chapter 6). The time 
from instillation of the irrigant to freeze storage takes less than 10 minutes in this 
study. Hence, this device may provide a potentially useful tool for the collection of 
wound fluid for immediate analysis in cutaneous wound healing research, which 
has not been described before in the literature (see section 1.4.4). 
Unfortunately, this study did not examine whether proteins or other factors might 
be trapped within the foam dressing during suction. There has been no evidence 
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reported in the literature that the foam dressing is capable of trapping proteins or 
extracellular matrix factors directly. It is possible that the results shown in this 
study reflect differences in proteins sticking to the foam. Despite this, it is not likely 
that during the two 3-hourly off phase sampling times, sufficient sticking of protein 
to the foam would account for the reduction in protein concentrations measured. 
Importantly, during these 'off collection times, the suction is switched on 
transiently (1 minute) to extract the fluid sample, and it might be expected that any 
trapped proteins might be released with the irrigant fluid during this time. 
It is possible that the increases in protein concentrations measured during the 
'suction-on' phase, may be attributable to the increase in blood flow, which has 
been demonstrated both in this thesis (chapter 3, section 3.3.3.2) and by Banwell 
et al. (2000) using laser Doppler imaging. The mechanical effects of suction 
through the foam interface is likely to explain the measured increases in protein 
concentrations. 
There are a number of other possible reasons for variations in measurements 
obtained in this study. These might include the age and sex of each patient, the 
depth of the burn or dermatome depth and time from burning, in addition to 
differences in the systemic effects of burns or haematological variations. 
Nonetheless, each patient wound acts as its own control, which makes 
comparisons between the on and off suction phases more straightforward. Care 
was taken to perform each set of experiments over the same time period or within 
a 48-hour burn period. The method of fluid sampling was the same. 
A valid criticism of this study concerns the interpretation following wound irrigation. 
It became apparent during the study designs in chapter 3, that irrigation was 
necessary in order to provide enough quantity of fluid for sampling, and that 
pooling of fluid within the chamber was possible. Although the method of fluid 
retrieval was the same, the observed reductions in protein concentrations obtained 
during the off-phase may be due to a dilutional effect from the build up of irrigant 
fluid from the previous sampling. Unfortunately, the exact volume of fluid retrieved 
over the 1-minute collection time was not equal to the 2mls of irrigant fluid placed 
into the chamber prior to each sampling. As Figure 37 and Figure 38 show, the 
amounts retrieved were variable. This variation might be due to previous build up 
of fluid within the chamber. This might alter the relative concentrations of protein 
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during each collection time, which is dependent on the timing of the previous 
collection within either the on or off phase. 
4.4.4 The potential effects of TNP on Total Protein in other wounds 
It has been well documented that TNP therapy provides a useful alternative in the 
management of chronic wounds. Falanga and Eaglstein (1993) proposed the 
'trap' hypothesis in which macromolecular proteins (including albumin and a2- 
macroglobulin) might contribute to the development and maintenance of venous 
ulceration by the persistent leakage of these proteins into the dermis which they 
hypothesised might bind to or 'trap' growth factors and matrix material, making 
them unavailable for tissue repair (Falanga and Eaglstein, 1993). With this in 
mind, the use of TNP therapy in chronic dermal wound healing might be of 
advantage by actively removing such proteins from the wound and thus increasing 
the bioavailability of endogenous growth factors to wound healing. 
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4.5 Conclusion 
This study has determined that the irrigation TNP device, which mimics V. A. C. TM 
dressings, modulates the wound fluid constituents of cutaneous wounds by 
actively removing extracellular proteins under subatmospheric pressure. 
Indirectly, this might explain one of the possible mechanisms by which TNP 
therapy promotes healing. It is likely that the increased levels of protein measured 
during the suction phase is related to the direct mechanical effects of suction on 
the wound fluid and its constituents, enhanced by the increased blood flow that is 
present in the wound under the TNP device. 
The irrigation TNP device employed in this study has been used safely on human 
dermal wounds and might be a useful research tool in collecting dermal wound 
fluid from a number of acute and chronic wounds for temporal analysis in wound 
healing studies. 
The ability to apply selective Topical Negative Pressure therapy to a wound, 
provides an opportunity to compare the cells of treated and control wounds more 
closely. This is investigated in chapter 5. 
If some of the constituents of the wound fluid (such as proteases, which are known 
to be present at increased levels in difficult-to-heal wound fluids) are also 
modulated by TNP therapy then this might explain one possible mechanism of 
action of this type of therapy. This hypothesis is explored in chapter 6. 
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5 Histological investigation into the effects of Topical Negative 
Pressure therapy on neutrophils and their distribution in 
partial thickness dermal wounds 
5.1 Introduction 
Applying selective TNP therapy to partial thickness dermal wounds in human 
subjects provides an opportunity to identify cellular differences that might occur 
between TNP-treated and control sites within each patient. 
This observational study was conducted in order to establish whether TNP therapy 
is able to modulate the number of neutrophils and their temporal distribution within 
the dermis of open human dermal wounds over 48 hours post-injury, compared to 
untreated controls. An immunohistological stain using a specific monoclonal 
antibody (NP57) to Neutrophil Elastase (NE), was used to identify neutrophils 
more clearly for cell counting, as well as to identify areas in which degranulation of 
NE from neutrophils may be occurring. 
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5.2 Materials and Methods 
5.2.1 Study design 
A longitudinal intra-patient controlled histological study was performed on biopsy 
samples taken from patients with donor site wounds undergoing TNP therapy over 
the first 48 hours following injury. A similar study was performed on biopsy 
samples taken from partial thickness burn wounds undergoing TNP therapy from 
the time of admission up until 48 hours following burning. 
5.2.2 Patient selection 
Tissue biopsies were collected from six donor site wounds (n=6 patients) and six 
partial thickness burn wounds (n=4 patients). Four patients who participated in the 
wound fluid studies earlier, also consented for biopsies of their wounds. Two 
further patient biopsy samples were obtained from two further donor site patients 
(ID 8 and ID 9). Patients selected for this study are identified in Table 12 below. 
The same burn cases used in the previous studies were also used in this study, 
supplemented with a further case (ID F). See Table 13 below. The differences in 
TNP management between burn F and the other burn cases was that TNP therapy 
was applied continuously, without 6-hourly on/off cycles. 
136 
Table 12 Patient details of donor site biopsy sites and times 






1 74 F Right thigh in theatre at bedside at bedside 
2 42 M Right thigh in theatre at bedside at bedside 
4 19 F Right thigh in theatre at bedside at bedside 
5 32 F Right thigh in theatre at bedside at bedside 
8 20 M Right thi h in theatre at bedside at bedside 
9 64 F Left thigh in theatre at bedside at bedside 
Table 13 Patient details of partial thickness biopsy sites and times 






A 44 M Right chest DPT t12 t46 t46 
Ba 19 F Right buttock DPT t10 t30 t30 
Bb 19 F Left buttock DPT t10 t30 t30 
Ca 26 M Left leg SPT t16 t49 t49 
Cb 26 M Left leg SPT t16 t49 t49 
F 18 M Left arm SPT t3 t48 t48 
DPT - Clinical deep partial thickness burn (required surgery) 
SPT - Clinical superficial partial thickness burn (healed within 3 weeks) 
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5.2.3 Collection and storage of biopsy specimens 
The following procedure was used to obtain donor site wound biopsies. 
In the operating theatre, immediately after skin graft harvesting, a 4mm-diameter 
punch biopsy (Stiefel, Germany) of dermis was taken of one area of the donor site 
wound from each patient. See Figure 29 on page 116. The biopsies were placed 
into a square basket, and orientated length ways along its side to prevent 
distortion of the specimen. The basket was placed directly into 4% neutral 
buffered formaldehyde ((Cellstor(D Pot, CellPath Ltd., UK. ). 
Following application of the TNP irrigation device adjacent to the non-biopsied 
area of donor site wound, the surrounding control wound was dressed using 
standard dressings (KaltostatTM, cotton gauze and crepe) in theatre. 
After 48 hours, on completion of the last 48-hour wound fluid sample collection, 
the irrigation device and control dressings were removed from the wound for 
inspection. A further series of biopsies were taken under local anaesthetic; one 
from the control-treated wound (not less than 1.5cm from the previous biopsy site 
and one from directly under the TNP-treated site. The biopsy specimens were 
processed as described above. 
2mls of 1% plain lignocaine was used to surround each biopsy site prior to 
harvesting, with infiltration under and not within the dermis, to reduce any possible 
artifactual errors imposed by the infiltration of a volume of fluid within the dermis. 
Each biopsy site was sutured with interrupted 5/0 Prolene, and the entire donor 
site wound was then redressed with standard KaltostatTM, gauze and crepe 
dressings. 
The following procedure was used to obtain partial-thickness burn wound biopsies. 
Following clinical assessment of the patient's burn wounds on arrival in the Burn's 
Unit at Stoke Mandeville Hospital, biopsy specimens were taken from partial- 
thickness burn sites at the time of admission under local anaesthetic as described 
above. 
Intermittent TNP therapy was commenced on non-biopsied contiguous burn 
wound areas and wound fluid collected up to 48 hours as described in Chapter 4 
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(except for burn F in which continuous suction was applied). Standard BactigrasTM 
and gauze dressings were placed on adjacent burn wound sites. 
After the last 48-hour wound fluid collection using the irrigation TNP device, all the 
dressings were removed and the burn wound surface examined. A further two 
biopsy specimens were taken from control and TNP-treated burn sites and 
processed in the same fashion as described above, under local anaesthetic. An 
example of these biopsies can be seen in Figure 27 on page 107. The entire burn 
wound was redressed in the same standard burn dressings as described for the 
control sites. 
5.2.4 Formaldehyde fixation and sectioning 
After 24 hours, each biopsy was transferred (within its basket) to an automated 
machine (Shandon Scientific Ltd., UK. ) for further 10% formaldehyde fixation for 5 
hours prior to graded dehydration in Industrial Methylated Spirit (IMS) at 70%, 
85%, 90%, and three lots of 100% for 1 hour each. This was followed by two lots 
of 1-hour xylene and three lots of 1-hour paraffin waxing before being embedded 
in a block of paraffin wax for sectioning. 
For immunohistochemical staining, 3µm thick sections were cut (Anglia Scientific 
microtome) from each biopsy block and between 2-3 sections placed onto 
SuperFrost® Plus (Menzel-Glaser, Germany) slides. These slides were dried and 
stored at room temperature prior to staining for Neutrophil Elastase. 
5.2.5 Immunohistochemistry for Neutrophil Elastase 
The use of the mouse anti-human neutrophil Elastase primary monoclonal 
antibody, NP57 (Dako, UK. ), was chosen as both a marker for neutrophils, in order 
to aid cell counting, and to assess the extent of neutrophil degranulation of 
Elastase from the intracellular azurophilic granules. The primary antibody, in turn, 
was labelled with a highly sensitive, commercial system, EnVision TM+, based on a 
peroxidase labelled dextran polymer conjugated to goat anti-mouse 
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immunoglobulins. Further incubation with a 3,3'-diaminobenzidine (DAB) 
chromogen solution results in a brown-coloured precipitate at the antigen 
(Neutrophil Elastase) site. See Figure 39 below. 
Figure 39 The indirect immunohistochemical staining technique with the EnVisionTM+ 
system 
WAZ 
ANTI-MOUSE ANTIBODIES AND 
PEROXIDASE MOLECULES CONJUGATED 
TO DEXTRAN MOLECULE 
00 
'4111111ý PRIMARY ANTIBODY 
NP57 
(MOUSE ANTI-HUMAN) 
The EnVisionTM+ reagents were purchased as a kit (K4006, Dako, UK) and used 
in the immunohistochemical protocol as described in Appendix 10.4. 
All immunohistochemical staining of biopsy sections taken from donor site wounds 
were performed in one batch, and repeated for the biopsy sections taken from 
partial thickness burns. Human tonsillar tissue and one spare patient test slide of 
human skin were used as positive and negative control tissue respectively, to 
validate the staining technique in each batch. The use of PBS was used to 




5.2.6 Neutroghil counting technique 
A representative section of each biopsy was chosen for neutrophil cell counting. 
Neutrophil Elastase-stained neutrophils were quantified in the section by manual 
cell counting of the brown cells under a Zeiss light microscope, using a 10x10 
square graticule chamber placed in one eyepiece. 
The graticule was orientated over the whole section parallel to the wound surface, 
ensuring that the graticule was in view within the biopsy section at low power. At 
400x magnification, cell counts were made in each 10x10 graticule, starting from 
the surface of the orientated section and counting 10 consecutive grid squares at 
90° from the wound surface, in 7 completed columns. In this way, 70 high power 
field (HPF) counts of the graticule can be made. The length and breadth of each 
small square was 2.5pm, and therefore each 10x10 graticule was 250pm by 
250pm square. 
The cell counts for each of the 70 squares of the graticule were recorded and 
mapped directly into a7 by 10 grid on an excel spreadsheet. A section for each of 
the three sets of biopsy specimens for each patient was recorded. In this way, a 
large representative number of cells can be counted in defined areas of the 
section, thus providing an indication of the distribution of cells within the section 
from the surface of the wound and down into its depth. 
The author, using the same light microscope, performed cell counts blind. Details 
of these counting grids are displayed in Appendix 10.5 and 10.6. 
5.2.7 Reproducibility of counting technique 
Reproducibility of the counting technique was assessed by the blind repetition of 
cell counting for a random sample of 5 biopsy sections. An Altman-Bland plot was 
constructed as shown in Figure 40 below. 
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Figure 40 Altman-Bland plot of neutrophil counts of 5 random biopsy sections, using 
the method of counting as described in the text. No significant differences 
were seen between the paired counts taken at two different times. 
(Correlation = 0.99) 
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This graph highlights that each of the paired values (n=50, diamonds) obtained 
within the grid at various levels measured from the surface of the wound correlate 
very well when repeat counts were performed (R= 0.99). The mean paired 
neutrophil counts for each of the five random sections measured are shown by 
squares. There is no significant difference between the % difference in paired 
neutrophil count values, which were counted on separate occasions. This 
procedure supports the reproducibility and accuracy of the cell counting technique 




The following results display histological differences in neutrophil numbers and 
their distribution within wound biopsies between TNP-treated and control sites as 
identified by the NP57-positive stained cells. Examples of the 
immunohistochemical stains can be seen in Figure 41 and Figure 42 on page 146. 
5.3.1 Histological assessment of donor site biopsies 
Time 0 control biopsy sections showed evidence of a denuded dermis without 
evidence of an epidermal layer. NP57 staining for neutrophils revealed little or no 
neutrophils within the connective tissue of the dermis or within or surrounding the 
dermal vessels as would be expected at this time. 
At 48 hours, there were large numbers of neutrophils within each TNP-treated and 
control-treated section, almost exclusively in or around the vessels, with a few 
interspersed within the dermis proper. In some cases, NP57 staining was seen as 
'clouds' within the sections accompanying ghost-like neutrophils consistent with 
degranulation, although no clear differences could be seen between the TNP- 
treated and control sections. Occasionally, some sections were stained with fibrin 
clot on the surface of the wound. Within the clots, large numbers of red blood cells 
(shown clearly on the PAS sections) and NP57 positive cells were seen. The 
demarcation between the clot and the surface of the wound was clearly defined. 
Cell counts from these sections were only performed from immediately under the 
surface, avoiding the NP57 positive cells within the clot. 
The most striking differences were noted in the neutrophil counts within the dermis 
between the paired intra-patient biopsy sections at 48 hours. There were fewer 
neutrophil numbers in the TNP-treated biopsy section compared to their intra- 
patient control-treated biopsy section taken at the same time in all six cases 
(P<0.002). See Table 14 and Figure 43. 
Furthermore, differences can be observed in the number of neutrophils between 
donor site wounds, suggesting a degree of inter-patient variability (see Table 14). 
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ID 1 0.07 12.2 9.13 
ID 2 0.21 10.63 6.27 
ID 4 0.14 7.34 3.76 
ID 5 0.16 17.71 9.66 
ID 8 0.06 16.49 8.03 
ID 9 0.36 25.81 4.76 
5.3.2 Histological assessment of partial thickness burn wounds 
Each set of burn wound biopsies differ between patients both in terms of the times 
at which they are taken, and also because of the nature and extent of the burn and 
its depth. Many more variables are present in these than the donor site wounds, 
making paired intra-patient comparisons more critical. 
Neutrophils were observed in perivascular areas, with many more within the 
connective tissues of the damaged dermis compared to donor site wound 
biopsies. Heavy degranulation of neutrophils with scattered NP57 staining outside 
cells was particularly noticed at and near the surface of the sections. 
Observations of each biopsy section did not reveal any gross differences between 
the clinically superficial or deep partial thickness burn wounds with respect to 
neutrophil degranulation. Furthermore, no obvious differences in degranulation 
were seen between TNP-treated and control biopsies. 
Biopsies taken at the time of admission into the Burns Unit varied from time 3 to 
10 hours post burn. Average neutrophil numbers ranged from between 2.13 to 
13.3 per 70 HPF section. See Table 15 below. 
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Comparing the paired 48-hour TNP-treated and control sections, the average 
neutrophil count per paired 70 HPF sections followed a similar pattern for that of 
the donor sites biopsy sections. Except in one case, (ID F), all the paired counts 
demonstrated a reduction in neutrophil counts in TNP-treated biopsy sections 
compared to their controls (P<0.008) as shown in Figure 44. 















IDA DPT t48 16.8 7.31 
t5 10.3 
ID Ba DPT t30 34.4 20.0 
t5 12.4 
ID Bb DPT t30 29.9 9.04 
t10 2.13 
ID Ca SPT t48 1.94 2.91 
t10 5.99 
ID Cb SPT t48 3.64 2.43 
t3 13.3 
ID F SPT t48 39.5 21.8 
DPT - deep partial thickness 
SPT - superficial partial thickness 
Again, inter-patient differences in neutrophil counts were observed, especially in 
the superficial partial thickness burn cases. 
There appeared to be a greater number of neutrophils in the clinically deeper 
partial thickness burns compared to the superficial partial thickness ones, although 
this is not statistically significant. 
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Figure 41 Section of NP57 positive-stained neutrophils (brown) in a burn wound at 48 













Figure 42 High-powered view of NP57-stained neutrophils. Extravasating neutrophils are 
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Figure 43 The effects of TNP therapy on neutrophil numbers within paired donor site 
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Figure 44 The effects of TNP therapy on neutrophil numbers in paired deep (squares) and 
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5.3.3 Histological assessment of neutrophil distribution within biopsies 
Since cell counting was performed using a strict 7x10 grid pattern in each section, 
a spatial distribution of neutrophil numbers within the section from the surface of 
the wound deeper into the dermis can be observed. An indication of this can be 
seen in the raw data in Appendix 10.5 and 10.6. 
The distribution of neutrophil numbers between sections taken at the time of 
operation, and later at time 48 hours in both control and TNP-treated donor site 
wound biopsy sections, are illustrated in Figure 45. The graph shows that the 
distribution of neutrophils within the section is dependant on the distance from the 
wound surface, with the majority of neutrophils within the first 250pm of dermis 
with very few cell counts beneath 1000pm. 
Furthermore, gross comparisons between the mean distribution of neutrophil cell 
counts from the t48 control wounds (n=6) with the mean distribution of neutrophil 
cell counts with their respective TNP-treated sites (n=6), demonstrates that there 
are fewer neutrophils in the TNP-treated groups at each 250pm incremental depth 
up to 1000pm. The numbers of neutrophils are reduced the deeper from the 
wound surface. 
The distribution of neutrophils between control and TNP-treated deep partial 
thickness burn biopsy sections (Figure 46) and superficial partial thickness burn 
biopsy sections (Figure 47) are also illustrated below. 
In a similar fashion to the donor site biopsy sections, the distribution of neutrophils 
in burn biopsy sections relate to the depth of the burn wound. Again, the greatest 
number of cells can be seen within the first 250{ßm of the wound in both partial 
thickness burn types. The difference between the mean control and TNP-treated 
neutrophil numbers at each incremental depth is less clear and no differences can 
be noted statistically. Nonetheless, there appears to be fewer neutrophils in the 
TNP-treated sections than controls. 
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Figure 45 The effects of TNP therapy on the spatial distribution of neutrophils within 





















Figure 46 The effects of TNP therapy on the spatial distribution of neutrophils within 
sections of deep partial thickness burn dermis (n=3) 
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Figure 47 The effects of TNP therapy on the spatial distribution of neutrophils within 
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5.4 Discussion 
There is only one published histological report on the effects of TNP therapy on 
intra-patient controlled human dermal wound studies (Genecov et al. 1998). In it, 
the authors identified that reepithelialisation was more pronounced after seven 
days in TNP-treated human and pig acute donor site wounds compared to control 
dressings, although no detailed histological data was given. 
Morykwas et at. (1999a) observed that the overall numbers of inflammatory cells in 
TNP-treated partial thickness experimental burns on the dorsum of pigs were less 
than an intra-pig control group, although they did not provide details of the types of 
inflammatory cells that were affected or provide details as to how these were 
counted. 
Gouttefangeas et at. (2001) identified cell populations that infiltrated the PVA foam 
during 14 days of continuous TNP therapy in human subjects. The foam sponges 
were fixed and sectioned to reveal that the dominant cell type seen within the foam 
were neutrophils. They observed a gradual decrease in cell distribution from the 
surface to the inner structure of the foam. This suggests that TNP therapy sucks 
cells up directly into the foam from the wound bed (Gouttefangeas et at., 2001). 
Morykwas et at. (1997) have also shown that biopsies from TNP-treated pig 
wounds showed reductions in the level of bacterial species grown on blood agar 
plates compared to within-pig controls, suggesting that the bacteria might have 
been actively removed from the wound. 
Ford et at. (2002) have also shown in a randomised controlled trial of 22 patients 
with chronic ulcers undergoing either 6 weeks of TNP therapy versus wound gel 
dressings, that the numbers of neutrophils decreased in the TNP group and 
increased in the wound gel dressings group (Ford et al., 2002). 
These findings support the view that TNP modulates cells and their number within 
wounds. 
5.4.1 TNP modulates neutrophil cell counts and their distribution 
This study has demonstrated that TNP therapy is capable of reducing neutrophil 
numbers within the dermis, as shown in both the donor site and partial thickness 
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burn wound biopsy sections compared to controls, and that the distribution of 
NP57 positive-stained cells within the injured dermis of donor site and partial 
thickness burn wounds is also affected by TNP therapy when comparing the 
numbers of cells at the same distance from the surface of the wound. These 
findings are consistent with the effects of TNP on cells within wounds as described 
by others. 
Interestingly, donor site wounds ID 2 and ID 4 were taken from patients 19 days 
post 4% full-thickness burn wounds and 11 days post 13% mixed partial thickness 
burn wounds, respectively. All the other donor site wounds were taken from 
patients requiring grafting for non-acute inflammatory conditions. Table 14 
showed that average neutrophil cell counts for both the control and TNP-treated 
biopsy sections for donor sites ID 2 and ID 4 were less than those from other 
donor site biopsy sections. These differences might be accounted for, in part, by 
the relative systemic neutropenia seen in some burn patients although this cannot 
be verified. Unfortunately, the numbers of patients in this study are very few. 
Although an objective assessment of neutrophil degranulation was not made in 
this study, there were no obvious (subjective) differences observed in 
degranulation between TNP-treated and control donor site and partial thickness 
burn wound biopsy sections, or between superficial and deep partial thickness 
burn biopsy sections. 
This study does not provide any direct evidence to demonstrate how or why there 
are fewer neutrophils in the TNP-treated biopsies, although the following 
hypotheses might be proposed: 
1. The action of subatmospheric pressure on the wound surface might remove 
neutrophils indirectly by sucking them up in wound fluid. 
2. TNP might exert a direct effect on cell migration through effects of 
mechanical sheer stress. 
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3. There may be few cells in the first instance since the effects of irrigating and 
applying suction to the wound may wash the wound surface compared to 
non-irrigated kaltostat dressing (control) sites, 
4. During the removal of the suction device, the top layer of fibrin exudate- 
containing cells may have been removed along with the foam dressing, 
thereby reducing the uppermost neutrophil-laden layer from the wound. 
This thesis did not examine these four potential mechanisms directly. Despite this, 
there is good evidence to suggest that TNP might remove cells and cellular debris 
via its behaviour on the wound fluid. Firstly, cells and cellular debris have been 
observed in smears made from the pellets of centrifuged wound fluid samples 
taken from patient wounds undergoing TNP therapy without the use of an irrigant 
fluid vehicle which might 'wash' the wound surface of cells (Banwell, Personal 
communication). Secondly, it has been demonstrated that on/off TNP therapy is 
capable of modulating the removal of proteins directly within wound fluid as shown 
in Chapter 4, and therefore might modulate cell numbers in a similar fashion. 
Unfortunately, this thesis did not attempt to identify cells or their numbers in the 
wound fluids from those samples taken during the on- and off- phases of suction, 
which might have answered this question. Thirdly, the effects of TNP therapy 
appeared more marked on the neutrophil distribution in donor site wound than 
partial thickness burn wound biopsy specimens. The donor site wound creates a 
blood-exposed exudate with potentially direct access to the neutrophils within the 
intravascular system since the donor site wound exposes the ends of dermal 
capillaries to the TNP device. Meanwhile, the partial thickness burn wound is a 
'plasma-free' wound because the surface of the wound is burn-sealed without 
direct contact to the dermal capillaries. This may reduce the capacity of the 
subatmospheric pressure to pull neutrophils (accompanying the fluid) out of the 
wound directly. 
The implication that TNP therapy, by reducing neutrophil cell counts within dermal 
wounds, might be beneficial to wound healing remains highly speculative, and is 
not suggested from this work. This thesis did not examine whether TNP therapy 
actually improves the clinical outcome in donor site wound or partial thickness 
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burn wound healing, despite some evidence that this might be do so (Genecov et 
al. 1998; Morykwas et al. 1999) and made no attempt in defining the role of the 
neutrophil in this system. 
Great care is taken to ensure that TNP-treated and control groups are as identical 
as possible. This is easier to establish with the donor site wound in which a 
uniform, mechanical injury was created on the skin using an electrical dermatome. 
Although it was essential to choose identical looking partial thickness burn wounds 
for both the TNP and control sites, the decision was based solely on clinical 
inspection, pinprick testing and capillary return. Objective, independent 
confirmation of the depth (extent) of the wound was not obtained for no 
satisfactory, accurate technique was available. 
Few references in the literature describe techniques for cell counting within 
sections of human skin. The main problem is that the distribution of the cells 
within the dermis is not random, as can be seen in these sections and which are 
clearly illustrated in Figures 45 to 47. Inflammatory cells are often localised in and 
around blood vessels. Sections of injured dermis with greater vessel density might 
increase the neutrophil cell counts within that section. Control biopsies are taken 
about 6-10 cm away from TNP biopsies within the same patient and it cannot be 
guaranteed that the same vessel distribution is present. Despite this, when the 
mean cell counts are compared between control and TNP biopsy sections using a 
grid which covers the whole section, any differences in perivascular neutrophil 
numbers is not observed. This study has demonstrated that neutrophils are most 
prevalent near the wound surface, therefore taking random HPF counts of a 
section of a biopsy wound would yield marked differences in cell counts depending 
on where in the dermal section the counts are made. Hence, a 7x10 fixed grid 
map may be a more accurate method of counting cells within dermal sections. 
This study has questioned the reliability of `random' cell counting under the 
microscope, as an accurate means of determining cell populations within dermal 
biopsy sections. 
If the results of this study are true, then the effects of TNP therapy on neutrophil 
numbers might be highly significant to the concept of burn depth and its 
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progression. For example, Tyler (1998) has observed that the extravasating 
neutrophil counts in partial thickness human thermal burns correlated directly with 
burn depth. Bucky et al. (1994), Choi et al. (1995) and Nwariaku et al. (1996) 
have shown experimentally that by blocking extravasating neutrophils from within 
burn wounds improved microvascular blood flow, and secondary progressive 
dermal necrosis. In a similar fashion, TNP therapy on burn wounds might also 
reduce the effects of neutrophil-mediated tissue injury by both enhancing blood 
flow and also by reducing the neutrophil numbers in the burn wound. This 
histological study did not examine the direct effect of TNP therapy on burn depth 
progression between TNP-treated versus control wounds. This would represent 
interesting future work and might support the experimental findings of Morykwas et 
al. (1999a) in pig studies, suggesting that TNP therapy might prevent progressive 
partial thickness burn injury. 
There are a number of criticisms of this study mentioned below. 
Firstly, donor site sections stained heavily for neutrophils within the fibrin clot on 
the surface of each wound. It was important to delineate the surface of the wound 
carefully in each case, and exclude the wound surface and fibrin clot during 
neutrophil cell counting to be certain not to include these cells in the overall cell 
counts. It was important to establish the wound surface accurately so that 
comparisons could be made between TNP-treated and kaltostat-treated (control) 
wounds could be made. This was also important when comparing treated and 
control burn wounds. 
The optimum dressing used on the control wound would ideally have been the 
TNP device alone without suction, instead of the standard Kaltostat dressings 
used in the treatment of donor site wounds and partial thickness burns, as this is 
the biggest drawback to this study design. Indeed, one reason for the reduction in 
neutrophil cell counts observed in the TNP-treated sections may be due to the fact 
that after 48 hours of TNP therapy, the semi-adherent foam dressing is gently 
peeled off the wound surface. This might have created a mechanical debridement 
of the top layer of the wound and reduced the number of neutrophils on or near the 
surface. Although this might explain the reported reduction in neutrophil counts in 
TNP-treated biopsy sections, care was taken to count only neutrophils within the 
dermis and not those cells on the surface. 
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However, in support of this work, there was no evidence of dermal tissue sticking 
to the foam itself when it was removed and the depths of the dermis in each 
biopsy section between paired TNP-treated and control sections did not differ, 
suggesting that peeling off the TNP dressing did not remove layers of upper 
dermis. However, no accurate measurements of the depth of the dermis was 
made. Future studies using this TNP device might best be achieved by placing a 
layer of non-adherent dressing (such as MepitalTM) between the wound and foam 
to prevent any foam from adhering to the wound surface. In this fashion, 'foam- 
stripping' of the wound surface might be prevented, and a more accurate method 
of histological assessment may be made. Additionally, the control group should 
ideally be the foam dressing alone, although this might be difficult for the ethics 
committee to accept. 
Secondly, TNP therapy was used in conjunction with the irrigation device and not 
with the standard TNP device. It might be useful to repeat the study without the 
irrigation effect on the wound surface and with continuous (rather than intermittent) 
suction since this may have an effect on the neutrophil numbers. 
Thirdly, it must also be recognised that the immunohistochemical staining for 
Neutrophil Elastase using the monoclonal antibody, NP57, might also stain for 
other Neutrophil Elastase-expressing cells. Indeed, a subpopulation of 
macrophages are also known to express Neutrophil Elastase on their cell surface 
and represent up to 6.2% of Neutrophil Elastase content (Campbell et at, 1989). 
However, Herrick et al. (1997) staining for Neutrophil Elastase in acute and 
chronic tissue biopsies, confirmed that most of their cells expressing elastase, 
using NP57, were found to be granulocytes by double localization with the marker 
CD15. However, they reported some elastase expressing cells, mainly in the deep 
dermis, that were not CD15-positive, which instead displayed a fibroblast-like 
phenotype. Despite these potential inconsistencies, the same methodological 
staining procedure was used in this study, in both TNP-treated and control 
sections within the same patient and staining performed in the same batch, so it 
might be assumed that any differences in neutrophil and macrophage staining for 
Neutrophil Elastase would be relative to both groups. No attempt was made to 
carry out dual staining procedures in this case. 
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5.4.2 Advantages in using the TNP device in wound healing studies 
The differences between neutrophil cell counts between wounds of the same type 
vary significantly. This finding supports the need for robust intra-patient control 
groups, which can be provided by using the selective TNP device on the same 
wound type with closely matched wound controls as described above. The error 
associated with the use of historical or inter-patient control groups becomes more 
evident. Although biopsy collection times between burn patients differed 
according to their clinical situation, the exact timing was less crucial if intra-patient 
matched controls could be obtained. 
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5.5 Conclusion 
Selective application of TNP using the irrigation device described in this thesis has 
provided the opportunity to directly compare the neutrophil cell counts in sections 
of biopsies taken from TNP-treated and adjacent control wounds in donor site and 
partial thickness burn wounds. 
Neutrophil cell counts from within the dermis of six paired donor site wounds and 
six paired partial thickness burn wounds has shown that TNP-treated areas 
demonstrate reduced neutrophil numbers. The significance of this finding to 
wound healing is not clear. It is proposed that the effects of subatmospheric 
pressure on a wound surface promote the removal of cells by its effect on wound 
fluid, although a direct mechanical effect of TNP on cell motility and adhesion 
cannot be ruled out. 
The distribution of neutrophils up to 1000pm within the depth of the dermis also 
appears to be reduced by the effects of TNP. This finding highlights the need to 
define the exact location of neutrophils within the dermis, since random cell counts 
within the dermis has been shown not to be an accurate method of cell counting. 
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6 The influence of Topical Negative Pressure therapy on the 
temporal analysis of Neutrophil Elastase activity and a-, 
Protease Inhibitor in wound fluid of human donor site and 
partial-thickness burn wounds 
6.1 Introduction 
The potent serine protease, neutrophil elastase (NE) is released from neutrophils 
during inflammation. It has broad substrate specificity and when released in 
excessive amounts, is capable of significant pathological tissue damage. Indirect 
evidence suggests that NE might contribute to impaired wound healing by 
degrading provisional extracellular matrix proteins. There is good evidence that 
NE activity is increased in some tissues of poor-to-heal cutaneous wounds and in 
wound fluids of both chronic wounds and burn wounds. 
at-protease inhibitor (a, -PI) is the most important endogenous inhibitor to NE 
activity in vivo. An imbalance between the relative levels of NE and plasma- 
derived a, -PI may play an important part in the failure or delay of some wounds to 
heal. 
TNP therapy is widely used in the treatment of acute and chronic wounds, 
although the exact mechanisms of action are not understood. One such 
mechanism may involve a direct ability of TNP to modulate the constituents of the 
wound fluid (including tissue damaging proteases) that might be sucked out of 
cutaneous wounds. 
Since on/off TNP therapy is capable of modulating the total protein concentration 
of wound fluids as demonstrated in Chapter 4, and that neutrophil cell counts are 
reduced in wounds under the influence of TNP as shown in Chapter 5, this study 
was designed with the following aims: 
1. To determine the relative levels of NE activity within the wound fluid 
samples (from donor site and partial thickness burn wounds) during 'on/off 
TNP therapy 
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2. To determine the relative concentration of ai-PI in the same samples 
3. To identify whether `on/off suction TNP therapy is capable of modulating 
the NE/a1-PI balance 
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6.2 Materials and Methods 
6.2.1 Wound fluid Neutrophil Elastase activity assay 
The same set of wound fluid samples taken from patients with donor site wounds 
(Table 9 on page 114), and burn wounds (Table 10 on page 115) were used. 
Two different NE immunochemical assays were performed on both sets of wound 
fluid samples in this study. Both activity assay methods employed in this study are 
detailed below. 
6.2.2 Colourimetric NE assay of fluid samples 
Principles: 
An immunochemical spectrophotometric assay takes advantage of the ability of a 
coloured solution to absorb light of a specific wavelength. The absorption of light 
is related directly to the concentration of the coloured substances in the solution 
(Beer-Lambert Law). In the following assay, a commercially prepared substrate 
combines irreversibly to human NE in both known and unknown fluid samples on a 
stociometric 1: 1 ratio, to liberate a yellow colour change in the substrate, which is 
measured colourimetrically. 
Reagents: 
A. 100µg human neutrophil elastase (Calbiochem, UK. ) was diluted in 1 ml 
ddH2O to make up a stock solution (100µg/ml). Following reconstitution, the 
stock solution was stored at -20°C in aliquots of 1 00µI until required. 
B. 10mg chromogenic elastase substrate (Calbiochem, UK. ) was stored at - 
20°C until required. This product is a very specific, synthetic, nitroanilide 
(NA) substrate (Methoxysuccinyl-Ala-Ala-Pro-Val-pNA) for NE. 
C. 0.1M HEPES buffer (pH 7.4) was freshly prepared as described in the 
Appendix (section 10.3 on page 200). 
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The colourimetric assay technique (after Nakajima et al., 1979) is described below: 
Using the total protein data from Chapter 4, a small volume of each wound fluid 
sample (<70pl) containing an equivalent amount of protein was pipetted into a 96- 
microwell plate in triplicate. HEPES buffer (pH 7.4) was added to make up to 
100µI. 
50µI human neutrophil elastase (Calbiochem, UK. ) standards ranging from 5- 
0.01µg/ml diluted in 0.1M HEPES buffer (pH 7.4) were also pipetted into the 96 
microwell plate in triplicate. HEPES buffer (pH 7.4) was also added to make up to 
100µI. HEPES buffer test blanks (1001f) were also added in triplicate. 
100µI of 6mM elastase substrate, MeOSuc-Ala-Ala-Pro-Val-pNA (dissolved in 10% 
dimethyl sulfoxide, DMSO) diluted in 0.1M HEPES buffer (pH 7.4) was added to 
each well plate. The plate was incubated for 1 hour at 37°C and substrate 
degradation was determined by measuring the absorbance spectrophotometrically 
at 405nm. 
A standard curve for degradation was prepared using the known set of standard 
NE concentrations and plotted to determine an equation from which the unknown 
wound fluid samples could be compared. The results were expressed as units/ml 
of NE activity/100pg Total Protein (x10-4) and displayed graphically using Excel 
2000 software. 
6.2.3 Fluorometric NE assay of fluid samples 
Principles: 
A photometric assay using the same synthetic NE substrate (MeOSuc-Ala-Ala- 
Pro-Val-pNA) can be used when coupled to a fluorescent 7-amino-4- 
methlycoumarin (7-AMC) compound. The (almost) nonfluorescent substrate is 
hydrolysed by NE to liberate the intensely fluorescent 7-AMC, which is quantified 
fluorometrically (Barrett et al., 1981). The intensity of fluorescence is directly 
proportional to the concentration of the reaction between substrate and NE. A 
molecule at the ground state energy level is excited by light absorption to a higher 
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excited energy level. As the molecule returns to the more stable ground state 
level, light is emitted. The instrument for measuring fluorescence differs from that 
of spectrophotometers in that a fluorometer contains two monochromators, one to 
regulate the wavelength of light striking the sample and one to isolate the desired 
wavelength of light emitted from the sample following excitation. The sensitivity of 
the fluorometric assay may be 103 times that of absorption spectrophotometry 
(Nguyen et al., 1996). 
Reagents: 
A. MeOSuc-Ala-Ala-Pro-Val-pNA(-7-AMC) (Bachem, UK) is dissolved in 
DMSO as a 1mM solution and stored at 4°C 
B. 0.1% Triton X-100 
C. 0.2M Tris-HCI buffer is prepared at pH 8.5 
D. Soybean-trypsin inhibitor (Sigma Chemical, UK. ) in ddH2O (100Ng/mI) is 
prepared as the stopping solution 
The fluorometric assay technique (after Barrett et al., 1981) is described below: 
500pl of sample fluid, diluted (1: 10) in 0.1% Triton X-100, was prepared in 
triplicate in labelled glass tubes. 500pl of a 1OnM NE standard solution, diluted in 
Triton X-100, was also prepared in triplicate. Blanks were prepared with 500pl of 
Triton X-100 in triplicate. Each set of patient samples were analysed in the same 
batch run. 
25Opl of Tris-HCI buffer was mixed with each sample solution, NE standard and 
blanks and the tubes warmed in a water bath for 5 minutes at 40°C. 
250PI of the MeOSuc-Ala-Ala-Pro-Val-pNA(-7-AMC) substrate stock solution 
(1mM), diluted to 20pM in ddH2O, was added to each tube in the water bath to start 
the reaction. The reaction was stopped at 10 minutes by the addition of 1 ml of 
soybean inhibitor (100pg). 
Each sample solution was transferred to a glass cuvet and placed in a fluorometer 
(Perkins Elmer Model LSOB, Norwalk, CT, USA). The sample was excited with 
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light at 350nm and the release of 7-AMC was measured at 460nm. A 
fluorescence reading, taken over a 10 second integration time, was displayed on a 
Windows 95 computer screen and recorded for each of the samples. 
The following equation was used to calculate the NE activity (pmol/min/litre or 
arbitrary units of activity/litre) of each unknown sample in triplicate: 
(reading of sample - reading of substrate blank) x (dilution factor) x (vol. of enzyme in mis) 
(average of standards) x (number of minutes of the reaction) 
where: 
reading of substrate blank was the average of three blank readings 
the dilution factor = 10 (1: 10) 
vol. of enzyme in mis = 0.5 
number of minutes for the reaction = 10 
NE activity in units/litre were plotted for each sample over time using Microsoft 
Excel 2000 software. 
Using this method, the generation of a standard curve for a series of known NE 
solutions is not required, reducing the amount of NE and its fluorogenic substrate 
required for the assay. 
Coefficient of variation: intra assay determination 1.3% 
inter assay determination 1.92% 
Each set of 20 wound fluid samples per donor site patient and each set of partial 
thickness burn wound fluid samples (between 8 and 16 samples) were measured 
in triplicate, separately in batches, in both a 96-well plate (colourimetric assay) or 
in glass tubes (fluorometric assay). 
The emphasis of these experiments was to identify differences in neutrophil 
elastase in within-patient samples during on/off suction. 
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6.2.4 Nephelometry measurements of a, -PI in wound fluid samples 
Principles: 
Nephelometry is the measurement of antigen-antibody complexes formed in 
enzyme immunoassays. The occurrence of immune complex formation is related 
to the amount of light scattering and is the basis of antigen quantification 
(Kasahara and Nakamura, 1996). The instrument measures scattered light during 
the formation rate of insoluble immunoprecipitation products resulting from a 
specific antigen combining with a specific antibody. Fully automated testing of 
many proteins can be performed using this technique. 
The method for measuring a1-PI was established using rate nephelometry on a 
Beckman Immage Array (Beckman, Coulter Instruments, UK). The identical 
wound fluid samples were analysed. This work was kindly performed courtesy of 
the staff at the Protein Reference and Immunopathology Unit, St. George's 
Hospital. The results were displayed as g/I and represent total a1-PI 
concentration. 
This automated method was standardised with processed human serum 
(Beckman, UK). A calibrant was sold and cross-calibrated against the 
International Reference Preparation for plasma proteins, CRM 470 (Whicher et at. 
1994). 
This method of measurement is used in the Protein Reference Unit for the routine 
determination of serum albumin, immunoglobulins complement and other plasma 
proteins (including al-PI). This method measures total al-PI, including both bound 
and free anti-protease. For quality control purposes, Beckman quote within batch 
coefficient of variation of <5%, which has also been confirmed on informal 
instrument evaluation in the laboratory (Personal Communication, Dr. J. Sheldon). 
Only one measurement per sample was obtained, rather than in triplicate. 
165 
6.3 Results 
Neutrophil elastase in the donor site samples was measured using the fluorometric 
activity assay and the results are reported in section 6.3.1 below. Neutrophil 
efastase in the burn wound fluid samples was measured using both the 
colourimetric activity assay and fluorometric activity assay, and the results 
reported in section 6.3.2 below. 
6.3.1 Neutrophil elastase activity assay of donor site wound fluids 
The results of the fluorometric activity assay for donor site wound fluids are 
displayed in Figure 48 below. The neutrophil elastase activity in each sample is 
modulated by 'on' and 'off suction cycles. In the same way as total protein 
concentrations, the elastase level is greatest during the 'on' phase and drops 
during the 'off phase (P<0.0035). There appears to be wide variations in elastase 
activity between the six donor site wounds (P=0.0001), but the variation within the 
20 sample cases remained consistent. 
The NE activity in wound fluid samples from ID3 and ID5 are greater than those of 
ID2, ID4, ID6a or ID6b (P=0.05). These latter four donor site wound fluid samples 
were all obtained from patients that had been previously burnt (see Table 9 on 
page 114). ID6a and ID6b were donor site wounds taken from a man with 40% 
burns. 
6.3.2 Neutrophil elastase activity assay of partial thickness burn wound fluids 
The results of the colourimetric (Figure 49) and fluorometric (Figure 50) activity 
assays for each of the burn wound fluid samples are shown below. 
The two assays yield different results with respect to the effects of 'on' and 'off 
suction for identical samples (both measured in triplicate). 
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The colourimetric assay of the burn wound fluid show that on/off suction does not 
appear to modulate NE activity (P=0.57). Furthermore, the relative NE activity in 
each set of samples differ to each other, although there appears to be greater 
activity in the clinically deep partial thickness burns, ID A, ID Ba and ID Bb than 
the clinically superficial partial thickness burns, ID Ca and ID Cb (P=0.0002). 
Meanwhile, the fluorometric assay of the burn wound fluid (Figure 50) show that 
on/off suction does appear to modulate NE activity (P=0.0002) with on = highest, 
and off = lowest. There appeared to be no difference in overall activity between 
the clinically deep and clinically superficial partial thickness burns (P=0.46). 
6.3.3 Neutrophil Elastase activity between wound types 
Since the same fluorometric assay was performed on the donor site and burn 
wound fluid samples, the neutrophil elastase results can be broadly compared. 
There is no evidence in this study that the activity within wound fluid samples is 
greater in the burns than donor sites (P=0.9091). The highest activity in the burn 
samples is 0.16 units/litre (ID Ba, t12 hours) and the lowest is 0.05 units/litre (ID 
Cb, t43 hours). The greatest activity in the donor site samples is 0.27 units/litre 
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6.3.4 a1-PI concentrations of donor site wound fluids 
The relative ai-PI concentrations for each of the donor site wound fluid samples, 
measured using Nephelometry, are shown in Figure 51 below. In a similar fashion 
to the fluorometric NE assay and total protein concentrations, a, -PI concentrations 
increased during the 'on' phase and dropped during the 'off phase. 
By comparing the a, -PI concentrations for each of the donor site wound fluid 
samples with their respective total protein concentrations (as a denominator), as 
shown in Figure 53, an increase in the nature of the acute phase protein, a1-PI, 
can be seen throughout the collection times, and in particular in those donor site 
wound fluid samples taken from patients who had been burnt. Table 9 on page 
114 reveals that some wound fluids were obtained from donor site wounds of 
patients who had been burnt up to 19 days previously (ID 2, ID 4, ID 6a and ID 
6b). Three donor site wound fluids were obtained from patients who had not been 
burnt (ID 1, ID 3 and ID 5). The results show that the a, -PI to total protein ratios in 
those donor site wound fluid samples from patients who had been burnt 
previously, are greater than those donor fluid samples from patients who have not 
been burnt (P=0.014). 
6.3.5 a, -PI concentrations of partial thickness burn wound fluids 
The relative a, -PI concentrations for each of the burn wound fluid samples, 
measured using Nephelometry, are shown in Figure 52. Like the donor site wound 
fluid samples, the concentrations within each set of fluid samples are affected by 
on/off suction. More plasma-derived a1-PI is obtained during the 'on' suction than 
`off suction phases, as indicated by the green and red bars (P<0.0001). 
The graph also reveals that ID A, ID Ba and ID Bb (deep partial thickness burn 
wounds) have greater a1-PI concentrations than ID Ca and ID Cb (superficial 
partial thickness burn wounds) (P=0.0392). 
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6.3.6 Neutrophil Elastase / a1-PI balance in the donor site wound fluid samples 
The results of the protease (elastase) activity, determined fluorometrically, and 
anti-protease (a, -PI) concentrations are displayed for each set of donor site wound 
fluids in Figure 54 on page 177. When combined in this way, there is no evidence 
to show that the Neutrophil Elastase / a1-PI balance is altered during the on/off 
phases of suction. The relative levels of elastase and a1-PI mirror each other 
closely. This observation can be supported by the fact that the ratios of both NE 
activity to a, -PI concentration demonstrate no differences in the donor site wound 
fluid samples (P=0.2926). 
6.3.7 Neutrophil Elastase / a, -PI balance in partial thickness burn wound fluid 
samples 
The results of the protease activity determined fluorometrically, and a, -PI 
concentrations are displayed together for each set of burn wound fluids in Figure 
55 on page 180. There is also no evidence to suggest that the neutrophil 
elastase/a1-PI balance is altered during the on/off phases of suction. Again, the 
relative levels of the two enzymes mirror each other closely, with the ratios of the 
protease and anti-protease showing no differences (P=0.202). 
When the same sets of graphs are displayed for the protease activity determined 
colourimetrically, with a1-PI concentrations (as shown in Figure 56 on page 183) 
the results are less clear, although a similar pattern emerges during on/off suction. 
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Figure 54 Combined elastase activity (fluorometric) and a, -PI concentration in donor site 
wound fluid samples 
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thickness burn wound fluid samples 
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Figure 56 Combined elastase activity (colourimetric) and a, -PI concentration in partial 
thickness burn wound fluid samples 
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6.4 Discussion 
6.4.1 The balance of neutrophil elastase and a1-PI in acute dermal wound fluids 
Because tissue turnover is likely to be partly mediated by the balance between the 
protease, neutrophil elastase (NE), and its endogenous inhibitor, a, -PI, there is 
interest in measuring the relative levels of NE to a1-PI for each of the donor site 
wound fluid and partial thickness burn wound fluid samples. 
It is important to appreciate that NE was measured in terms of its activity and not 
concentration. a, -PI values are expressed as relative concentrations and not as 
activity. There was no assay currently available that was able to measure a, -PI as 
units of activity. Hence, displaying the relative ratio of NE activity to a1-PI 
concentration within each fluid sample in each patient, to determine a 
protease/anti-protease imbalance, is not valid. However, Bullen et al. (1995) have 
published similar wound fluid data, analysing MMP-9 (Gelatinase B) activity with 
its endogenous inhibitor concentration, TIMP-1, in surgical drains of five patients 
who underwent mastectomies. In their study, they compared the relative ratios of 
MMP-9 activity with the relative concentration of TIMP-1. 
The results in this chapter clearly demonstrate that TNP therapy is able to 
modulate NE activity both in donor site and burn wound fluids. Similar results 
could be observed for a1-PI concentrations, the results of which mirror the total 
protein data described in Chapter 4. 
NE is actively released from degranulating neutrophils locally at sites of tissue 
injury. a1-PI is predominantly a serum-derived acute phase protein that enters the 
wound during the inflammatory response. It was not possible to determine 
whether a greater amount of at-PI was being sucked from the wound relative to 
NE because of the different measurement techniques. However, since TNP is 
capable of sucking a, -PI from the plasma, through the interstitial fluid and onto the 
wound surface, it is possible that large quantities of ai-PI will be significantly 
augmented during suction. By encouraging a, -PI to bath the wound in this way 
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might alter the 1: 1 presence (and therefore potentially the reaction) in favour of a, - 
Pl. 
However the NE activity assay, which measures 'free' elastase present in the fluid, 
might not include membrane-bound NE, which has been shown to develop a 
resistance to inhibition by naturally occurring inhibitors (Owen et al. 1995). 
6.4.2 Considerations in assay technique 
The NE activities measured by both the colourimetric and fluorometric assay 
techniques described in this study utilised the substrate, Methoxysuccinyl-Ala-Ala- 
Pro-Val-pNA, which is specific to neutrophil elastase alone. This substrate is not 
reactive to the other serine proteases, Cathepsin G or Proteinase 3, also present 
in azurophilic granules of neutrophils (Nakajima et al. 1979). However, these 
assays cannot discriminate between NE that might have been released by a small 
sub-population of macrophages (Owen et al., 1994), which might also contribute to 
the measured elastase activity in the wound fluid samples. However, an 
assumption has to be made that any possible contribution by macrophages to NE 
activity measured in these assays is minimal; the majority released from activated 
neutrophils. Moreover, this study is interested in the relative activities of NE within 
the same wound, and one might assume the same levels of macrophage activity is 
present during the first 48 hours. 
The wound fluid samples from each patient were assayed in the same batch and 
variables such as pH, temperature, timing of recordings, and concentration of 
solutions remained the same for each of the wound fluid samples within each set. 
In this way, all of these variables were kept constant. 
Despite reading the activity at a wavelength of 405nm, the colourimetric assay was 
unable to dissociate between the pink/red colours observed in the diluted donor 
site samples. This colour is likely to be due to haem pigments liberated from red 
blood cells obtained during the collection process by the TNP device. It was noted 
that the activity readings measured in the donor site assay were giving 
erroneously large results because of the coloured nature of the samples. 
Haemoglobin and its pigments have a wide range of absorption spectra varying 
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from 400 to 640nm. Confirmation that the coloured pigments within the samples 
might be contributing towards the high absorption measurements obtained was 
made by omitting the colourimetric substrate to a series of donor site wound fluid 
samples. The results showed very high readings on the spectrophotometer, which 
corresponded to a number of different pink/red coloured samples in the wells. 
This problem was not evident in the burn wound fluid samples since they were not 
contaminated by blood. However, it is also possible that both types of wound fluid 
affected the colourimetric assay in other ways. For example, even the burn wound 
fluid samples were never very clear during absorption readings, often having a 
faint yellow colour to them despite centrifugation. This alone might explain the 
less consistent results in this assay compared to the more sensitive fluorometric 
assay technique. 
6.4.3 Neutrophil Elastase activity in donor site and burn wound fluids 
The literature review in this thesis was unable to find any study that compared 
protease activity in donor site wound fluid and burn wound fluid directly. The 
nearest comparative study to the one in this chapter is that of Neely et at. (1997), 
who examined the proteolytic activity in 20 homogenised paediatric burn wound 
tissue samples and harvested donor site tissue. They determined that MMP 
activity was greater in burn tissues than donor site or control skin. This thesis did 
not examine proteolytic activities within biopsy specimens. Other studies have 
shown greater NE activity in wound fluids from chronic cutaneous wounds than 
acute (non-cutaneous) wounds (Grinnell and Zhu, 1996; Hoffman et al., 1998). 
Rao et at. (1995), using the same colourimetric assay described above, also 
showed that NE activity was greater in chronic wound fluid than donor site wound 
fluid (Rao et al., 1995). 
The results described in this chapter do not support the view that NE activity is 
greater in burn wound fluid than acute donor site wound fluid, suggesting that 
these two wounds are much the same in terms of their proteolytic activities. 
Nonetheless, this inconsistency might be confirmed by testing the fluid samples for 
MMP activity, for a greater amount of work has been published on these 
proteases. Despite the similar pathophysiological proteolytic mechanisms that 
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might be occurring in burn wound and chronic wound fluids, the similar levels of 
NE activity in acute burn wound and acute donor site wound fluid measured in this 
study does not support the concept that burn wounds behave like chronic wounds. 
Nonetheless, although this study measured protease activity in wound fluid, this 
may not necessarily reflect protease activity in the tissues directly. 
Despite the compelling evidence that connective tissue proteolysis is occurring in 
inflamed tissues, in the presence of increased NE activity, does not prove that 
neutrophil-derived NE is responsible; the injury might be produced, in part, by 
other proteases released from other cells, and that the measurable increases in 
NE activity, for example, are simply a reflection of this. 
It must be emphasised that this thesis neither provides evidence to demonstrate 
that neutrophil elastase directly contributes to burn wound pathophysiology nor 
attempts to establish whether TNP therapy might improve burn wound healing. 
Instead, this study does demonstrate that the protease activities can be altered by 
this novel device, which supports the view that TNP therapy might modulate the 
protease environment of the wound to favour healing. 
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6.5 Conclusion 
This chapter support the hypothesis that TNP therapy is capable of modulating the 
protease activity of acute dermal wounds by altering the activity within the wound 
fluid environment. These conclusive findings might explain one mechanism of 
action by which TNP might improve the healing of some difficult-to-heal wounds, 
by actively removing proteases from the wound environment. The effects of TNP 
on the inhibitor of Neutrophil Elastase, a, -PI, is also shown. This suggests that 
TNP is capable of drawing the NE inhibitor from the intravascular system through 
the wound and onto the surface. However, this study fails to establish whether a 
true protease/anti-protease imbalance might be occurring during intermittent TNP 




The first aim of this thesis was to develop a method of applying selective TNP to 
dermal wound surfaces (based on commercially available V. A. C. TM dressings) to 
allow, for the first time, an opportunity to study its effects using intra-patient 
controls. Chapter 3 explained how this was achieved and provided evidence to 
show that the TNP device was capable of mimicking normal V. A. C. TM dressings. 
A further device was developed as a research tool that enabled the device to 
collect wound fluid samples. 
To test the hypothesis that TNP (V. A. C. TM) therapy might be capable of 
modulating the wound fluid constituents of a wound, chapter 4 described how the 
irrigation TNP device was used to collect wound fluid intermittently on the same 
wound, using the `off phase of collection as a control. On both donor site and 
burn wounds, the levels of total protein mirrored the intermittent phases of suction, 
thereby providing evidence that TNP might indeed alter the wound environment by 
its behaviour on wound fluid. 
Chapter 5 provided evidence that, not only wound fluid, but also the presence of 
inflammatory cells might also be influenced by TNP therapy. Neutrophil cell 
counts performed on paired TNP-treated and control wound biopsy sections were 
compared in both donor site and burn wounds. The results showed that TNP 
therapy was capable of significantly reducing neutrophil cell numbers compared to 
controls in donor site wounds with similar trends in burn wounds, although this was 
not significant. Furthermore, TNP therapy was capable of reducing the distribution 
of cells for up to 1 mm beneath the surface of the wound. 
The pathophysiological role of neutrophil-derived proteases in mediating tissue 
damage in difficult-to-heal wounds and ways in which TNP therapy might be able 
to alter this was tested in chapter 6. On the same set of wound fluid samples 
obtained in chapter 4, neutrophil elastase activity was determined on both donor 
site and burn wound fluids using two different activity assay techniques. The 
endogenous inhibitor to neutrophil elastase, a1-PI, was determined by 
nephefometry. 
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Further evidence that intermittent TNP therapy is capable of modulating the wound 
fluid environment was also demonstrated by showing that the activity of neutrophil 
elastase was directly related to the on/off phases of suction. This might explain 
one of the possible mechanisms by which TNP therapy promotes healing of some 
chronic wounds in vivo. Given the constraints of measuring protease activity and 
a, -PI concentrations in wound fluids, direct comparisons between the balance of 
the protease and its inhibitor could not be made. This chapter also demonstrated 
that there was no significant difference between the neutrophil elastase activity of 
donor site and burn wound fluids over a 48-hour period. 
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8 CONCLUSION 
1. A TNP device was developed to provide selective subatmospheric pressure 
to cutaneous wounds 
2. Validation studies confirmed that the TNP device mimics V. A. CTM dressings 
in a clinical setting 
3. An irrigation TNP device was developed as a research tool to allow frequent 
and instantaneous collections of wound fluid in vivo 
4. TNP therapy was capable of altering the constituents of wound fluid, 
including proteases, in acute dermal wounds 
5. TNP therapy was able to reduce the number of neutrophils present in donor 
site and partial thickness burn wounds 
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9 FUTURE WORK 
The TNP device described in this thesis is capable of generating future research 
work in the following areas: 
1. Comparing the effects of TNP therapy on acute or chronic wound healing in 
intra-patient clinically controlled trials to establish whether a true difference 
between treated and control groups can be observed or measured 
2. To further investigate other putative mechanisms of action that have been 
ascribed to TNP (including measurements of dermal oedema, bacterial 
content, granulation tissue formation and mechanical influences of TNP on 
cells) 
3. As a research tool, the irrigation TNP device can be used in the collection of 
wound fluid during wound healing studies (especially those of chronic 
wounds) 
1. Intra-patient clinically controlled trials 
A number of intra-patient clinical trials on different wound types, including acute, 
chronic and burn wounds are now possible using the TNP device to test whether 
TNP-treated wounds might heal more quickly than controls. Only two randomised 
controlled studies have been published describing its efficacy in chronic wounds, 
and these have been conducted in between-patient groups. Applying two TNP 
devices to the same wound type, one under suction and the other simply as a 
control, might be used to establish a true clinical benefit. For example, the rates of 
reepithelialisation in donor site wounds (and other wounds) can be determined 
using this selective TNP device. Wound biopsies can be harvested from TNP- 
treated areas and compared to control areas after 7-10 days. 
The use of the TNP device with portable suction pumps does not necessarily limit 
these trials to the bedside. 
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2. Testing other suggested mechanisms of action of TNP 
One of the proposed beneficial effects of TNP may be due to the attenuation of 
oedema present in some wounds. Many investigators have suggested that 
oedema may be responsible for the delay in wound healing by limiting the blood 
flow to the wound. Using the donor site wound model, some preliminary work has 
been performed using high frequency (20MHz) ultrasound to measure directly the 
thickness of the dermis in TNP-treated versus control sites. There is some 
evidence that TNP therapy reduces the thickness of the dermis but this work 
requires more study using this device. 
The effects of constant versus intermittent suction can also be evaluated in a 
number of ways. Laser Doppler imaging of the skin comparing both modes of 
action on dermal blood flow can be determined. There is some evidence that 
intermittent (5 minutes on /2 minutes off) therapy may be more beneficial to 
wound healing than constant suction alone. Measuring the protease profiles from 
samples taken using each of these modes of therapy may also determine whether 
constant or intermittent therapy may be better at removing proteases during 
wound healing. 
The effects of mechanical loading by TNP therapy on wounds could also be 
addressed using selective TNP therapy. There is evidence that tissues respond 
differently to changes in mechanical loads (for example in granulation tissue 
formation and keratinocyte proliferation). 
3. The TNP device as a research tool in wound healing studies 
The irrigation TNP device could be used specifically as a research tool to obtain 
wound fluid samples from any cutaneous wound surface in the temporal analysis 
of a number of wound fluid parameters. For example, other neutral proteases 
(including the metalloproteases, MMP-8 and MMP-9) may be measured for 
protease activity and compared directly to serine proteases (such as neutrophil 
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elastase) to determine the relative temporal levels of expression in a number of 
wounds and during different stages of healing. The device might also be used to 
establish the relative levels of other wound constituents, including local cytokine 
and growth factor production in different wound types. In these cases, the device 
could be placed on a wound surface as a simple dressing (without suction) and 
switched on at various times just to retrieve wound fluid from the wound and not as 
a treatment per se. The advantage of this system as a research tool is in its ability 
to obtain wound fluid as frequently as desired, easily and reliably. Importantly, the 
collection method can be achieved over minutes and not hours. 
The irrigation TNP device might also be used to apply topical nutrition or growth 
factors (such as TGF-ß) to a wound surface as part of a drug release system for 
topical wound treatment. 
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10.3 Materials used in the biochemical Assays 
(see text for details) 
A. 0.1 M HEPES buffer (pH7.4) 
100mt of OA M HEPES buffer was prepared by mixing 2.38gm HEPES (Sigma 
Chemical UK. ) and 2.92gm NaCl (0.5M) with 100mis ddH2O. The pH was 
calibrated to 7.4. 
B. BCA working reagent 
Reagent A (hydroxide) includes sodium carbonate, sodium bicarbonate, BCA 
detection reagent and sodium tartrate in 0.1 M NaOH 
Reagent B (Cu2+) includes 4% CuSO4 in distilled water. 
C. Tris-HCI buffer 
0.2M Tris-HCI was prepared by mixing 2.422g Trizma Base and 5.844g NaCl 
up to 100ml ddH2O. The pH was calibrated to 8.5. 
D. 7-AMC standard 
For a1 mM solution, 0.0876g of standard is added to 500ml of acetone. 
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10.4 Protocol for immunohistochemical staining for Neutrophil Elastase 
The following protocol was used for both donor site and partial thickness burn 
biopsy sections 
1. Sections placed in an oven at 60°C for 30 minutes 
2. De-wax in 2 changes of xylene for 3 minutes each 
3. Rehydrate in graded alcohols (100%, 100%, 70% for 1 minute each) 
4. Block endogenous peroxidase with 3% hydrogen peroxide in methanol for 
20 minutes 
5. Wash in running tap water for 5 minutes 
6. Perform antigen retrieval using 0.1% trypsin digestion method at 37°C for 
30 minutes in a humidity chamber (see Trypsin preparation on page 202) 
7. Rinse sections with PBST 
8. Ring around sections with a hydrophobic pen (Dako, UK) 
9. Incubate sections with 10% Normal Swine Serum (NSS, Dako, UK) in PBS 
for 10 minutes to reduce non-specific background staining for polyclonal 
primary antibodies 
10. Rinse off NSS with PBST 
11. Apply NP57 (Dako, UK) primary antibody (optimally diluted in PBS) for 30 
minutes covered from direct sunlight in a humidity chamber 
12. Rinse with three 3 minute changes of PBST 
13. Apply the Dako EnVisionTM+ reagent for 30 minutes (see page 139) 
14. Rinse with three 3 minute changes of PBST 
15. Cover the sections with freshly prepared diaminobenzidine solution (DAB, 
Dako, UK) 
16. Stop the reaction with PBS after 10 minutes 
17. Wash in running tap water for 5 minutes 
18. Counterstain with Mayer's haematoxylin for 3 minutes 
19. Blue in water for 5 minutes in water bath 
20. Dehydrate in graded alcohols (70% for 15 seconds, 2 changes of 100% for 
30 seconds) 
21. Clear in two 1 minute changes of xylene 
22. Mount slides in DPX and leave to dry for 24 hours 
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Antigen retrieval with Trypsin digestion: 
Formaldehyde fixation leads to cross-linking "methylene bridges" between proteins 
in the tissues. Subsequent processing to paraffin wax in these biopsies can 
further mask the antigenic epitopes, thereby reducing the sensitivity of the 
immunocytochemical labelling technique. These masked antigens can be 
retrieved using a proteolytic (trypsin) digestion technique, in which the 
formaldehyde crossing-linking is broken down and the antigenic sites uncovered. 
Under-digestion results in very little staining of the primary antibody. Similarly, 
over-digestion can lead to tissue damage. 
Using the manufacturers' instructions, preparation of the trypsin solution 
proceeded as follows: 
A. 0.1% CaCI2 (pH 7.8) was prepared by dissolving 50mg CACI2 (BDH 
Laboratory Supplies, UK) in 50mts of 0.05mol/l Tris/HCI, 0.15mol/I NaCl, pH 
7.8. 
B. 2% trypsin stock solution was prepared by dissolving the contents of one 
500mg vial of DAKO trypsin (Code No. S2012) in freshly prepared 0.1% 
CaC12, pH 7.8 
C. A 0.1% trypsin working solution was prepared from aliquots of stored 2% 
stock solution mixed with 0.1% CaCI2, pH 7.8 as described in the 
manufacturers' instructions. This working solution was used in the protocol 
described above at an optimal time of 30 minutes based upon previous 
experience at the Stoke Mandeville Burns & Reconstructive Surgery 
Research Trust. 
10% Normal Swine Serum (NSS) 
10% NSS (Dako, UK) was prepared by mixing the stock solution with PBS. This 
was then brought up to 37°C prior to use in the above protocol. 
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Monoclonal mouse anti-human Neutrophil Elastase (NP57) 
The primary monoclonal NP57 antibody (Dako, UK. Code No. M0752) was 
optimally diluted (1: 120) with PBS. 
Phosphate buffered saline (PBS) with TWEEN (PBST) 
Standard PBS was prepared by dissolving 1 tablet (Oxoid, Ltd. UK) in 100mis of 
ddH2O. Up to 10 litres of PBS was prepared, much of it being used with TWEEN 
as a wash buffer (see below). PBS was stored at 2°C and used with 3 days. 
For the wash buffer, 0.05% TWEEN detergent (courtesy Mr. K. Miller, Department 
of Histopathology, University College London) was added to PBS. The use of 
TWEEN helps avoid excessive background staining. 
Dako EnVisionTM+ System, Peroxidase (DAB) 
This commercial product, purchased as a kit from Dako (K4006), containing both 
the peroxidase labelled polymer and the DAB substrate-chromogen solution was 
used in accordance to the manufacturers' instructions. 
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10.5 Cell counting data for donor site wound biopsies 
Donor ID 1 
I IOCON cut 1 001.2 0*1.3 col. 4 001.5 col. 5 oal. 79 . ca 9n 
heft .11 110001 071 
hp2 
.-00000 0 00 
h, 1 I 
hp4 0000000 0 00 
nos 2C000000 000 
npß 0000000 0 00 
npv a0000000 000 
bpt8 00000000 000 
npt 20000000 070 
hpf10 20000000 OOC 
letal 10001 ' 
-. 9. 1000 05 01 0 001 
1 040600 0011 cv1 2 Y, W5001.6001.7 total. . 000ya. 
hpfl 
_ 
52 54 61 32 58 322 4600 
npf2 28 14 5 62 20 156 2221 
5p13 I6 36 9 15 95 13 1 
hpf4 3 49 23 3220 82 it11 
hp5 28 3303 62 886 
hpf6 26 30 731I 50 111 
hp" 044 10 000 1C 25] 
hp 18 28502 13 30 4 29 
hp19 12000 13 8 24 343 
np010 3002633 14 200 
total 158 159 134 09 130 111 111011 
a verap. 4''18 15.9 13.4 8.9 1 11 1 854 1220 
1148TNP 001.1 pp1.2 44111111W 901.6001.7104114 . 00,19.1 
npft 2C 33 47 25 36 
_ 
211 3300 
np2 12 26 t5 35 
_ 16B 2-1 
npf3 0-6 29 23 19 _ 14 036 1941 
'P f4 0328 20 11 53 15' 
M1pb 4015 00 24 343 
hpf6 041203 11 157 
hpf! .12111101 0 86 
np18 0016007 100 
hpf9 0000000 000 
hpfl0 60030003 043 
total :9 53 55 117 97 111 175 639 9125 
. 0*004. 285.3 5.8 11.7 9.7 11.1 17.5 63.9 III 
Donor ID 5 
S t000N colt pp1 2.1 3-1 4 001 5 col 6 cot. 7 totals . Wnq. s 
npl2 0 0 0 01 
p13 -0 000 0 0o 00 
opra 0 000 0 
"15 0 000 0 0 014 
'pt6 0 000 0 000 00 
0p17 10 000 0 00 000 
, pill 0 000 0 00 000 
hp19 0 000 0 00 000 
70110 0 000 0 00 
t041 3 211 0 2 
000109. IIa 92 0.1 0.1 0 C. 015 
5 f41CON col. 13,1.2 9. j1.7 toWS averages 
Cpf, 60 61 53 55 62 -,.. 
102 29 .' 58 67 42 60 52 032 4'43 
M1pf3 1 29 46 36 16 2114 
11M . 
2I 
17 25 38 5 5 119 16 56 
0p5 10 15 76 8 5 60 8 57 
7016 2 14 28 6 5 1 67 9 57 
9017 6 438 5 4 39 5 51 
np16 3 622 5 3 23 3 29 
'PS 7 444 3 0 22 0I< 
"(10 3 432 1 0 I3 1 f6 
total 09 190 212 238 199 170 92 1240 
i 19 21.2 23.6 19.9 11 12 Ioa i, i 
614ETNP col I I clots . Wrap.. 
rp/1 60 72 57 48 37 83 all 58 9n 
hp/2 19 46 25 8 6 67 174 14 
hplO 3 9 19 8 9 
CVi4 2 202 5 0I 200 
'P15 0 213 2 0e1 11 
hpf6 0 231 2 06 11 
hptl 0 003 3 06 066 
7016 0 000 0 000.00 
hp19 0 000 0 00 000 
hp110 0 000 0 00 000 
la. l 64 133 90 94 63 169 616 96 57 
sWrsy. 6.4 13.3 9 8.4 63 1 S9 671 966 
Donor ID 2 Donor ID 4 
2 taCAN col 1 cal 2 001.3 001.4 001.5 001.6 001.7 total.. -, ago. 41oCON ccl 1 001 2 001.3 001.4 001 5 pal 6 cal. 7 totals inne.. 
np Pl 0137f, 011. hptl iI300 081 
hp2 `000 11 ý- 6p2 0 1! 0 029 
npla '00072 hpI3 000000 000 
hp14 00007G0 hpN 0000 
hpf5 '1 100030I 014 hp5 '0000000 000 
6918 000022 020 np16 o0000011 14 
tlpA 00000020.29 npA 10000001 014 
hp16 0000001 014 hp15 I00000000.00 
hp19 0000000o 00 hp5 10000000 00 
hpt10 0000000 000 hpNO 000000 000 
total 1,1 1402 15 214 01.1 II4I0 10 143 
"-g. 0G01 01 O10.4 002150 21 0000090 !I010.1 0.4 01010 14 
2 ta6CON CO, 1 cal. 20.1.3-1.4 aal. 50016001.7 total. . a. 0. ga6 4046GON col 1 001.2 t0I. 3 1I 061.7 t01ak Mag. 
hptt 1 56 45 65 45 62 69 382 54 1' hptl 54 51 50 51 38 363 14 13 
npll 
.. 
-99068 90 11 hp2 5 21 10 64 01 9 1- 
IQ1-'360 03 0 00 npf3 02S7 
8954 i520 03 4 71 hpt4 03313 19 2 71 
hp6 0 10 14 9611 46 6 5' Itp5 I5331 16 2.29 
hpIB B 2B 15 222 58 8.211 hpt I30061.14 
hpf7 6 10 15 520 38 5 4. i np17 021000000.43 
hp/6 4250302.40 np85 020000020.29 14 
hPI9 21300080.86 hp19 00000000.00 
hpflO 0 13 1000 14 2 01.50810 .. 
0000110 14 
tatal 130 132 76 85 8 .l 50103 ['' 
119 74 83 65 65 514 7343 
100509$ 
144 
170 192 76 85 5 "44 1061 . 70009.74 8.3 6.5 65 4 514 ] 34 
2 t48TNP col 1391.2 
. 
g01,3 Mi. 5001.0001.7 totals av. rag. s 4146TNP col 1 col. 2 , 
6001.780301009.09.0 
npIl 47 41 51 33 40 42 109 1ý hptl 1 11 32 24 23 25 2- 202 0516 
np2 23B41,. np2 876 I' 7: 9 
5383 '44557 14 50 hp(3 5212C 
npt4 10200192 hpt4 2210I0' 29 
hpi5 1360 11 np5 00000 314 
hpal 031223 12 1'11 1 p6 J001140.57 
hpA 01012040 5' hpA 000000000 00 
hptS 000023s 6558 0000000a 00 
btpt9 00000000 00 5910 -0000000.00 
hpn0 0000000 000 111 0300000000.00 
fatal 54 56 62 59 71 70 439 627' total 11 70 47 35 32 33 33 263 37.57 
. Nr09o - 14 5.6 6.2 691.1 7 43.9 6.27 .. 'ago 0^ 37 47 3.5 3.2 3.3 33 2113 3.76 
Donor ID 8 Donor ID 9 
0 00 0 014 hpm oo9 1 29 
0 00 
_ 
I npl2 11 00 is 
0 0 00 0 o ", hp13 01_ 0 
0 0 00 00 0 00o hp14 1o00100 014 
0 0 00 00 0 0 30 M1p5 12 100 
0 0 00 00 0 0 00 npl6 000000I 0.14 
,. 0 0 00 0 1 814 npl] o0000000 0.00 
0 0 00 01 1 014 hp16 90000101 04 
0 0 00 00 0 030 0319 30001001 0.14 
a 0 00 00 0 000 npr1C 000100I 014 
0 0 00 I2 4 05' total 10s16 1s 117 
0 0 00 1 .. 
90 005 awri9e 01 0.3 06 07 .n ,_ 036 
001 1 0C1 '9 001.4001.5 sn1.6 soll 1C1a18 averages 9549CON col 1 c, 1.2' cal. 7totals 900009"9 
'10 55 129 /9 357 -. 4771 '' ' 
121 88 107 115 96 ', 2 1_114 
6 17 i, _ . 
- I o M1pf - f fit 66 69 56 +v 
.. n 
6 3 49 6 '2 02 4 f npl3 - .. 65 75 44 53 01 14 43 
36 3 26 1 01 09 1p14 'I 29 18 19 14 1 
4 02 64 24 329 npf5 Is 20 7251 54 
5'1 
3 7 23 13 3 32 4 57 '1316 62233 16 37 5.29 
7 5 25 15 37 5.29 hp17 2289 15 38 5.43 
7 2 24 12 45 640 M1p18 0111227 00 
2 3 12 55 30 t3 1196 hp9 20000000 0.00 
3 4 19 6 45 69 971 3110 000001 014 
156 103 199 174 151 153 1154 161 971 total 21, ' 217 302 279 253 257 249 1607 258 14 
56 103 389 17.4 151 153 1154 1649 8005498 .. 
' 302 279 253 257 249 I80" 2585 
001 1 304. ''l01.7 t01ah a99nyes 9119TNP pol 1 col 2'1 , 
U9L7 aam a99fap9 
37 47 69 31 59 5 370 5276 hp? 1 26 35 26 IB , 
3 21 12 6 2 5 49 711 hp(2 11 31 33 6 29 
3 03 I8 22 3 14 hp" 37433 10 4 39 
4 2 84 22 22 314 hpf4 2129 16 ,2 
2 3 93 20 20 2.66 I1p15 I300153 15 2.14 
.3 
3 5 11 1 26 371 npö .10002 10 13 1.96 
8 44 13 4 35 500 hpfl 0001135 0.71 
2 32 20 11 157 hpI5 I100004s 0.96 
0 0I 00 6 086 M1p19 000001 0.14 
0 0 00 10 1 014 hpfI 0 40000000 000 
s9 10.59 96 72 562 80 29 5.. 1 79 42 74 37 41 34 333 47 57 
59 9s 106 5.9 96 7.2 56.2 903 awrapa 6 7.9 42 74 3.7 41 14 33.3 4.79 
204 
10.6 Cell counting data for burn wound biopsies 
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